

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
21 June 2001 (21.06.2001)

PCT

(10) International Publication Number  
**WO 01/43693 A2**


- (51) International Patent Classification<sup>7</sup>: **A61K** [US/US]; 126 East Lincoln Avenue, Rahway, NJ 07065-0907 (US).
- (21) International Application Number: PCT/US00/34162
- (22) International Filing Date:  
15 December 2000 (15.12.2000)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:  
60/172,442 17 December 1999 (17.12.1999) US
- (71) Applicant (for all designated States except US): **MERCK & CO., INC.** [US/US]; 126 East Lincoln Avenue, Rahway, NJ 07065-0907 (US).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): **SHIVER, John, W.** [US/US]; 126 East Lincoln Avenue, Rahway, NJ 07065-0907 (US). **LIANG, Xiaoping** [CA/US]; 126 East Lincoln Avenue, Rahway, NJ 07065-0907 (US). **FU, Tong-Ming**
- (74) Common Representative: **MERCK & CO., INC.**; 126 East Lincoln Avenue, Rahway, NJ 07065-0907 (US).
- (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.
- (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

— Without international search report and to be republished upon receipt of that report.

[Continued on next page]

(54) Title: **POLYNUCLEOTIDE VACCINES EXPRESSING CODON OPTIMIZED HIV-1 NEF AND MODIFIED HIV-1 NEF**



(57) Abstract: Pharmaceutical compositions which comprise HIV Nef DNA vaccines are disclosed, along with the production and use of these DNA vaccines. The nef-based DNA vaccines of the invention are administered directly introduced into living vertebrate tissue, preferably humans, and express the HIV Nef protein or biologically relevant portions thereof, inducing a cellular immune response which specifically recognizes human immunodeficiency virus-1 (HIV-1). The DNA molecules which comprise the open reading frame of these DNA vaccines are synthetic DNA molecules encoding codon optimized HIV-1 Nef and derivatives of optimized HIV-1 Nef, including nef modifications comprising amino terminal leader peptides, removal of the amino terminal myristylation site, and/or modification of the Nef dileucine motif. These modifications may effect wild type characteristics of Nef, such as myristylation and down regulation of host CD4.

WO 01/43693 A2

BEST AVAILABLE COPY

WO 01/43693 A2



---

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

## TITLE OF THE INVENTION

5 POLYNUCLEOTIDE VACCINES EXPRESSING CODON OPTIMIZED HIV-1  
NEF AND MODIFIED HIV-1 NEF

## CROSS-REFERENCE TO RELATED APPLICATIONS

10 This application claims the benefit, under 35 U.S.C. §119(e), of U.S.  
provisional application 60/172,442, filed December 17, 1999.

## STATEMENT REGARDING FEDERALLY-SPONSORED R&amp;D

Not Applicable

15

## REFERENCE TO MICROFICHE APPENDIX

Not Applicable

## FIELD OF THE INVENTION

20 The present invention relates to HIV Nef polynucleotide pharmaceutical  
products, as well as the production and use thereof which, when directly introduced  
into living vertebrate tissue, preferably a mammalian host such as a human or a  
non-human mammal of commercial or domestic veterinary importance, express the  
HIV Nef protein or biologically relevant portions thereof within the animal, inducing  
25 a cellular immune response which specifically recognizes human immunodeficiency  
virus-1 (HIV-1). The polynucleotides of the present invention are synthetic DNA  
molecules encoding codon optimized HIV-1 Nef and derivatives of optimized HIV-1  
Nef, including nef mutants which effect wild type characteristics of Nef, such as  
myristylation and down regulation of host CD4. The polynucleotide vaccines of the  
30 present invention should offer a prophylactic advantage to previously uninfected  
individuals and/or provide a therapeutic effect by reducing viral load levels within an  
infected individual, thus prolonging the asymptomatic phase of HIV-1 infection.

## BACKGROUND OF THE INVENTION

Human Immunodeficiency Virus-1 (HIV-1) is the etiological agent of acquired human immune deficiency syndrome (AIDS) and related disorders. HIV-1 is an RNA virus of the Retroviridae family and exhibits the 5' LTR-*gag-pol-env*-LTR 3' organization of all retroviruses. The integrated form of HIV-1, known as the provirus, is approximately 9.8 Kb in length. Each end of the viral genome contains flanking sequences known as long terminal repeats (LTRs). The HIV genes encode at least nine proteins and are divided into three classes; the major structural proteins (Gag, Pol, and Env), the regulatory proteins (Tat and Rev); and the accessory proteins (Vpu, Vpr, Vif and Nef).

The *gag* gene encodes a 55-kilodalton (kDa) precursor protein (p55) which is expressed from the unspliced viral mRNA and is proteolytically processed by the HIV protease, a product of the *pol* gene. The mature p55 protein products are p17 (matrix), p24 (capsid), p9 (nucleocapsid) and p6.

The *pol* gene encodes proteins necessary for virus replication; a reverse transcriptase, a protease, integrase and RNase H. These viral proteins are expressed as a Gag-Pol fusion protein, a 160 kDa precursor protein which is generated via a ribosomal frame shifting. The viral encoded protease proteolytically cleaves the Pol polypeptide away from the Gag-Pol fusion and further cleaves the Pol polypeptide to the mature proteins which provide protease (Pro, P10), reverse transcriptase (RT, P50), integrase (IN, p31) and RNase H (RNase, p15) activities.

The *nef* gene encodes an early accessory HIV protein (Nef) which has been shown to possess several activities such as down regulating CD4 expression, disturbing T-cell activation and stimulating HIV infectivity.

The *env* gene encodes the viral envelope glycoprotein that is translated as a 160-kilodalton (kDa) precursor (gp160) and then cleaved by a cellular protease to yield the external 120-kDa envelope glycoprotein (gp120) and the transmembrane 41-kDa envelope glycoprotein (gp41). Gp120 and gp41 remain associated and are displayed on the viral particles and the surface of HIV-infected cells.

The *tat* gene encodes a long form and a short form of the Tat protein, a RNA binding protein which is a transcriptional transactivator essential for HIV-1 replication.

The *rev* gene encodes the 13 kDa Rev protein, a RNA binding protein. The Rev protein binds to a region of the viral RNA termed the Rev response element

(RRE). The Rev protein is promotes transfer of unspliced viral RNA from the nucleus to the cytoplasm. The Rev protein is required for HIV late gene expression and in turn, HIV replication.

Gp120 binds to the CD4/chemokine receptor present on the surface of helper  
5 T-lymphocytes, macrophages and other target cells in addition to other co-receptor molecules. X4 (macrophage tropic) virus show tropism for CD4/CXCR4 complexes while a R5 (T-cell line tropic) virus interacts with a CD4/CCR5 receptor complex. After gp120 binds to CD4, gp41 mediates the fusion event responsible for virus entry. The virus fuses with and enters the target cell, followed by reverse transcription of its  
10 single stranded RNA genome into the double-stranded DNA via a RNA dependent DNA polymerase. The viral DNA, known as provirus, enters the cell nucleus, where the viral DNA directs the production of new viral RNA within the nucleus, expression of early and late HIV viral proteins, and subsequently the production and cellular release of new virus particles. Recent advances in the ability to detect viral load  
15 within the host shows that the primary infection results in an extremely high generation and tissue distribution of the virus, followed by a steady state level of virus (albeit through a continual viral production and turnover during this phase), leading ultimately to another burst of virus load which leads to the onset of clinical AIDS. Productively infected cells have a half life of several days, whereas chronically or  
20 latently infected cells have a 3-week half life, followed by non-productively infected cells which have a long half life (over 100 days) but do not significantly contribute to day to day viral loads seen throughout the course of disease.

Destruction of CD4 helper T lymphocytes, which are critical to immune defense, is a major cause of the progressive immune dysfunction that is the hallmark  
25 of HIV infection. The loss of CD4 T-cells seriously impairs the body's ability to fight most invaders, but it has a particularly severe impact on the defenses against viruses, fungi, parasites and certain bacteria, including mycobacteria.

Effective treatment regimens for HIV-1 infected individuals have become available recently. However, these drugs will not have a significant impact on the  
30 disease in many parts of the world and they will have a minimal impact in halting the spread of infection within the human population. As is true of many other infectious diseases, a significant epidemiologic impact on the spread of HIV-1 infection will only occur subsequent to the development and introduction of an effective vaccine. There are a number of factors that have contributed to the lack of successful vaccine

development to date. As noted above, it is now apparent that in a chronically infected person there exists constant virus production in spite of the presence of anti-HIV-1 humoral and cellular immune responses and destruction of virally infected cells. As in the case of other infectious diseases, the outcome of disease is the result of a balance between the kinetics and the magnitude of the immune response and the pathogen replicative rate and accessibility to the immune response. Pre-existing immunity may be more successful with an acute infection than an evolving immune response can be with an established infection. A second factor is the considerable genetic variability of the virus. Although anti-HIV-1 antibodies exist that can neutralize HIV-1 infectivity in cell culture, these antibodies are generally virus isolate-specific in their activity. It has proven impossible to define serological groupings of HIV-1 using traditional methods. Rather, the virus seems to define a serological "continuum" so that individual neutralizing antibody responses, at best, are effective against only a handful of viral variants. Given this latter observation, it would be useful to identify immunogens and related delivery technologies that are likely to elicit anti-HIV-1 cellular immune responses. It is known that in order to generate CTL responses antigen must be synthesized within or introduced into cells, subsequently processed into small peptides by the proteasome complex, and translocated into the endoplasmic reticulum/Golgi complex secretory pathway for eventual association with major histocompatibility complex (MHC) class I proteins. CD8<sup>+</sup> T lymphocytes recognize antigen in association with class I MHC via the T cell receptor (TCR) and the CD8 cell surface protein. Activation of naive CD8<sup>+</sup> T cells into activated effector or memory cells generally requires both TCR engagement of antigen as described above as well as engagement of costimulatory proteins. Optimal induction of CTL responses usually requires "help" in the form of cytokines from CD4<sup>+</sup> T lymphocytes which recognize antigen associated with MHC class II molecules via TCR and CD4 engagement.

As introduced above, the *nef* gene encodes an early accessory HIV protein (Nef) which has been shown to possess several activities such as down regulating CD4 expression, disturbing T-cell activation and stimulating HIV infectivity. Zazopoulos and Haseltine (1992, *Proc. Natl. Acad. Sci.* 89: 6634-6638) disclose mutations to the HIV-1 *nef* gene which effect the rate of virus replication. The authors show that the *nef* open reading frame mutated to encode Ala-2 in place of Gly-2 inhibits myristolation of the protein and results in delayed viral replication rates

in Jurkat cells and PBMCs.

Kaminchik et al. (1991, *J. Virology* 65(2): 583-588) disclose an amino-terminal nef open reading frame mutated to encode Met-Ala-Ala in place of Met-Gly-Gly. The authors show that this mutant is deficient in myristolation.

5        Saksela et al. (1995, *EMBO J.* 14(3): 484-491) and Lee et al. (1995, *EMBO J.* 14(20): 5006-5015) show the importance of a proline rich motif in HIV-1 Nef which mediates binding to a SH3 domain of the Hck protein. The authors conclude that this motif is important in the enhancement of viral replication but not down-regulation of CD4 expression.

10        Calarota et al. (1998, *The Lancet* 351: 1320-1325) present human clinical data concerning immunization of three HIV infected individuals with a DNA plasmid expressing wild type Nef. The authors conclude that immunization with a Nef encoding DNA plasmid induced a cellular immune response in the three individuals. However, two of the three patients were on alternative therapies during the study, and  
15        the authors conclude that the CTL response was most likely a boost to a pre-existing CTL response. In addition, the viral load increased substantially in two of the three patients during the course of the study.

          Tobery et al. (1997, *J. Exp. Med.* 185(5): 909-920) constructed two ubiquitin-nef (Ub-nef) fusion constructs, one which encoded the Nef initiating methionine and  
20        the other with an Arg residue at the amino terminus of the Nef open reading frame. The authors state that vaccinia- or plasmid-based immunization of mice with a Ub-nef construct containing an Arg residue at the amino terminus induces a Nef-specific CTL response. The authors suggest the expressed fusion protein is more efficiently presented to the MHC class I antigen presentation pathway, resulting in an improved  
25        cellular immune response.

          Kim et al. (1997, *J. Immunol.* 158(2): 816-826) disclose that co-administration of a plasmid DNA construct expressing IL-12 with a plasmid construct expressing Nef results in an improved cellular immune response in mice when compared to inoculation with the Nef construct alone. The authors reported a reduction in the  
30        humoral response from the Nef / IL-12 co-administration as compared to administration of the plasmid construct expressing Nef alone.

          Moynier et al. (1998, *Vaccine* 16(16): 1523-1530) show varying humoral responses in mice immunized with a DNA plasmid encoding Nef, depending upon the presence of absence of Freund's adjuvant. No data is disclosed regarding a cellular

immune response in mice vaccinated with the aforementioned DNA construct alone.

Hanna et al. (1998, *Cell* 95:163-175) suggest that wild type Nef may play a critical role in AIDS pathogenicity.

It would be of great import in the battle against AIDS to produce a  
5 prophylactic- and/or therapeutic-based HIV vaccine which generates a strong cellular  
immune response against an HIV infection. The present invention addresses and  
meets this needs by disclosing a class of DNA vaccines based on host delivery and  
expression of the early HIV gene, *nef*.

## 10 SUMMARY OF THE INVENTION

The present invention relates to synthetic DNA molecules (also referred to  
herein as "polynucleotides") and associated DNA vaccines (also referred to herein as  
"polynucleotide vaccines") which elicit CTL responses upon administration to the  
host, such as a mammalian host and including primates and especially humans, as  
15 well as non-human mammals of commercial or domestic veterinary importance.  
The CTL-directed vaccines of the present invention should lower transmission rate to  
previously uninfected individuals and/or reduce levels of the viral loads within an  
infected individual, so as to prolong the asymptomatic phase of HIV-1 infection. In  
particular, the present invention relates to DNA vaccines which encode various forms  
20 of HIV-1 Nef, wherein administration, intracellular delivery and expression of the  
HIV-1 *nef* gene of interest elicits a host CTL and Th response. The preferred  
synthetic DNA molecules of the present invention encode codon optimized versions  
of wild type HIV-1 Nef, codon optimized versions of HIV-1 Nef fusion proteins, and  
codon optimized versions of HIV-1 Nef derivatives, including but not limited to *nef*  
25 modifications involving introduction of an amino-terminal leader sequence, removal  
of an amino-terminal myristylation site and/or introduction of dileucine motif  
mutations. The Nef-based fusion and modified proteins disclosed within this  
specification may possess altered trafficking and/or host cell function while retaining  
the ability to be properly presented to the host MHC I complex and in turn elicit a  
30 host CTL and Th response.

A particular embodiment of the present invention relates to a DNA molecule  
encoding HIV-1 Nef from the HIV-1 jfrl isolate wherein the codons are optimized for  
expression in a mammalian system such as a human. The DNA molecule which  
encodes this protein is disclosed herein as SEQ ID NO:1, while the expressed open



reading frame is disclosed herein as SEQ ID NO:2.

In another embodiment of the present invention, a codon optimized DNA molecule encoding a protein containing the human plasminogen activator (tpa) leader peptide fused with the NH<sub>2</sub>-terminus of the HIV-1 Nef polypeptide. The DNA  
5 molecule which encodes this protein is disclosed herein as SEQ ID NO:3, while the expressed open reading frame is disclosed herein as SEQ ID NO:4.

In an additional embodiment, the present invention relates to a DNA molecule encoding optimized HIV-1 Nef wherein the open reading frame codes for modifications at the amino terminal myristylation site (Gly-2 to Ala-2) and  
10 substitution of the Leu-174-Leu-175 dileucine motif to Ala-174-Ala-175, herein described as opt nef (G2A,LLAA). The DNA molecule which encodes this protein is disclosed herein as SEQ ID NO:5, while the expressed open reading frame is disclosed herein as SEQ ID NO:6.

Another additional embodiment of the present invention relates to a DNA  
15 molecule encoding optimized HIV-1 Nef wherein the amino terminal myristylation site and dileucine motif have been deleted, as well as comprising a tPA leader peptide. This DNA molecule, opt tpanef (LLAA), comprises an open reading frame which encodes a Nef protein containing a tPA leader sequence fused to amino acid residue 6-216 of HIV-1 Nef (jfrl), wherein Leu-174 and Leu-175 are substituted with Ala-174  
20 and Ala-175, herein referred to as opt tpanef (LLAA) is disclosed herein as SEQ ID NO:7, while the expressed open reading frame is disclosed herein as SEQ ID NO:8.

The present invention also relates to non-codon optimized versions of DNA molecules and associated DNA vaccines which encode the various wild type and modified forms of the HIV Nef protein disclosed herein. Partial or fully codon  
25 optimized DNA vaccine expression vector constructs are preferred, but it is within the scope of the present invention to utilize "non-codon optimized" versions of the constructs disclosed herein, especially modified versions of HIV Nef which are shown to promote a substantial cellular immune response subsequent to host administration.

The DNA backbone of the DNA vaccines of the present invention are  
30 preferably DNA plasmid expression vectors. DNA plasmid expression vectors utilized in the present invention include but are not limited to constructs which comprise the cytomegalovirus promoter with the intron A sequence (CMV-intA) and a bovine growth hormone transcription termination sequence. In addition, the DNA plasmid vectors of the present invention preferably comprise an antibiotic resistance

marker, including but not limited to an ampicillin resistance gene, a neomycin resistance gene or any other pharmaceutically acceptable antibiotic resistance marker. In addition, an appropriate polylinker cloning site and a prokaryotic origin of replication sequence are also preferred. Specific DNA vectors of the present invention include but are not limited to V1, V1J (SEQ ID NO:14), V1Jneo (SEQ ID NO:15), V1Jns (Figure 1A, SEQ ID NO:16), V1R (SEQ ID NO:26), and any of the aforementioned vectors wherein a nucleotide sequence encoding a leader peptide, preferably the human tPA leader, is fused directly downstream of the CMV-intA promoter, including but not limited to V1Jns-tpa, as shown in Figure 1B and SEQ ID NO:19.

The present invention especially relates to a DNA vaccine and a pharmaceutically active vaccine composition which contains this DNA vaccine, and the use as a prophylactic and/or therapeutic vaccine for host immunization, preferably human host immunization, against an HIV infection or to combat an existing HIV condition. These DNA vaccines are represented by codon optimized DNA molecules encoding HIV-1 Nef of biologically active Nef modifications or Nef-containing fusion proteins which are ligated within an appropriate DNA plasmid vector, with or without a nucleotide sequence encoding a functional leader peptide. DNA vaccines of the present invention relate in part to codon optimized DNA molecules encoding HIV-1 Nef of biologically active Nef modifications or Nef-containing fusion proteins ligated in DNA vectors V1, V1J (SEQ ID NO:14), V1Jneo (SEQ ID NO:15), V1Jns (Figure 1A, SEQ ID NO:16), V1R (SEQ ID NO:26), or any of the aforementioned vectors wherein a nucleotide sequence encoding a leader peptide, preferably the human tPA leader, is fused directly downstream of the CMV-intA promoter, including but not limited to V1Jns-tpa, as shown in Figure 1B and SEQ ID NO:19. Especially preferred DNA vaccines of the present invention include codon optimized DNA vaccine constructs V1Jns/nef, V1Jns/tpanef, V1Jns/tpanef(LLAA) and V1Jns/(G2A,LLAA), as exemplified in Example Section 2.

The present invention also relates to HIV Nef polynucleotide pharmaceutical products, as well as the production and use thereof, wherein the DNA vaccines are formulated with an adjuvant or adjuvants which may increase immunogenicity of the DNA polynucleotide vaccines of the present invention, namely by increasing a humoral response to inoculation. A preferred adjuvant is an aluminum phosphate-based adjuvant or a calcium phosphate based adjuvant,

with an aluminum phosphate adjuvant being especially preferred. Another preferred adjuvant is a non-ionic block copolymer, preferably comprising the blocks of polyoxyethylene (POE) and polyoxypropylene (POP) such as a POE-POP-POE block copolymer. These adjuvanted forms comprising the DNA  
 5 vaccines disclosed herein are useful in increasing humoral responses to DNA vaccination without imparting a negative effect on an appropriate cellular immune response.

As used herein, a DNA vaccine or DNA polynucleotide vaccine or polynucleotide vaccine is a DNA molecule (i.e., "nucleic acid", "polynucleotide")  
 10 which contains essential regulatory elements such that upon introduction into a living, vertebrate cell, it is able to direct the cellular machinery to produce translation products encoded by the respective nef genes of the present invention.

#### BRIEF DESCRIPTION OF THE FIGURES

15 Figure 1A-B show a schematic representation of DNA vaccine expression vectors VIJns (A) and VIJns/tpa utilized for HIV-1 nef and HIV-1 modified nef constructs.

Figure 2A-B show a nucleotide sequence comparison between wild type nef(jrfl) and codon optimized nef. The wild type nef gene from the jrfl isolate  
 20 consists of 648 nucleotides capable of encoding a 216 amino acid polypeptide. WT, wild type sequence (SEQ ID NO:9); opt, codon-optimized sequence (contained within SEQ ID NO:1). The Nef amino acid sequence is shown in one-letter code (SEQ ID NO:2).

Figure 3A-C show nucleotide sequences at junctions between nef coding  
 25 sequence and plasmid backbone of nef expression vectors VIJns/nef (Figure 3A), VIJns/nef(G2A,LLAA) (Figure 3B), VIJns/tpanef (Figure 3C) and VIJns/tpanef(LLAA) (Figure 3C, also). 5' and 3' flanking sequences of codon optimized nef or codon optimized nef mutant genes are indicated by bold/italic letters; nef and nef mutant coding sequences are indicated by plain letters. Also indicated (as  
 30 underlined) are the restriction endonuclease sites involved in construction of respective nef expression vectors. VIJns/tpanef and VIJns/tpanef(LLAA) have identical sequences at the junctions.

Figure 4 shows a schematic presentation of nef and nef derivatives. Amino acid residues involved in Nef derivatives are presented. Glycine 2 and Leucine 174

and 175 are the sites involved in myristylation and dileucine motif, respectively. For both versions of the tpanef fusion genes, the putative leader peptide cleavage sites are indicated with "\*", and a exogenous serine residue introduced during the construction of the mutants is underlined.

5        Figure 5 shows Western blot analysis of nef and modified nef proteins expressed in transfected 293 cells. 293 cells grown in 100 mm culture dish were transfected with respective codon optimized nef constructs. Sixty hours post transfection, supernatant and cells were collected separately and separated on 10% SDS-PAGE under reducing conditions. The proteins were transferred into a PVDF  
10        membrane and probed with a mixture of Gag mAb and Nef mAbs, both at 1:2000 dilution. The protein signals were detected with ECL. (A) cells transfected with V1Jns/gag only; (B) cells transfected with V1Jns/gag and V1Jns/nef; (C) cells transfected with V1Jns/gag and V1Jns/nef(G2A, LLAA); (D) cells transfected with V1Jns/gag and V1Jns/tpanef; (E) cells transfected with V1Jns/gag and  
15        V1Jns/tpanef(LLAA). The low case letter c and m represent medium and cellular fractions, respectively. M.W. = molecular weight marker.

Figure 6 shows an Elispot assay of cell-mediated responses to Nef peptides. Three strains of mice, Balb/c, C57BL/6 and C3H, were immunized with 50 mcg of V1Jns/nef (codon optimized) and boosted twice with a two-week interval. Two  
20        weeks following the final immunization, splenocytes were isolated and tested in an Elispot assay against respective Nef peptide pools. As a control, splenocytes were from non-immunized naive mice were tested in parallel. Nef peptide pool A consists of all 21 Nef peptides; Nef peptide pool B consists of 11 non-overlapping peptide started from residue 1; Nef peptide pool C consists of 10 non-overlapping peptides  
25        started from residue 11. SFC, INF-gamma secreting spot-forming cells.

Figure 7A-C show Nef-specific CD8 and CD4 epitope mapping. The immunization regime is as per Figure 6. Mouse splenocytes were isolated and fractionated into CD8<sup>+</sup> and CD8<sup>-</sup> cells using Miltenyi's magnetic cell separator. The resultant CD8<sup>+</sup> and CD8<sup>-</sup> cells were then tested in an Elispot assay against individual  
30        Nef peptides. SFC, INF-gamma secreting spot-forming cells. The mice strains tested are Balb/c mice (Figure 7A), C57BL/6 mice (Figure 7B), and C3H mice (Figure 7C).

Figure 8A-C show identification of a Nef CTL epitope. Splenocytes from nef immunized C57BL/6 mice were stimulated *in vitro* with peptide-pulsed, irradiated naïve splenocytes for 7 days. Following the *in vitro* stimulation, cells were harvested

and tested in a standard  $^{51}\text{Cr}$ -releasing assay using peptide pulsed EL-4 cells as targets. Open symbol, specific killings of EL-4 cells without peptide; solid symbol, specific killing of EL-4 cells with peptide. Panel A - peptide Nef 51-70; Panel B - peptide Nef 60-68, Panel C - peptide Nef 58-70.

5        Figure 9A-B shows a comparison of the immunogenicity of codon optimized DNA vaccine vectors expressing Nef and modified forms of Nef C57BL/6 mice, five per group, were immunized with 100 mcg of the indicated nef constructs. Fourteen days following immunization, splenocytes were collected and tested against the Nef CD8 (aa58-66) and CD4 (aa81-100) peptides. Identical immunization regimens were  
10        used for both experiments. In experiment 1 (Panel A), three codon optimized nef constructs were tested, namely, VIJns/nef, VIJns/tpanef(LLAA) and VIJns/nef(G2A,LLAA), whereas in experiment 2 (Panel B) all four codon optimized nef constructs were tested. The data represent means plus standard deviation of 5 mice per group.

15

#### DETAILED DESCRIPTION OF THE INVENTION

The present invention relates to synthetic DNA molecules (also referred to herein as "nucleic acid" molecules or "polynucleotides") and associated DNA vector vaccines (also referred to herein as "polynucleotide vaccines") which elicit CTL and  
20        humoral responses upon administration to the host, including primates and especially humans. In particular, the present invention relates to DNA vector vaccines which encode various forms of HIV-1 Nef, wherein administration, intracellular delivery and expression of the HIV-1 nef gene of interest elicits a host CTL and Th response. The synthetic DNA molecules of the present invention encode codon optimized  
25        versions of wild type HIV-1 Nef, codon optimized versions of HIV-1 Nef fusion proteins, and codon optimized versions of HIV-1 Nef derivatives, including but not limited to *nef* modifications involving introduction of an amino-terminal leader sequence, removal of an amino-terminal myristylation site and/or introduction of dileucine motif mutations. In some instances the Nef-based fusion and modified  
30        proteins disclosed within this specification possess altered trafficking and/or host cell function while retaining the ability to be properly presented to the host MHC I complex. Those skilled in the art will recognize that the use of nef genes from HIV-2 strains which express Nef proteins having analogous function to HIV-1 Nef would be expected to generate immune responses analogous to those described herein for

HIV-1 constructs.

In order to generate a CTL response, the immunogen must be synthesized within (MHC I presentation) or introduced into cells (MHC II presentation). For intracellular synthesized immunogens, the protein is expressed and then processed  
 5 into small peptides by the proteasome complex, and translocated into the endoplasmic reticulum/Golgi complex secretory pathway for eventual association with major histocompatibility complex (MHC) class I proteins. CD8<sup>+</sup> T lymphocytes recognize antigen in association with class I MHC via the T cell receptor (TCR). Activation of naive CD8<sup>+</sup> T cells into activated effector or memory cells generally requires both  
 10 TCR engagement of antigen as described above as well as engagement of co-stimulatory proteins. Optimal induction of CTL responses usually requires "help" in the form of cytokines from CD4<sup>+</sup> T lymphocytes which recognize antigen associated with MHC class II molecules via TCR.

The HIV-1 genome employs predominantly uncommon codons compared to  
 15 highly expressed human genes. Therefore, the nef open reading frame has been synthetically manipulated using optimal codons for human expression. As noted above, a preferred embodiment of the present invention relates to DNA molecules which comprise a HIV-1 nef open reading frame, whether encoding full length nef or a modification or fusion as described herein, wherein the codon usage has been  
 20 optimized for expression in a mammal, especially a human.

In a particular embodiment of the present invention, a DNA molecule encoding HIV-1 Nef from the HIV-1 jfr1 isolate wherein the codons are optimized for expression in a mammalian system such as a human. The nucleotide sequence of the codon optimized version of HIV-1 jfr1 nef gene is disclosed herein as SEQ ID NO:1,  
 25 as shown herein:

```
GATCTGCCAC CATGGGCGGC AAGTGGTCCA AGAGGTCCGT GCCCGGCTGG TCCACCGTGA
GGGAGAGGAT GAGGAGGGCC GAGCCCGCCG CCGACAGGGT GAGGAGGACC GAGCCCGCCG
CCGTGGGCGT GGGCGCCGTG TCCAGGGACC TGGAGAAGCA CGGCGCCATC ACCTCCTCCA
ACACCGCCGC CACCAACGCC GACTGCGCCT GGCTGGAGGC CCAGGAGGAC GAGGAGGTGG
30 GCTTCCCCGT GAGGCCCCAG GTGCCCCCTGA GGCCCATGAC CTACAAGGGC GCCGTGGACC
TGTCCTCACTT CCTGAAGGAG AAGGGCGGCC TGGAGGGCCT GATCCACTCC CAGAAGAGGC
AGGACATCCT GGACCTGTGG GTGTACCACA CCCAGGGCTA CTTCCCCGAC TGGCAGAACT
ACACCCCCGG CCCCGGCATC AGGTTCCTCC TGACCTTCGG CTGGTGCTTC AAGCTGGTGC
CCGTGGAGCC CGAGAAGGTG GAGGAGGCCA ACGAGGGCGA GAACAACTGC CTGCTGCACC
```

CCATGTCCCA GCACGGCATC GAGGACCCCG AGAAGGAGGT GCTGGAGTGG AGGTTCGACT  
 CCAAGCTGGC CTTCCACCAC GTGGCCAGGG AGCTGCACCC CGAGTACTAC AAGGACTGCT  
 AAAGCCCGGG C (SEQ ID NO:1).

- As can be discerned from comparing native to optimized codon usage in  
 5 Figure 2A-B, the following codon usage for mammalian optimization is preferred:  
 Met (ATG), Gly (GGC), Lys (AAG), Trp (TGG), Ser (TCC), Arg (AGG), Val (GTG),  
 Pro (CCC), Thr (ACC), Glu (GAG), Leu (CTG), His (CAC), Ile (ATC), Asn (AAC),  
 Cys (TGC), Ala (GCC), Gln (CAG), Phe (TTC) and Tyr (TAC). For an additional  
 discussion relating to mammalian (human) codon optimization, see WO 97/31115  
 10 (PCT/US97/02294), which is hereby incorporated by reference.

- The open reading frame for SEQ ID NO:1 above comprises an initiating  
 methionine residue at nucleotides 12-14 and a "TAA" stop codon from nucleotides  
 660-662. The open reading frame of SEQ ID NO:1 provides for a 216 amino acid  
 HIV-1 Nef protein expressed through utilization of a codon optimized DNA vaccine  
 15 vector. The 216 amino acid HIV-1 Nef (jfrl) protein is disclosed herein as SEQ ID  
 NO:2, and as follows:

- Met Gly Gly Lys Trp Ser Lys Arg Ser Val Pro Gly Trp Ser Thr Val  
 Arg Glu Arg Met Arg Arg Ala Glu Pro Ala Ala Asp Arg Val Arg Arg  
 Thr Glu Pro Ala Ala Val Gly Val Gly Ala Val Ser Arg Asp Leu Glu  
 20 Lys His Gly Ala Ile Thr Ser Ser Asn Thr Ala Ala Thr Asn Ala Asp  
 Cys Ala Trp Leu Glu Ala Gln Glu Asp Glu Glu Val Gly Phe Pro Val  
 Arg Pro Gln Val Pro Leu Arg Pro Met Thr Tyr Lys Gly Ala Val Asp  
 Leu Ser His Phe Leu Lys Glu Lys Gly Gly Leu Glu Gly Leu Ile His  
 Ser Gln Lys Arg Gln Asp Ile Leu Asp Leu Trp Val Tyr His Thr Gln  
 25 Gly Tyr Phe Pro Asp Trp Gln Asn Tyr Thr Pro Gly Pro Gly Ile Arg  
 Phe Pro Leu Thr Phe Gly Trp Cys Phe Lys Leu Val Pro Val Glu Pro  
 Glu Lys Val Glu Glu Ala Asn Glu Gly Glu Asn Asn Cys Leu Leu His  
 Pro Met Ser Gln His Gly Ile Glu Asp Pro Glu Lys Glu Val Leu Glu  
 Trp Arg Phe Asp Ser Lys Leu Ala Phe His His Val Ala Arg Glu Leu  
 30 His Pro Glu Tyr Tyr Lys Asp Cys (SEQ ID NO:2).

HIV-1 Nef is a 206 amino acid cytosolic protein which associates with the  
 inner surface of the host cell plasma membrane through myristylation of Gly-2  
 (Franchini et al., 1986, *Virology* 155: 593-599). While not all possible Nef functions  
 have been elucidated, it has become clear that correct trafficking of Nef to the inner

plasma membrane promotes viral replication by altering the host intracellular environment to facilitate the early phase of the HIV-1 life cycle and by increasing the infectivity of progeny viral particles. In one aspect of the invention regarding codon-optimized, protein-modified polypeptides, either the DNA vaccine vector molecule or the HIV-1 nef construct is modified to contain a nucleotide sequence which encodes a heterologous leader peptide such that the amino terminal region of the expressed protein will contain the leader peptide. The diversity of function that typifies eukaryotic cells depends upon the structural differentiation of their membrane boundaries. To generate and maintain these structures, proteins must be transported from their site of synthesis in the endoplasmic reticulum to predetermined destinations throughout the cell. This requires that the trafficking proteins display sorting signals that are recognized by the molecular machinery responsible for route selection located at the access points to the main trafficking pathways. Sorting decisions for most proteins need to be made only once as they traverse their biosynthetic pathways since their final destination, the cellular location at which they perform their function, becomes their permanent residence. Maintenance of intracellular integrity depends in part on the selective sorting and accurate transport of proteins to their correct destinations. Defined sequence motifs exist in proteins which can act as 'address labels'. A number of sorting signals have been found associated with the cytoplasmic domains of membrane proteins. An effective induction of CTL responses often required sustained, high level endogenous expression of an antigen. In light of its diverse biological activities, vaccines composed of wild-type Nef could potentially have adverse effects on the host cells. As membrane-association via myristylation is an essential requirement for most of Nef's function, mutants lacking myristylation, by glycine-to-alanine change, change of the dileucine motif and/or by substitution with a tpa leader sequence as described herein, will be functionally defective, and therefore will have improved safety profile compared to wild-type Nef for use as an HIV-1 vaccine component.

In a preferred and exemplified embodiment of this portion of the invention, either the DNA vector or the HIV-1 nef nucleotide sequence is modified to include the human tissue-specific plasminogen activator (tPA) leader. As shown in Figure 1A-B for the DNA vector VIJns, a DNA vector which may be utilized to practice the present invention may be modified by known recombinant DNA methodology to contain a leader signal peptide of interest, such that downstream



cloning of the modified HIV-1 protein of interest results in a nucleotide sequence which encodes a modified HIV-1 tPA/Nef protein. In the alternative, as noted above, insertion of a nucleotide sequence which encodes a leader peptide may be inserted into a DNA vector housing the open reading frame for the Nef protein of interest.

- 5 Regardless of the cloning strategy, the end result is a polynucleotide vaccine which comprises vector components for effective gene expression in conjunction with nucleotide sequences which encode a modified HIV-1 Nef protein of interest, including but not limited to a HIV-1 Nef protein which contains a leader peptide. The amino acid sequence of the human tPA leader utilized herein is as follows:

10 MDAMKRGLCCVLLCGAVFVSPSEISS (SEQ ID NO:19).

- It has been shown that myristylation of Gly-2 in conjunction with a dileucine motif in the carboxy region of the protein is essential for Nef-induced down regulation of CD4 (Aiken et al., 1994, *Cell* 76: 853-864) via endocytosis. It has also been shown that Nef expression promotes down regulation of MHCI (Schwartz et al.,  
15 1996, *Nature Medicine* 2(3): 338-342) via endocytosis. The present invention relates in part to DNA vaccines which encode modified Nef proteins altered in trafficking and/or functional properties. The modifications introduced into the DNA vaccines of the present invention include but are not limited to additions, deletions or substitutions to the nef open reading frame which results in the expression of a  
20 modified Nef protein which includes an amino terminal leader peptide, modification or deletion of the amino terminal myristylation site, and modification or deletion of the dileucine motif within the Nef protein and which alter function within the infected host cell. Therefore, a central theme of the DNA molecules and DNA vaccines of the present invention is (1) host administration and intracellular delivery of a codon  
25 optimized nef-based DNA vector vaccine; (2) expression of a modified Nef protein which is immunogenic in terms of eliciting both CTL and Th responses; and, (3) inhibiting or at least altering known early viral functions of Nef which have been shown to promote HIV-1 replication and load within an infected host.

- In another preferred and exemplified embodiment of the present invention, the  
30 nef coding region is altered, resulting in a DNA vaccine which expresses a modified Nef protein wherein the amino terminal Gly-2 myristylation residue is either deleted or modified to express alternate amino acid residues.

In another preferred and exemplified embodiment of the present invention, the nef coding region is altered, resulting in a DNA vaccine which expresses a modified

Nef protein wherein the dileucine motif is either deleted or modified to express alternate amino acid residues.

Therefore, the present invention relates to an isolated DNA molecule, regardless of codon usage, which expresses a wild type or modified Nef protein as described herein, including but not limited to modified Nef proteins which comprise a deletion or substitution of Gly 2, a deletion or substitution of Leu 174 and Leu 175 and/or inclusion of a leader sequence.

The present invention also relates to a substantially purified protein expressed from the DNA polynucleotide vaccines of the present invention, especially the purified proteins set forth below as SEQ ID NOs: 2, 4, 6, and 8. These purified proteins may be useful as protein-based HIV vaccines.

In a specific embodiment of the invention as it relates DNA vaccines encoding modified forms of HIV-1, an open reading frame which encodes a Nef protein which comprises a tPA leader sequence fused to amino acid residue 6-216 of HIV-1 Nef (jfr1) is referred to herein as opt tpanef. The nucleotide sequence comprising the open reading frame of opt tpanef is disclosed herein as SEQ ID NO:3, as shown below:

```

CATGGATGCA ATGAAGAGAG GGCTCTGCTG TGTGCTGCTG CTGTGTGGAG CAGTCTTCGT
TTCGCCCAGC GAGATCTCCT CCAAGAGGTC CGTGCCCGGC TGGTCCACCG TGAGGGAGAG
GATGAGGAGG GCCGAGCCCG CCGCCGACAG GGTGAGGAGG ACCGAGCCCG CCGCCGTGGG
20 CGTGGGCGCC GTGTCCAGGG ACCTGGAGAA GCACGGCGCC ATCACCTCCT CCAACACCGC
CGCCACCAAC GCCGACTGCG CCTGGCTGGA GGCCAGGAG GACGAGGAGG TGGGCTTCCC
CGTGAGGCCC CAGGTGCCCC TGAGGCCCAT GACCTACAAG GGCGCCGTGG ACCTGTCCCA
CTTCCTGAAG GAGAAGGGCG GCCTGGAGGG CCTGATCCAC TCCCAGAAGA GGCAGGACAT
CCTGGACCTG TGGGTGTACC ACACCCAGGG CTACTTCCCC GACTGGCAGA ACTACACCCC
25 CGGCCCCGGC ATCAGGTTCC CCCTGACCTT CGGCTGGTGC TTCAAGCTGG TGCCCGTGGG
GCCCAGAAAG GTGGAGGAGG CCAACGAGGG CGAGAACAAC TGCCTGCTGC ACCCATGTC
CCAGCACGGC ATCGAGGACC CCGAGAAGGA GGTGCTGGAG TGGAGGTCG ACTCCAAGCT
GGCCTTCCAC CACGTGGCCA GGGAGCTGCA CCCCAGTAC TACAAGGACT GCTAAAGCC
(SEQ ID NO:3) .

```

The open reading frame for SEQ ID NO:3 comprises an initiating methionine

residue at nucleotides 2-4 and a "TAA" stop codon from nucleotides 713-715. The open reading frame of SEQ ID NO:3 provides for a 237 amino acid HIV-1 Nef protein which comprises a tPA leader sequence fused to amino acids 6-216 of HIV-1 Nef, including the dileucine motif at amino acid residues 174 and 175. This 237 amino acid tPA/Nef (jfrl) fusion protein is disclosed herein as SEQ ID NO:4, and is shown as follows:

Met Asp Ala Met Lys Arg Gly Leu Cys Cys Val Leu Leu Leu Cys Gly  
Ala Val Phe Val Ser Pro Ser Glu Ile Ser Ser Lys Arg Ser Val Pro  
Gly Trp Ser Thr Val Arg Glu Arg Met Arg Arg Ala Glu Pro Ala Ala  
10 Asp Arg Val Arg Arg Thr Glu Pro Ala Ala Val Gly Val Gly Ala Val  
Ser Arg Asp Leu Glu Lys His Gly Ala Ile Thr Ser Ser Asn Thr Ala  
Ala Thr Asn Ala Asp Cys Ala Trp Leu Glu Ala Gln Glu Asp Glu Glu  
Val Gly Phe Pro Val Arg Pro Gln Val Pro Leu Arg Pro Met Thr Tyr  
Lys Gly Ala Val Asp Leu Ser His Phe Leu Lys Glu Lys Gly Gly Leu  
15 Glu Gly Leu Ile His Ser Gln Lys Arg Gln Asp Ile Leu Asp Leu Trp  
Val Tyr His Thr Gln Gly Tyr Phe Pro Asp Trp Gln Asn Tyr Thr Pro  
Gly Pro Gly Ile Arg Phe Pro Leu Thr Phe Gly Trp Cys Phe Lys Leu  
Val Pro Val Glu Pro Glu Lys Val Glu Glu Ala Asn Glu Gly Glu Asn  
Asn Cys Leu Leu His Pro Met Ser Gln His Gly Ile Glu Asp Pro Glu  
20 Lys Glu Val Leu Glu Trp Arg Phe Asp Ser Lys Leu Ala Phe His His  
Val Ala Arg Glu Leu His Pro Glu Tyr Tyr Lys Asp Cys (SEQ ID NO:4).

Therefore, this exemplified Nef protein, Opt tPA-Nef, contains both a tPA leader sequence as well as deleting the myristylation site of Gly-2A DNA molecule encoding HIV-1 Nef from the HIV-1 jfrl isolate wherein the codons are optimized for expression in a mammalian system such as a human.

In another specific embodiment of the present invention, a DNA molecule is disclosed which encodes optimized HIV-1 Nef wherein the open reading frame codes for modifications at the amino terminal myristylation site (Gly-2 to Ala-2) and substitution of the Leu-174-Leu-175 dileucine motif to Ala-174-Ala-175. This open reading frame is herein described as opt nef (G2A,LLAA) and is disclosed as SEQ ID NO:5, which comprises an initiating methionine residue at nucleotides 12-14 and a "TAA" stop codon from nucleotides 660-662. The nucleotide sequence of this codon optimized version of HIV-1 jfrl nef gene with the above mentioned modifications is disclosed herein as SEQ ID NO:5, as follows:

GATCTGCCAC CATGGCCGGC AAGTGGTCCA AGAGGTCCGT GCCCGGCTGG TCCACCGTGA  
 GGGAGAGGAT GAGGAGGGCC GAGCCCGCCG CCGACAGGGT GAGGAGGACC GAGCCCGCCG  
 CCGTGGGCGT GGGCGCCGTG TCCAGGGACC TGGAGAAGCA CGGCGCCATC ACCTCCTCCA  
 ACACCGCCGC CACCAACGCC GACTGCGCCT GGCTGGAGGC CCAGGAGGAC GAGGAGGTGG  
 5 GCTTCCCCGT GAGGCCCCAG GTGCCCTGA GGCCCATGAC CTACAAGGGC GCCGTGGACC  
 TGTCCTCACTT CCTGAAGGAG AAGGGCGGCC TGGAGGGCCT GATCCACTCC CAGAAGAGGC  
 AGGACATCCT GGACCTGTGG GTGTACCACA CCCAGGGCTA CTCCCCGAC TGGCAGAACT  
 ACACCCCCGG CCCCGGCATC AGGTTCCCCC TGACCTTCGG CTGGTGCTTC AAGCTGGTGC  
 CCGTGGAGCC CGAGAAGGTG GAGGAGGCCA ACGAGGGCGA GAACAACATGC GCCGCCACCC  
 10 CCATGTCCCA GCACGGCATC GAGGACCCCG AGAAGGAGGT GCTGGAGTGG AGGTTGCACT  
 CCAAGCTGGC CTTCCACCAC GTGGCCAGGG AGCTGCACCC CGAGTACTAC AAGGACTGCT  
 AAAGCCCGGG C (SEQ ID NO:5).

The open reading frame of SEQ ID NO:5 encodes Nef (G2A,LLAA), disclosed herein as SEQ ID NO:6, as follows:

15 Met Ala Gly Lys Trp Ser Lys Arg Ser Val Pro Gly Trp Ser Thr Val  
 Arg Glu Arg Met Arg Arg Ala Glu Pro Ala Ala Asp Arg Val Arg Arg  
 Thr Glu Pro Ala Ala Val Gly Val Gly Ala Val Ser Arg Asp Leu Glu  
 Lys His Gly Ala Ile Thr Ser Ser Asn Thr Ala Ala Thr Asn Ala Asp  
 Cys Ala Trp Leu Glu Ala Gln Glu Asp Glu Glu Val Gly Phe Pro Val  
 20 Arg Pro Gln Val Pro Leu Arg Pro Met Thr Tyr Lys Gly Ala Val Asp  
 Leu Ser His Phe Leu Lys Glu Lys Gly Gly Leu Glu Gly Leu Ile His  
 Ser Gln Lys Arg Gln Asp Ile Leu Asp Leu Trp Val Tyr His Thr Gln  
 Gly Tyr Phe Pro Asp Trp Gln Asn Tyr Thr Pro Gly Pro Gly Ile Arg  
 Phe Pro Leu Thr Phe Gly Trp Cys Phe Lys Leu Val Pro Val Glu Pro  
 25 Glu Lys Val Glu Glu Ala Asn Glu Gly Glu Asn Asn Cys Ala Ala His  
 Pro Met Ser Gln His Gly Ile Glu Asp Pro Glu Lys Glu Val Leu Glu  
 Trp Arg Phe Asp Ser Lys Leu Ala Phe His His Val Ala Arg Glu Leu  
 His Pro Glu Tyr Tyr Lys Asp Cys Ser (SEQ ID NO:6).

30 An additional embodiment of the present invention relates to another DNA molecule encoding optimized HIV-1 Nef wherein the amino terminal myristylation site and dileucine motif have been deleted, as well as comprising a tPA leader peptide. This DNA molecule, opt tpanef (LLAA) comprises an open reading frame which encodes a Nef protein containing a tPA leader sequence fused to amino acid residue 6-216 of HIV-1 Nef (jfrl), wherein Leu-174 and Leu-175 are substituted with Ala-174

and Ala-175 (Ala-195 and Ala-196 in this tPA-based fusion protein). The nucleotide sequence comprising the open reading frame of opt tpanef (LLAA) is disclosed herein as SEQ ID NO:7, as shown below:

```

CATGGATGCA ATGAAGAGAG GGCTCTGCTG TGTGCTGCTG CTGTGTGGAG CAGTCTTCGT
5  TTCGCCCAGC GAGATCTCCT CCAAGAGGTC CGTGCCCGGC TGGTCCACCG TGAGGGAGAG
  GATGAGGAGG GCCGAGCCCG CCGCCGACAG GGTGAGGAGG ACCGAGCCCG CCGCCGTGGG
  CGTGGGCGCC GTGTCCAGGG ACCTGGAGAA GCACGGCGCC ATCACCTCCT CCAACACCGC
  CGCCACCAAC GCCGACTGCG CCTGGCTGGA GGCCAGGAG GACGAGGAGG TGGGCTTCCC
  CGTGAGGCCC CAGGTGCCCC TGAGGCCCAT GACCTACAAG GGCGCCGTGG ACCTGTCCCA
10  CTTCTGAAG GAGAAGGGCG GCCTGAGGGG CCTGATCCAC TCCCAGAAGA GGCAGGACAT
  CCTGGACCTG TGGGTGTACC ACACCAGGG CTACTTCCCC GACTGGCAGA ACTACACCCC
  CGGCCCCGGC ATCAGGTTC CCCTGACCTT CGGCTGGTGC TTCAAGCTGG TGCCCGTGGG
  GCCCGAGAAG GTGGAGGAGG CCAACGAGGG CGAGAACAAC TGCGCCGCC ACCCCATGTC
  CCAGCACGGC ATCGAGGACC CCGAGAAGGA GGTGCTGGAG TGGAGGTTCTG ACTCCAAGCT
15  GGCCTTCCAC CACGTGGCCA GGGAGCTGCA CCCCAGTAC TACAAGGACT GCTAAAGCCC
  (SEQ ID NO:7).

```

The open reading frame of SEQ ID NO:7 encoding tPA-Nef (LLAA), disclosed herein as SEQ ID NO:8, is as follows:

```

Met Asp Ala Met Lys Arg Gly Leu Cys Cys Val Leu Leu Leu Cys Gly
20  Ala Val Phe Val Ser Pro Ser Glu Ile Ser Ser Lys Arg Ser Val Pro
  Gly Trp Ser Thr Val Arg Glu Arg Met Arg Arg Ala Glu Pro Ala Ala
  Asp Arg Val Arg Arg Thr Glu Pro Ala Ala Val Gly Val Gly Ala Val
  Ser Arg Asp Leu Glu Lys His Gly Ala Ile Thr Ser Ser Asn Thr Ala
  Ala Thr Asn Ala Asp Cys Ala Trp Leu Glu Ala Gln Glu Asp Glu Glu
25  Val Gly Phe Pro Val Arg Pro Gln Val Pro Leu Arg Pro Met Thr Tyr
  Lys Gly Ala Val Asp Leu Ser His Phe Leu Lys Glu Lys Gly Gly Leu
  Glu Gly Leu Ile His Ser Gln Lys Arg Gln Asp Ile Leu Asp Leu Trp
  Val Tyr His Thr Gln Gly Tyr Phe Pro Asp Trp Gln Asn Tyr Thr Pro
  Gly Pro Gly Ile Arg Phe Pro Leu Thr Phe Gly Trp Cys Phe Lys Leu
30  Val Pro Val Glu Pro Glu Lys Val Glu Glu Ala Asn Glu Gly Glu Asn
  Asn Cys Ala Ala His Pro Met Ser Gln His Gly Ile Glu Asp Pro Glu
  Lys Glu Val Leu Glu Trp Arg Phe Asp Ser Lys Leu Ala Phe His His
  Val Ala Arg Glu Leu His Pro Glu Tyr Tyr Lys Asp Cys (SEQ ID NO:8).

```

The present invention also relates in part to any DNA molecule, regardless of

codon usage, which expresses a wild type or modified Nef protein as described herein, including but not limited to modified Nef proteins which comprise a deletion or substitution of Gly 2, a deletion of substitution of Leu 174 and Leu 175 and/or inclusion of a leader sequence. Therefore, partial or fully codon optimized DNA vaccine expression vector constructs are preferred since such constructs should result in increased host expression. However, it is within the scope of the present invention to utilize "non-codon optimized" versions of the constructs disclosed herein, especially modified versions of HIV Nef which are shown to promote a substantial cellular immune response subsequent to host administration.

The DNA backbone of the DNA vaccines of the present invention are preferably DNA plasmid expression vectors. DNA plasmid expression vectors are well known in the art and the present DNA vector vaccines may be comprised of any such expression backbone which contains at least a promoter for RNA polymerase transcription, and a transcriptional terminator 3' to the HIV nef coding sequence. In one preferred embodiment, the promoter is the Rous sarcoma virus (RSV) long terminal repeat (LTR) which is a strong transcriptional promoter. A more preferred promoter is the cytomegalovirus promoter with the intron A sequence (CMV-intA). A preferred transcriptional terminator is the bovine growth hormone terminator. In addition, to assist in large scale preparation of an HIV nef DNA vector vaccine, an antibiotic resistance marker is also preferably included in the expression vector. Ampicillin resistance genes, neomycin resistance genes or any other pharmaceutically acceptable antibiotic resistance marker may be used. In a preferred embodiment of this invention, the antibiotic resistance gene encodes a gene product for neomycin resistance. Further, to aid in the high level production of the pharmaceutical by fermentation in prokaryotic organisms, it is advantageous for the vector to contain an origin of replication and be of high copy number. Any of a number of commercially available prokaryotic cloning vectors provide these benefits. In a preferred embodiment of this invention, these functionalities are provided by the commercially available vectors known as pUC. It is desirable to remove non-essential DNA sequences. Thus, the lacZ and lacI coding sequences of pUC are removed in one embodiment of the invention.

DNA expression vectors exemplified herein are also disclosed in PCT International Application No. PCT/US94/02751, International Publication No. WO 94/21797, hereby incorporated by reference. A first DNA expression vector

is the expression vector pnRSV, wherein the rous sarcoma virus (RSV) long terminal repeat (LTR) is used as the promoter. A second embodiment relates to plasmid V1, a mutated pBR322 vector into which the CMV promoter and the BGH transcriptional terminator is cloned. Another embodiment regarding DNA vector backbones relates to plasmid VIJ. Plasmid VIJ is derived from plasmid V1 and removes promoter and transcription termination elements in order to place them within a more defined context, create a more compact vector, and to improve plasmid purification yields. Therefore, VIJ also contains the CMVintA promoter and (BGH) transcription termination elements which control the expression of the HIV nef-based genes disclosed herein. The backbone of VIJ is provided by pUC18. It is known to produce high yields of plasmid, is well-characterized by sequence and function, and is of minimum size. The entire *lac* operon was removed and the remaining plasmid was purified from an agarose electrophoresis gel, blunt-ended with the T4 DNA polymerase, treated with calf intestinal alkaline phosphatase, and ligated to the CMVintA/BGH element. In another DNA expression vector, the ampicillin resistance gene is removed from VIJ and replaced with a neomycin resistance gene, to generate VIJneo. A DNA expression vector specifically exemplified herein is VIJns, which is the same as VIJ except that a unique SfiI restriction site has been engineered into the single KpnI site at position 2114 of VIJ-neo. The incidence of SfiI sites in human genomic DNA is very low (approximately 1 site per 100,000 bases). Thus, this vector allows careful monitoring for expression vector integration into host DNA, simply by SfiI digestion of extracted genomic DNA. Another DNA expression vector for use as the backbone to the HIV-1 nef-based DNA vaccines of the present invention is VIR. In this vector, as much non-essential DNA as possible is "trimmed" from the vector to produce a highly compact vector. This vector is a derivative of VIJns. This vector allows larger inserts to be used, with less concern that undesirable sequences are encoded and optimizes uptake by cells when the construct encoding specific influenza virus genes is introduced into surrounding tissue.

It will be evident upon review of the teaching within this specification that numerous vector/Nef antigen constructs may be generated. While the exemplified constructs (VIJns/nef, VIJns/tpanef, VIJns/tpanef(LLAA) and VIJns/(G2A,LLAA) are preferred, any number of vector/Nef antigen combinations are within the scope of the present invention, especially wild type or modified Nef proteins which comprise a deletion or substitution of Gly 2, a deletion or substitution of Leu 174 and Leu 175

and/or inclusion of a leader sequence. Therefore, the present invention especially relates to DNA vaccines and a pharmaceutically active vaccine composition which contains this DNA vector vaccine, and the use as prophylactic and/or therapeutic vaccine for host immunization, preferably human host immunization, against an HIV infection or to combat an existing HIV condition. These DNA vaccines are represented by codon optimized DNA molecules encoding HIV-1 Nef of biologically active Nef modifications or Nef-containing fusion proteins which are ligated within an appropriate DNA plasmid vector, with or without a nucleotide sequence encoding a functional leader peptide. DNA vaccines of the present invention include but in no way are limited to codon optimized DNA molecules encoding HIV-1 Nef of biologically active Nef modifications or Nef-containing fusion proteins ligated in DNA vectors V1, V1J (SEQ ID NO:14), V1Jneo (SEQ ID NO:15), V1Jns (Figure 1A, SEQ ID NO:16), V1R (SEQ ID NO:26), or any of the aforementioned vectors wherein a nucleotide sequence encoding a leader peptide, preferably the human tPA leader, is fused directly downstream of the CMV-intA promoter, including but not limited to V1Jns-tpa, as shown in Figure 1B and SEQ ID NO:19. Especially preferred DNA vaccines of the present invention include as V1Jns/nef, V1Jns/tpanef, V1Jns/tpanef(LLAA) and V1Jns/(G2A,LLAA), as exemplified in Example Section 2.

The DNA vector vaccines of the present invention may be formulated in any pharmaceutically effective formulation for host administration. Any such formulation may be, for example, a saline solution such as phosphate buffered saline (PBS). It will be useful to utilize pharmaceutically acceptable formulations which also provide long-term stability of the DNA vector vaccines of the present invention. During storage as a pharmaceutical entity, DNA plasmid vaccines undergo a physiochemical change in which the supercoiled plasmid converts to the open circular and linear form. A variety of storage conditions (low pH, high temperature, low ionic strength) can accelerate this process. Therefore, the removal and/or chelation of trace metal ions (with succinic or malic acid, or with chelators containing multiple phosphate ligands) from the DNA plasmid solution, from the formulation buffers or from the vials and closures, stabilizes the DNA plasmid from this degradation pathway during storage. In addition, inclusion of non-reducing free radical scavengers, such as ethanol or glycerol, are useful to prevent damage of the DNA plasmid from free radical production that may still occur, even in apparently demetalated solutions. Furthermore, the buffer type, pH, salt concentration, light exposure, as well as the



type of sterilization process used to prepare the vials, may be controlled in the formulation to optimize the stability of the DNA vaccine. Therefore, formulations that will provide the highest stability of the DNA vaccine will be one that includes a demetalated solution containing a buffer (phosphate or bicarbonate) with a pH in the range of 7-8, a salt (NaCl, KCl or LiCl) in the range of 100-200 mM, a metal ion  
5 chelator (e.g., EDTA, diethylenetriaminepenta-acetic acid (DTPA), malate, inositol hexaphosphate, tripolyphosphate or polyphosphoric acid), a non-reducing free radical scavenger (e.g. ethanol, glycerol, methionine or dimethyl sulfoxide) and the highest appropriate DNA concentration in a sterile glass vial, packaged to protect the highly  
10 purified, nuclease free DNA from light. A particularly preferred formulation which will enhance long term stability of the DNA vector vaccines of the present invention would comprise a Tris-HCl buffer at a pH from about 8.0 to about 9.0; ethanol or glycerol at about 3% w/v; EDTA or DTPA in a concentration range up to about 5 mM; and NaCl at a concentration from about 50 mM to about 500 mM. The use of  
15 such stabilized DNA vector vaccines and various alternatives to this preferred formulation range is described in detail in PCT International Application No. PCT/US97/06655, PCT International Publication No. WO 97/40839, which is hereby incorporated by reference.

The DNA vector vaccines of the present invention may, in addition to  
20 generating a strong CTL-based immune response, provide for a measurable humoral response subsequent immunization. This response may occur with or without the addition of adjuvant to the respective vaccine formulation. To this end, the DNA vector vaccines of the present invention may also be formulated with an adjuvant or adjuvants which may increase immunogenicity of the DNA  
25 polynucleotide vaccines of the present invention. A number of these adjuvants are known in the art and are available for use in a DNA vaccine, including but not limited to particle bombardment using DNA-coated gold beads, co-administration of DNA vaccines with plasmid DNA expressing cytokines, chemokines, or costimulatory molecules, formulation of DNA with cationic lipids or with  
30 experimental adjuvants such as saponin, monophosphoryl lipid A or other compounds which increase immunogenicity of the DNA vaccine. One preferred adjuvant for use in the DNA vector vaccines of the present invention are one or more forms of an aluminum phosphate-based adjuvant. Aluminum phosphate is known in the art for use with live, killed or subunit vaccines, but is only recently

disclosed as a useful adjuvant in DNA vaccine formulations. The artisan may alter the ratio of DNA to aluminum phosphate to provide for an optimal immune response. In addition, the aluminum phosphate-based adjuvant possesses a molar  $\text{PO}_4/\text{Al}$  ratio of approximately 0.9, and may again be altered by the skilled artisan to provide for an optimal immune response. An additional mineral-based adjuvant may be generated from one or more forms of a calcium phosphate. These mineral-based adjuvants are useful in increasing humoral responses to DNA vaccination without imparting a negative effect on an appropriate cellular immune response. Complete guidance for use of these mineral-based compounds for use as DNA vaccines adjuvants are disclosed in PCT International Application No. PCT/US98/02414, PCT International Publication No. WO 98/35562, which are hereby incorporated by reference in their entirety. Another preferred adjuvant is a non-ionic block copolymer which shows adjuvant activity with DNA vaccines. The basic structure comprises blocks of polyoxyethylene (POE) and polyoxypropylene (POP) such as a POE-POP-POE block copolymer. Newman et al. (1998, *Critical Reviews in Therapeutic Drug Carrier Systems* 15(2): 89-142) review a class of non-ionic block copolymers which show adjuvant activity. The basic structure comprises blocks of polyoxyethylene (POE) and polyoxypropylene (POP) such as a POE-POP-POE block copolymer. Newman et al. *id.*, disclose that certain POE-POP-POE block copolymers may be useful as adjuvants to an influenza protein-based vaccine, namely higher molecular weight POE-POP-POE block copolymers containing a central POP block having a molecular weight of over about 9000 daltons to about 20,000 daltons and flanking POE blocks which comprise up to about 20% of the total molecular weight of the copolymer (see also U.S. Reissue Patent No. 36,665, U.S. Patent No. 5,567,859, U.S. Patent No. 5,691,387, U.S. Patent No. 5,696,298 and U.S. Patent No. 5,990,241, all issued to Emanuele, et al., regarding these POE-POP-POE block copolymers). WO 96/04932 further discloses higher molecular weight POE/POP block copolymers which have surfactant characteristics and show biological efficacy as vaccine adjuvants. The above cited references within this paragraph are hereby incorporated by reference in their entirety. It is therefore within the purview of the skilled artisan to utilize available adjuvants which may increase the immune response of the polynucleotide vaccines of the present invention in comparison to administration of a non-adjuvanted polynucleotide vaccine.

The DNA vector vaccines of the present invention are administered to the host by any means known in the art, such as enteral and parenteral routes. These routes of delivery include but are not limited to intramuscular injection, intraperitoneal injection, intravenous injection, inhalation or intranasal delivery, oral delivery, sublingual administration, subcutaneous administration, transdermal administration, transcutaneous administration, percutaneous administration or any form of particle bombardment, such as a biolistic device such as a "gene gun" or by any available needle-free injection device. The preferred methods of delivery of the HIV-1 Nef-based DNA vaccines disclosed herein are intramuscular injection and needle-free injection. An especially preferred method is intramuscular delivery.

The amount of expressible DNA to be introduced to a vaccine recipient will depend on the strength of the transcriptional and translational promoters used in the DNA construct, and on the immunogenicity of the expressed gene product. In general, an immunologically or prophylactically effective dose of about 1  $\mu$ g to greater than about 20 mg, and preferably in doses from about 1 mg to about 5 mg is administered directly into muscle tissue. As noted above, subcutaneous injection, intradermal introduction, impression through the skin, and other modes of administration such as intraperitoneal, intravenous, inhalation and oral delivery are also contemplated. It is also contemplated that booster vaccinations are to be provided in a fashion which optimizes the overall immune response to the Nef-based DNA vector vaccines of the present invention.

The aforementioned polynucleotides, when directly introduced into a vertebrate *in vivo*, express the respective HIV-1 Nef protein within the animal and in turn induce a cytotoxic T lymphocyte (CTL) response within the host to the expressed Nef antigen. To this end, the present invention also relates to methods of using the HIV-1 Nef-based polynucleotide vaccines of the present invention to provide effective immunoprophylaxis, to prevent establishment of an HIV-1 infection following exposure to this virus, or as a post-HIV infection therapeutic vaccine to mitigate the acute HIV-1 infection so as to result in the establishment of a lower virus load with beneficial long term consequences. As noted above, the present invention contemplates a method of administration or use of the DNA nef-based vaccines of the present invention using any of the known routes of introducing polynucleotides into living tissue to induce expression of proteins.

Therefore, the present invention provides for methods of using a DNA nef-

based vaccine utilizing the various parameters disclosed herein as well as any additional parameters known in the art, which, upon introduction into mammalian tissue induces *in vivo*, intracellular expression of these DNA nef-based vaccines. This intracellular expression of the Nef-based immunogen induces a CTL and humoral  
 5 response which provides a substantial level of protection against an existing HIV-1 infection or provides a substantial level of protection against a future infection in a presently uninfected host.

The following examples are provided to illustrate the present invention without, however, limiting the same hereto.

10

### EXAMPLE 1

#### Vaccine Vectors

*VI* – Vaccine vector *VI* was constructed from pCMVIE-AKI-DHFR (Whang et al., 1987, *J. Virol.* 61: 1796). The AKI and DHFR genes were removed by cutting  
 15 the vector with EcoRI and self-ligating. This vector does not contain intron A in the CMV promoter, so it was added as a PCR fragment that had a deleted internal SacI site [at 1855 as numbered in Chapman, et al., (1991, *Nuc. Acids Res.* 19: 3979)]. The template used for the PCR reactions was pCMVintA-Lux, made by ligating the HindIII and NheI fragment from pCMV6a120 (see Chapman et al., *ibid.*), which  
 20 includes hCMV-IE1 enhancer/promoter and intron A, into the HindIII and XbaI sites of pBL3 to generate pCMVintBL. The 1881 base pair luciferase gene fragment (HindIII-SmaI Klenow filled-in) from RSV-Lux (de Wet et al., 1987, *Mol. Cell Biol.* 7: 725) was ligated into the Sall site of pCMVintBL, which was Klenow filled-in and phosphatase treated. The primers that spanned intron A are: 5' primer:  
 25 5'-CTATATAAGCAGAGCTCGTTTAG-3' (SEQ ID NO:10); 3' primer:  
 5'-GTAGCAAAGATCTAAGGACGGTGACTGCAG-3' (SEQ ID NO:11). The primers used to remove the SacI site are: sense primer, 5'-GTATGTGTCTG AAAATGAGC GTGGAGATTGGGCTCGCAC-3' (SEQ ID NO:12) and the antisense primer, 5'-GTGCGAGCCCAATCTCCACGCTCATTTTCAGAC  
 30 ACATAC-3' (SEQ ID NO:13). The PCR fragment was cut with Sac I and Bgl II and inserted into the vector which had been cut with the same enzymes.

*VII* – Vaccine vector *VII* was generated to remove the promoter and transcription termination elements from vector *VI* in order to place them within a more defined context, create a more compact vector, and to improve plasmid

purification yields. V1J is derived from vectors V1 and pUC18, a commercially available plasmid. V1 was digested with SspI and EcoRI restriction enzymes producing two fragments of DNA. The smaller of these fragments, containing the CMVintA promoter and Bovine Growth Hormone (BGH) transcription termination elements which control the expression of heterologous genes, was purified from an agarose electrophoresis gel. The ends of this DNA fragment were then "blunted" using the T4 DNA polymerase enzyme in order to facilitate its ligation to another "blunt-ended" DNA fragment. pUC18 was chosen to provide the "backbone" of the expression vector. It is known to produce high yields of plasmid, is well- characterized by sequence and function, and is of small size. The entire *lac* operon was removed from this vector by partial digestion with the HaeII restriction enzyme. The remaining plasmid was purified from an agarose electrophoresis gel, blunt-ended with the T4 DNA polymerase treated with calf intestinal alkaline phosphatase, and ligated to the CMVintA/BGH element described above. Plasmids exhibiting either of two possible orientations of the promoter elements within the pUC backbone were obtained. One of these plasmids gave much higher yields of DNA in *E. coli* and was designated V1J. This vector's structure was verified by sequence analysis of the junction regions and was subsequently demonstrated to give comparable or higher expression of heterologous genes compared with V1. The nucleotide sequence of V1J is as follows:

```

TCGCGCGTTT CGGTGATGAC GGTGAAAACC TCTGACACAT GCAGCTCCCG GAGACGGTCA
CAGCTTGTCT GTAAGCGGAT GCCGGGAGCA GACAAGCCCG TCAGGGCGCG TCAGCGGGTG
TTGGCGGGTG TCGGGGCTGG CTTAACATG CGGCATCAGA GCAGATTGTA CTGAGAGTGC
ACCATATGCG GTGTGAAATA CCGCACAGAT GCGTAAGGAG AAAATACCGC ATCAGATTGG
25 CTATTGGCCA TTGCATACGT TGTATCCATA TCATAATATG TACATTTATA TTGGCTCATG
TCCAACATTA CCGCCATGTT GACATTGATT ATTGACTAGT TATTAATAGT AATCAATTAC
GGGGTCATTA GTTCATAGCC CATATATGGA GTTCCGCGTT ACATAACTTA CGGTAAATGG
CCCCTGTCG TGACCGCCCA ACGACCCCG CCCATTGACG TCAATAATGA CGTATGTTCC
CATAGTAACG CCAATAGGGA CTTTCCATTG ACGTCAATGG GTGGAGTATT TACGGTAAAC
30 TGCCCACTTG GCAGTACATC AAGTGTATCA TATGCCAAGT ACGCCCCCTA TTGACGTCAA
TGACGGTAAA TGGCCCGCCT GGCATTATGC CCAGTACATG ACCTTATGGG ACTTTCCTAC
TTGGCAGTAC ATCTACGTAT TAGTCATCGC TATTACCATG GTGATGCGGT TTTGGCAGTA
CATCAATGGG CGTGGATAGC GGTTTGACTC ACGGGGATTT CCAAGTCTCC ACCCCATTGA
CGTCAATGGG AGTTTGTTTT GGCACCAAAA TCAACGGGAC TTTCCAAAAT GTCGTAACAA

```

CTCCGCCCA TTGACGCAA TGGCGGTAG GCGGTACGG TGGGAGGTCT ATATAAGCAG  
 AGCTCGTTTA GTGAACCGTC AGATCGCCTG GAGACGCCAT CCACGCTGTT TTGACCTCCA  
 TAGAAGACAC CGGGACCGAT CCAGCTCCG CGGCCGGGAA CGGTGCATTG GAACGCGGAT  
 TCCCCGTGCC AAGAGTGACG TAAGTACCGC CTATAGAGTC TATAGGCCCA CCCCTTGCC  
 5 TTCTTATGCA TGCTATACTG TTTTGGCTT GGGGTCTATA CACCCCGCT TCCTCATGTT  
 ATAGGTGATG GTATAGCTTA GCCTATAGGT GTGGGTATT GACCATATT GACCACTCCC  
 CTATTGGTGA CGATACTTTC CATTACTAAT CCATAACATG GCTCTTTGCC ACAACTCTCT  
 TTATTGGCTA TATGCCAATA CACTGTCCTT CAGAGACTGA CACGGACTCT GTATTTTAC  
 AGGATGGGGT CTCATTTATT ATTTACAAAT TCACATATAC AACACCACCG TCCCCAGTGC  
 10 CCGCAGTTT TATTAAACAT AACGTGGGAT CTCCACGCGA ATCTCGGGTA CGTGTCCGG  
 ACATGGGCTC TTCTCCGTA GCGGCGGAGC TTCTACATCC GAGCCCTGCT CCCATGCCCTC  
 CAGCGACTCA TGGTCGCTCG GCAGCTCCTT GCTCCTAACA GTGGAGGCCA GACTTAGGCA  
 CAGCACGATG CCCACCACCA CCAGTGTGCC GCACAAGGCC GTGGCGGTAG GGTATGTGTC  
 TGAAATGAG CTCGGGGAGC GGGCTTGCAC CGCTGACGCA TTTGGAAGAC TTAAGGCAGC  
 15 GGCAGAAGAA GATGCAGGCA GCTGAGTTGT TGTGTTCTGA TAAGAGTCAG AGGTAACGCC  
 CGTTGCGGTG CTGTAAACGG TGGAGGGCAG TGTAGTCTGA GCAGTACTCG TTGCTGCCGC  
 GCGCGCCACC AGACATAATA GCTGACAGAC TAACAGACTG TTCCTTTCCA TGGGTCTTTT  
 CTGCAGTCAC CGTCCTTAGA TCTGCTGTGC CTCTAGTTG CCAGCCATCT GTTGTGTC  
 CCTCCCCCGT GCCTTCCTTG ACCCTGGAAG GTGCCACTCC CACTGTCTT TCCTAATAAA  
 20 ATGAGGAAAT TGCATCGCAT TGTCTGAGTA GGTGTCATT TATTCTGGGG GGTGGGGTGG  
 GGCAGCACAG CAAGGGGGAG GATTGGGAAG ACAATAGCAG GCATGCTGGG GATGCGGTGG  
 GCTCTATGGG TACCCAGGTG CTGAAGAATT GACCCGGTTC CTCCTGGGCC AGAAGAAGC  
 AGGCACATCC CCTTCTCTGT GACACACCCT GTCCACGCCC CTGGTTCTTA GTTCCAGCCC  
 CACTCATAGG AACTCATAG CTCAGGAGGG CTCCGCCTTC AATCCACCC GCTAAAGTAC  
 25 TTGGAGCGGT CTCTCCCTCC CTCATCAGCC CACCAAACCA AACCTAGCCT CCAAGAGTGG  
 GAAGAAATTA AAGCAAGATA GGCTATTAAG TGCAGAGGGA GAGAAATGC CTCCAACATG  
 TGAGGAAGTA ATGAGAGAAA TCATAGAATT TCTTCGCTT CCTCGCTCAC TGACTCGCTG  
 CGCTCGGTCG TTCGGCTGCG GCGAGCGGTA TCAGTCACT CAAAGGCGGT AATACGGTTA  
 TCCACAGAAT CAGGGGATAA CGCAGGAAAG AACATGTGAG CAAAAGGCCA GCAAAGGCC  
 30 AGGAACCGTA AAAAGGCCG GTTGTGGCG TTTTCCATA GGCTCCGCC CCCTGACGAG  
 CATCACAAA ATCGACGCTC AAGTCAGAGG TGGCGAAACC CGACAGGACT ATAAAGATAC  
 CAGGCGTTTC CCCCTGGAAG CTCCCTCGTG CGCTCTCTG TTCCGACCCT GCCGCTTACC  
 GGATACCTGT CCGCCTTTCT CCCCTCGGGA AGCGTGGCG TTTCTCAATG CTCACGCTGT  
 AGGTATCTCA GTTCGGTGTA GGTGTTCCG TCCAAGCTGG GCTGTGTGCA CGAACCCCCC

GTTCAGCCCG ACCGCTGCGC CTTATCCGGT AACTATCGTC TTGAGTCCAA CCCGGTAAGA  
 CACGACTTAT CGCCACTGGC AGCAGCCACT GGTAACAGGA TTAGCAGAGC GAGGTATGTA  
 GGCGGTGCTA CAGAGTTCCT GAAGTGGTGG CCTAACTACG GCTACACTAG AAGGACAGTA  
 TTTGGTATCT GCGCTCTGCT GAAGCCAGTT ACCTTCGGAA AAAGAGTTGG TAGCTCTTGA  
 5 TCCGGCAAAC AAACCACCGC TGGTAGCGGT GGTTTTTTTG TTGCAAGCA GCAGATTACG  
 CGCAGAAAAA AAGGATCTCA AGAAGATCCT TTGATCTTTT CTACGGGGTC TGACGCTCAG  
 TGGAACGAAA ACTCACGTTA AGGGATTTTG GTCATGAGAT TATCAAAAAG GATCTTCACC  
 TAGATCCTTT TAAATTAATA ATGAAGTTT AAATCAATCT AAAGTATATA TGAGTAAACT  
 TGGTCTGACA GTTACCAATG CTTAATCAGT GAGGCACCTA TCTCAGCGAT CTGTCTATTT  
 10 CGTTTCATCCA TAGTTGCC TGCTGCTGCT ACTCCCGTC GTGTAGATAA CTACGATACG GGAGGGCTTA  
 CCATCTGGCC CCAGTGCTGC AATGATACCG CGAGACCCAC GCTCACCAGG TCCAGATTTA  
 TCAGCAATAA ACCAGCCAGC CGGAAGGGCC GAGCGCAGAA GTGGTCCTGC AACTTTATCC  
 GCCTCCATCC AGTCTATTAA TTGTTGCCGG GAAGCTAGAG TAAGTAGTTC GCCAGTTAAT  
 AGTTTGCGCA ACGTTGTTGC CATGTGCTACA GGCATCGTGG TGTCACGCTC GTCGTTTGGT  
 15 ATGGGCTTCAT TCAGCTCCGG TTCCCAACGA TCAAGGCGAG TTACATGATC CCCCATGTTG  
 TGCAAAAAAG CGGTTAGCTC CTTCCGTCCT CCGATCGTTG TCAGAAGTAA GTTGGCCGCA  
 GTGTTATCAC TCATGGTTAT GGCAGCACTG CATAATTCTC TTAAGTGCAT GCCATCCGTA  
 AGATGCTTTT CTGTGACTGG TGAGTACTCA ACCAAGTCAT TCTGAGAATA GTGTATGCGG  
 CGACCGAGTT GCTCTTGCCC GCGTCAATA CGGGATAATA CCGCGCCACA TAGCAGAACT  
 20 TTAAAGTGC TCATCATTTG AAAACGTTCT TCGGGGCGAA AACTCTCAAG GATCTTACCG  
 CTGTTGAGAT CCAGTTCGAT GTAACCCACT CGTGCACCCA ACTGATCTTC AGCATCTTTT  
 ACTTTCACCA GCGTTTCTGG GTGAGCAAAA ACAGGAAGGC AAAATGCCGC AAAAAAGGGA  
 ATAAGGGCGA CACGGAATG TTGAATACTC ATACTCTTCC TTTTCAATA TTATTGAAGC  
 ATTTATCAGG GTTATTGTCT CATGAGCGGA TACATATTTG AATGTATTTA GAAAAATAAA  
 25 CAAATAGGGG TTCCGCGCAC ATTTCCCGA AAAGTGCCAC CTGACGTCTA AGAAACCATT  
 ATTATCATGA CATTAACCTA TAAAAATAGG CGTATCACGA GGCCCTTTTCG TC (SEQ ID  
 NO:14) .

*VIJneo* – Construction of vaccine vector *VIJneo* expression vector involved  
 removal of the *amp<sup>r</sup>* gene and insertion of the *kan<sup>r</sup>* gene (neomycin  
 30 phosphotransferase). The *amp<sup>r</sup>* gene from the pUC backbone of *VIJ* was removed by  
 digestion with *SspI* and *Eam1105I* restriction enzymes. The remaining plasmid was  
 purified by agarose gel electrophoresis, blunt-ended with T4 DNA polymerase, and  
 then treated with calf intestinal alkaline phosphatase. The commercially available  
*kan<sup>r</sup>* gene, derived from transposon 903 and contained within the pUC4K plasmid,

was excised using the PstI restriction enzyme, purified by agarose gel electrophoresis, and blunt-ended with T4 DNA polymerase. This fragment was ligated with the V1J backbone and plasmids with the kan<sup>r</sup> gene in either orientation were derived which were designated as V1Jneo #'s 1 and 3. Each of these plasmids was confirmed by  
 5 restriction enzyme digestion analysis, DNA sequencing of the junction regions, and was shown to produce similar quantities of plasmid as V1J. Expression of heterologous gene products was also comparable to V1J for these V1Jneo vectors. V1Jneo#3, referred to as V1Jneo hereafter, was selected which contains the kan<sup>r</sup> gene in the same orientation as the amp<sup>r</sup> gene in V1J as the expression construct and  
 10 provides resistance to neomycin, kanamycin and G418. The nucleotide sequence of V1Jneo is as follows:

```

TCGCGCGTTT CGGTGATGAC GGTGAAAACC TCTGACACAT GCAGCTCCCG GAGACGGTCA
CAGCTTGTCT GTAAGCGGAT GCCGGGAGCA GACAAGCCCG TCAGGGCGCG TCAGCGGGTG
TTGGCGGGTG TCGGGGCTGG CTTAACTATG CGGCATCAGA GCAGATTGTA CTGAGAGTGC
15 ACCATATGCG GTGTGAAATA CCGCACAGAT GCGTAAGGAG AAAATACCGC ATCAGATTGG
CTATTGGCCA TTGCATACGT TGTATCCATA TCATAATATG TACATTATA TTGGCTCATG
TCCAACATTA CCGCCATGTT GACATTGATT ATTGACTAGT TATTAATAGT AATCAATTAC
GGGGTCATTA GTTCATAGCC CATATATGGA GTTCCGCGTT ACATAACTTA CGGTAAATGG
CCCGCCTGGC TGACCGCCCA ACGACCCCGC CCCATTGACG TCAATAATGA CGTATGTTCC
20 CATAGTAACG CCAATAGGGA CTTTCCATTG ACGTCAATGG GTGGAGTATT TACGGTAAAC
TGCCCACTTG GCAGTACATC AAGTGTATCA TATGCCAAGT ACGCCCCCTA TTGACGTCAA
TGACGGTAAA TGGCCCGCCT GGCATTATGC CCAGTACATG ACCTTATGGG ACTTTCCTAC
TTGGCAGTAC ATCTACGTAT TAGTCATCGC TATTACCATG GTGATGCGGT TTTGGCAGTA
CATCAATGGG CGTGGATAGC GGTTTGACTC ACGGGGATTT CCAAGTCTCC ACCCCATTGA
25 CGTCAATGGG AGTTTGTTTT GGCACCAAAA TCAACGGGAC TTTCCAAAAT GTCGTAACAA
CTCCGCCCCA TTGACGCAAA TGGGCGGTAG GCGTGTACGG TGGGAGGTCT ATATAAGCAG
AGCTCGTTTA GTGAACCGTC AGATCGCCTG GAGACGCCAT CCACGCTGTT TTGACCTCCA
TAGAAGACAC CGGGACCGAT CCAGCCTCCG CGGCCGGGAA CCGTGCATTG GAACGCGGAT
TCCCCGTGCC AAGAGTGACG TAAGTACCGC CTATAGAGTC TATAGGCCCA CCCCTTGGC
30 TTCTTATGCA TGCTATACTG TTTTGGCTT GGGGTCTATA CACCCCGCT TCCTCATGTT
ATAGGTGATG GTATAGCTTA GCCTATAGGT GTGGGTATT GACCATTATT GACCACTCCC
CTATTGGTGA CGATACTTTC CATTACTAAT CCATAACATG GCTCTTTGCC ACAACTCTCT
TTATGGCTA TATGCCAATA CACTGTCCTT CAGAGACTGA CACGGACTCT GTATTTTAC
AGGATGGGGT CTCATTATTT ATTTACAAAT TCACATATAC AACACCACCG TCCCCAGTGC

```



CCGCAGTTTT TATTAAACAT AACGTGGGAT CTCCACGCGA ATCTCGGGTA CGTGTTCCGG  
 ACATGGGCTC TTCTCCGGTA GCGGCGGAGC TTCTACATCC GAGCCCTGCT CCCATGCCCTC  
 CAGCGACTCA TGGTCGCTCG GCAGCTCCTT GCTCCTAACA GTGGAGGCCA GACTTAGGCA  
 CAGCACGATG CCCACCACCA CCAGTGTGCC GCACAAGGCC GTGGCGGTAG GGTATGTGTC  
 5 TGAAAAATGAG CTCGGGGAGC GGGCTTGAC CGCTGACGCA TTTGGAAGAC TTAAGGCAGC  
 GGCAGAAGAA GATGCAGGCA GCTGAGTTGT TGTGTTCTGA TAAGAGTCAG AGGTAACCTC  
 CGTTGCGGTG CTGTTAACGG TGGAGGGCAG TGTAGTCTGA GCAGTACTCG TTGCTGCCGC  
 GCGCGCCACC AGACATAATA GCTGACAGAC TAACAGACTG TTCTTTTCCA TGGGTCTTTT  
 CTGCAGTCAC CGTCTTAGA TCTGCTGTGC CTCTAGTTG CCAGCCATCT GTTGTTCGCC  
 10 CCTCCCCCGT GCCTTCCTTG ACCCTGGAAG GTGCCACTCC CACTGTCTT TCCTAATAAA  
 ATGAGGAAAT TGCATCGCAT TGTCTGAGTA GGTGTCATTC TATTCTGGGG GGTGGGGTGG  
 GGCAGCACAG CAAGGGGGAG GATTGGGAAG ACAATAGCAG GCATGCTGGG GATGCGGTGG  
 GCTCTATGGG TACCCAGGTG CTGAAGAATT GACCCGGTTC CTCTGGGCC AGAAAGAAGC  
 AGGCACATCC CCTTCTCTGT GACACACCCT GTCCACGCCC CTGGTCTTA GTTCCAGCCC  
 15 CACTCATAGG AACTCATAG CTCAGGAGGG CTCCGCCTTC AATCCCACCC GCTAAAGTAC  
 TTGGAGCGGT CTCTCCCTCC CTCATCAGCC CACCAAACCA AACCTAGCCT CCAAGAGTGG  
 GAAGAAATTA AAGCAAGATA GGCTATTAAG TGCAGAGGGA GAGAAAATGC CTCCAACATG  
 TGAGGAAGTA ATGAGAGAAA TCATAGAATT TCTTCCGCTT CCTCGCTCAC TGACTCGCTG  
 CGCTCGGTG TTCGGCTGCG GCGAGCGGTA TCAGCTCACT CAAAGGCGGT AATACGGTTA  
 20 TCCACAGAAAT CAGGGGATAA CGCAGGAAAG AACATGTGAG CAAAAGGCCA GCAAAAGGCC  
 AGGAACCGTA AAAAGGCCGC GTTGCTGGCG TTTTCCATA GGCTCCGCC CCCTGACGAG  
 CATCAGAAA ATCGACGCTC AAGTCAGAGG TGGCGAAACC CGACAGGACT ATAAAGATAC  
 CAGGCGTTTC CCCCTGGAAG CTCCCTCGTG CGCTCTCCTG TTCCGACCCT GCCGCTTACC  
 GGATACCTGT CCGCCTTTCT CCCTTCGGGA AGCGTGGCG TTTCTCAATG CTCACGCTGT  
 25 AGGTATCTCA GTTCGGTGTA GGTGTTTCG TCCAAGCTGG GCTGTGTGCA CGAACCCCCC  
 GTTCAGCCCG ACCGCTGCGC CTTATCCGGT AACTATCGTC TTGAGTCCAA CCCGGTAAGA  
 CACGACTTAT CGCCACTGGC AGCAGCCACT GGTAACAGGA TTAGCAGAGC GAGGTATGTA  
 GGCGGTGCTA CAGAGTTCTT GAAGTGGTGG CCTAACTACG GCTACACTAG AAGGACAGTA  
 TTTGGTATCT GCGCTCTGCT GAAGCCAGTT ACCTTCGGA AAAGAGTTGG TAGCTCTTGA  
 30 TCCGGCAAAC AAACCACCGC TGGTAGCGGT GGTTTTTTTG TTTGCAAGCA GCAGATTACG  
 CGCAGAAAAA AAGGATCTCA AGAAGATCCT TTGATCTTTT CTACGGGGTC TGACGCTCAG  
 TGGAACGAAA ACTCACGTTA AGGGATTTTG GTCATGAGAT TATCAAAAAG GATCTTCACC  
 TAGATCCTTT TAAATTAATA ATGAAGTTTT AAATCAATCT AAAGTATATA TGAGTAAACT  
 TGGTCTGACA GTTACCAATG CTTAATCAGT GAGGCACCTA TCTCAGCGAT CTGTCTATTT

CGTTCATCCA TAGTTGCCTG ACTCCGGGGG GGGGGGGCGC TGAGGTCTGC CTCGTGAAGA  
 AGGTGTTGCT GACTCATACC AGGCCTGAAT CGCCCCATCA TCCAGCCAGA AAGTGAGGGA  
 GCCACGGTTG ATGAGAGCTT TGTGTAGGT GGACCAGTTG GTGATTTTGA ACTTTTGCTT  
 TGCCACGGAA CGGTCTGCGT TGTCGGGAAG ATGCGTGATC TGATCCTTCA ACTCAGCAAA  
 5 AGTTCGATTT ATTCAACAAA GCCGCCGTCC CGTCAAGTCA GCGTAATGCT CTGCCAGTGT  
 TACAACCAAT TAACCAATTC TGATTAGAAA AACTCATCGA GCATCAAATG AAAGTGAAT  
 TTATTCATAT CAGGATTATC AATACCATAT TTTTGAAAAA GCCGTTTCTG TAATGAAGGA  
 GAAAACTCAC CGAGGCAGTT CCATAGGATG GCAAGATCCT GGTATCGGTC TGCATTCCG  
 ACTCGTCCAA CATCAATACA ACCTATTAAT TTCCCTCGT CAAAAATAAG GTTATCAAGT  
 10 GAGAAATCAC CATGAGTGAC GACTGAATCC GGTGAGAATG GCAAAAGCTT ATGCATTTCT  
 TTCCAGACTT GTTCAACAGG CCAGCCATTA CGCTCGTCAT CAAAATCACT CGCATCAACC  
 AAACCGTTAT TCATTCGTGA TTGCGCCTGA GCGAGACGAA ATACGCGATC GCTGTTAAAA  
 GGACAATTAC AAACAGGAAT CGAATGCAAC CGGCGCAGGA AACTGCCAG CGCATCAACA  
 ATATTTTCAC CTGAATCAGG ATATTCTTCT AATACCTGGA ATGCTGTTTT CCCGGGGATC  
 15 GCAGTGGTGA GTAACCATGC ATCATCAGGA GTACGGATAA AATGCTTGAT GGTGCGAAGA  
 GGCATAAAT CCGTCAGCCA GTTTAGTCTG ACCATCTCAT CTGTAACATC ATTGGCAACG  
 CTACCTTTGC CATGTTTCAG AAACAACCTT GGCGCATCGG GCTTCCCATTA CAATCGATAG  
 ATTGTCGCAC CTGATTGCCC GACATTATCG CGAGCCCAT TATACCCATA TAAATCAGCA  
 TCCATGTTGG AATTTAATCG CGGCCTCGAG CAAGACGTTT CCCGTTGAAT ATGGCTCATA  
 20 ACACCCCTTG TATTACTGTT TATGTAAGCA GACAGTTTTA TTGTTTCATGA TGATATATTT  
 TTATCTTG TG CAATGTAACA TCAGAGATTT TGAGACACAA CGTGGCTTTC CCCCCCCCCC  
 CATTATTGAA GCATTTATCA GGGTTATTGT CTCATGAGCG GATACATATT TGAATGTATT  
 TAGAAAAATA AACAAATAGG GGTTCGCGC ACATTTCCTC GAAAAGTGCC ACCTGACGTC  
 TAAGAAACCA TTATTATCAT GACATTAACC TATAAAAATA GCGGTATCAC GAGGCCCTTT  
 25 CGTC (SEQ ID NO:15).

*V1Jns* - The expression vector *V1Jns* was generated by adding an *Sfi*I site to  
*V1Jneo* to facilitate integration studies. A commercially available 13 base pair *Sfi*I  
 linker (New England BioLabs) was added at the *Kpn*I site within the BGH sequence  
 of the vector. *V1Jneo* was linearized with *Kpn*I, gel purified, blunted by T4 DNA  
 30 polymerase, and ligated to the blunt *Sfi*I linker. Clonal isolates were chosen by  
 restriction mapping and verified by sequencing through the linker. The new vector  
 was designated *V1Jns*. Expression of heterologous genes in *V1Jns* (with *Sfi*I) was  
 comparable to expression of the same genes in *V1Jneo* (with *Kpn*I).

The nucleotide sequence of *V1Jns* is as follows:

TCGCGCGTTT CGGTGATGAC GGTGAAAACC TCTGACACAT GCAGCTCCCG GAGACGGTCA  
CAGCTTGTCT GTAAGCGGAT GCCGGGAGCA GACAAGCCCG TCAGGGCGCG TCAGCGGGTG  
TTGGCGGGTG TCGGGGCTGG CTTAACTATG CGGCATCAGA GCAGATTGTA CTGAGAGTGC  
ACCATATGCG GTGTGAAATA CCGCACAGAT GCGTAAGGAG AAAATACCGC ATCAGATTGG  
5 CTATTGGCCA TTGCATACGT TGTATCCATA TCATAATATG TACATTTATA TTGGCTCATG  
TCCAACATTA CCGCCATGTT GACATTGATT ATTGACTAGT TATTAATAGT AATCAATTAC  
GGGGTCATTA GTTCATAGCC CATATATGGA GTTCCGCGTT ACATAACTTA CGGTAAATGG  
CCCGCCTGGC TGACCGCCCA ACGACCCCG CCCATTGACG TCAATAATGA CGTATGTTCC  
CATAGTAACG CCAATAGGGA CTTTCCATTG ACGTCAATGG GTGGAGTATT TACGGTAAAC  
10 TGCCCACTTG GCAGTACATC AAGTGTATCA TATGCCAAGT ACGCCCCCTA TTGACGTCAA  
TGACGGTAAA TGGCCCGCCT GGCATTATGC CCAGTACATG ACCTTATGGG ACTTTCCTAC  
TTGGCAGTAC ATCTACGTAT TAGTCATCGC TATTACCATG GTGATGCGGT TTTGGCAGTA  
CATCAATGGG CGTGGATAGC GGTTTGACTC ACGGGGATTT CCAAGTCTCC ACCCCATTGA  
CGTCAATGGG AGTTTGT TTTT GGCACCAAAA TCAACGGGAC TTTCCAAAAT GTCGTAACAA  
15 CTCCGCCCCA TTGACGCAAA TGGGCGGTAG GCGTGACGG TGGGAGGTCT ATATAAGCAG  
AGCTCGTTTA GTGAACCGTC AGATCGCCTG GAGACGCCAT CCACGCTGTT TTGACCTCCA  
TAGAAGACAC CGGGACCGAT CCAGCCTCCG CGGCCGGGAA CGGTGCATTG GAACGCGGAT  
TCCCGTGCC AAGAGTGACG TAAGTACCGC CTATAGACTC TATAGGCACA CCCCTTTGGC  
TCTTATGCAT GCTATACTGT TTTTGGCTTG GGGCCTATAC ACCCCGCTT CCTTATGCTA  
20 TAGGTGATGG TATAGCTTAG CCTATAGGTG TGGGTATTG ACCATTATTG ACCACTCCCC  
TATTGGTGAC GATACTTTCC ATTACTAATC CATAACATGG CTCTTTGCCA CAACTATCTC  
TATTGGCTAT ATGCCAATAC TCTGTCTTC AGAGACTGAC ACGGACTCTG TATTTTACA  
GGATGGGGTC CCATTTATTA TTTACAAAT CACATATACA ACAACGCCGT CCCCCGTGCC  
CGCAGTTTTT ATTAAACATA GCGTGGGATC TCCACGCGAA TCTCGGTAC GTGTTCCGGA  
25 CATGGGCTCT TCTCCGTAG CGGCGGAGCT TCCACATCCG AGCCCTGGTC CCATGCCTCC  
AGCGGCTCAT GGTGCTCGG CAGCTCCTTG CTCCTAACAG TGGAGGCCAG ACTTAGGCAC  
AGCACAATGC CCACCACCAC CAGTGTGCCG CACAAGGCCG TGGCGGTAGG GTATGTGTCT  
GAAAATGAGC GTGGAGATTG GGCTCGCACG GCTGACGCAG ATGGAAGACT TAAGGCAGCG  
GCAGAAGAAG ATGCAGGCAG CTGAGTTGTT GTATTCTGAT AAGAGTCAGA GGTAACTCCC  
30 GTTGCGGTGC TGTTAACGGT GGAGGGCAGT GTAGTCTGAG CAGTACTCGT TGCTGCCGCG  
CGCGCCACCA GACATAATAG CTGACAGACT AACAGACTGT TCCTTTCCAT GGGTCTTTTC  
TGCAGTCACC GTCCTTAGAT CTGCTGTGCC TTCTAGTTGC CAGCCATCTG TTGTTTGCCC  
CTCCCCGTG CCTTCCTTGA CCCTGGAAGG TGCCACTCCC ACTGTCCTTT CCTAATAAAA  
TGAGGAAAT GCATCGCATT GTCTGAGTAG GTGTCATTCT ATTCTGGGGG GTGGGGTGGG

GCAGGACAGC AAGGGGGAGG ATTGGGAAGA CAATAGCAGG CATGCTGGGG ATGCGGTGGG  
CTCTATGGCC GCTGCGGCCA GGTGCTGAAG AATTGACCCG GTTCCTCCTG GGCCAGAAAG  
AAGCAGGCAC ATCCCTTCT CTGTGACACA CCCTGTCCAC GCCCCTGGTT CTTAGTTCCA  
GCCCCACTCA TAGGACTCTC ATAGCTCAGG AGGGCTCCGC CTTCAATCCC ACCCGCTAAA  
5 GTACTTGGAG CGGTCTCTCC CTCCCTCATC AGCCACCAA ACCAAACCTA GCCTCCAAGA  
GTGGGAAGAA ATTAAAGCAA GATAGGCTAT TAAGTGAGA GGGAGAGAAA ATGCCTCCAA  
CATGTGAGGA AGTAATGAGA GAAATCATAG AATTTCCTCC GCTTCCTCGC TCACTGACTC  
GCTGCGCTCG GTCGTTCGGC TCGGCGGAGC GGTATCAGCT CACTCAAAGG CGGTAATACG  
GTTATCCACA GAATCAGGGG ATAACGCAGG AAAGAACATG TGAGCAAAAG GCCAGCAAAA  
10 GGCCAGGAAC CGTAAAAAG CCGCTTGCT GCGGTTTTC CATAGGCTCC GCCCCCTGA  
CGAGCATCAC AAAAATCGAC GCTCAAGTCA GAGGTGGCGA AACCCGACAG GACTATAAAG  
ATACCAGGCG TTCCCTCTG GAAGCTCCCT CGTGCCTCT CCTGTTCCGA CCCTGCCGCT  
TACCGGATAC CTGTCCGCTT TTCTCCCTTC GGAAGCGTG GCGCTTCTC ATAGCTCAGC  
CTGTAGGTAT CTCAGTTCGG TGTAGGTCGT TCGCTCCAAG CTGGGTGTG TGCACGAACC  
15 CCCCCTTCAG CCCGACCGCT GCGCCTTATC CGGTAACAT CGTCTTGAGT CCAACCCGGT  
AAGACACGAC TTATCGCCAC TGGCAGCAGC CACTGGTAAC AGGATTAGCA GAGCGAGGTA  
TGTAGGCGGT GCTACAGAGT TCTTGAAGTG GTGGCCTAAC TACGGCTACA CTAGAAGAAC  
AGTATTTGGT ATCTGCGCTC TGCTGAAGCC AGTTACCTTC GGAAAAAGAG TTGGTAGCTC  
TTGATCCGCG AAACAAACCA CCGCTGGTAG CGGTGGTTTT TTTGTTTGCA AGCAGCAGAT  
20 TACGCGCAGA AAAAAAGGAT CTCAGAAGA TCCTTTGATC TTTTCTACGG GGTCTGACGC  
TCAGTGGAAC GAAAACTCAC GTTAAGGGAT TTGGTTCATG AGATTATCAA AAAGGATCTT  
CACCTAGATC CTTTTAAATT AAAAATGAAG TTTTAAATCA ATCTAAAGTA TATATGAGTA  
AACTTGGTCT GACAGTTACC AATGCTTAAT CAGTGAGGCA CCTATCTCAG CGATCTGTCT  
ATTTCTGTTCA TCCATAGTTG CCTGACTCGG GGGGGGGGGG CGCTGAGGTC TGCTCTGTGA  
25 AGAAGGTGTT GCTGACTCAT ACCAGGCCTG AATCGCCCCA TCATCCAGCC AGAAAGTGAG  
GGAGCCACGG TTGATGAGAG CTTTGTGTGA GGTGGACCAG TTGGTGATTT TGAACTTTTG  
CTTTGCCACG GAACGGTCTG CGTTGTCGGG AAGATGCGTG ATCTGATCCT TCAACTCAGC  
AAAAGTTCCA TTTATTCAAC AAAGCCGCGG TCCCGTCAAG TCAGCGTAAT GCTCTGCCAG  
TGTTACAACC AATTAACCAA TTCTGATTAG AAAAATCAT CGAGCATCAA ATGAACTGTC  
30 AATTTATTCA TATCAGGATT ATCAATACCA TATTTTGTGA AAAGCCGTTT CTGTAATGAA  
GGAGAAAAT CACCGAGGCA GTTCCATAGG ATGGCAAGAT CCTGGTATCG GTCTGCGATT  
CCGACTCGTC CAACATCAAT ACAACCTATT AATTCCCTT CGTCAAAAAT AAGGTTATCA  
AGTGAGAAAT CACCATGAGT GACGACTGAA TCCGGTGAGA ATGGCAAAAG CTTATGCATT  
TCTTTCAGA CTTGTTCAAC AGGCCAGCCA TTACGCTCGT CATCAAAATC ACTCGCATCA

ACCAAACCGT TATTCATTCTG TGATTGCGCC TGAGCGAGAC GAAATACGCG ATCGCTGTTA  
 AAAGGACAAT TACAAACAGG AATCGAATGC AACCGGCGCA GGAACACTGC CAGCGCATCA  
 ACAATATTTT CACCTGAATC AGGATATTCT TCTAATACCT GGAATGCTGT TTTCCCGGGG  
 ATCGCAGTGG TGAGTAACCA TGCATCATCA GGAGTACGGA TAAATGCTT GATGGTCGGA  
 5 AGAGGCATAA ATTCCGTCAG CCAGTTTAGT CTGACCATCT CATCTGTAAC ATCATGGCA  
 ACGCTACCTT TGCCATGTTT CAGAAACAAC TCTGGCGCAT CGGGCTTCCC ATACAATCGA  
 TAGATTGTCG CACCTGATTG CCCGACATTA TCGCGAGCCC ATTTATACCC ATATAAATCA  
 GCATCCATGT TGAATTTAA TCGCGGCCTC GAGCAAGACG TTTCCCGTTG AATATGGCTC  
 ATAACACCCC TTGTATTACT GTTTATGTAA GCAGACAGTT TTATTGTTCA TGATGATATA  
 10 TTTTATCTT GTGCAATGTA ACATCAGAGA TTTTGAGACA CAACGTGGCT TTCCCCCCCC  
 CCCCATTTATT GAAGCATTTA TCAGGGTTAT TGTCTCATGA GCGGATACAT ATTTGAATGT  
 ATTTAGAAAA ATAAACAAAT AGGGGTTCG CGCACATTTC CCCGAAAAGT GCCACCTGAC  
 GTCTAAGAAA CCATTATTAT CATGACATTA ACCTATAAAA ATAGGCGTAT CACGAGGCC  
 TTTCGTC (SEQ ID NO:16) .

15 The underlined nucleotides of SEQ ID NO:16 represent the Sfi I site introduced into the Kpn I site of V1Jneo.

*V1Jns-tPA* – The vaccine vector V1Jns-tPA was constructed in order to fuse an heterologous leader peptide sequence to the nef DNA constructs of the present invention. More specifically, the vaccine vector V1Jns was modified to include the
 20 human tissue-specific plasminogen activator (tPA) leader. As an exemplification, but by no means a limitation of generating a nef DNA construct comprising an amino-terminal leader sequence, plasmid V1Jneo was modified to include the human tissue-specific plasminogen activator (tPA) leader. Two synthetic complementary oligomers were annealed and then ligated into V1Jneo which had been BglII digested. The
 25 sense and antisense oligomers were 5' GATCACCATGGATGCAATGAAGAGAG GGCTCTGCTGTGTGCTGCTGCTGTGTGGAGCAGTCTTCGTTTCGCCCAG CGA-3' (SEQ ID NO:17); and, 5'-GATCTCGCTGGGCGAAACGAAGACTGC TCCACACAGCAGCAGCACACAGCAGAGCCCTCTCTTCATTGCATCCAT GGT-3' (SEQ ID NO:18). The Kozak sequence is underlined in the sense oligomer.
 30 These oligomers have overhanging bases compatible for ligation to BglII-cleaved sequences. After ligation the upstream BglII site is destroyed while the downstream BglII is retained for subsequent ligations. Both the junction sites as well as the entire tPA leader sequence were verified by DNA sequencing. Additionally, in order to conform with V1Jns (=V1Jneo with an Sfi I site), an Sfi I restriction site was placed at

the KpnI site within the BGH terminator region of VIJneo-tPA by blunting the KpnI site with T4 DNA polymerase followed by ligation with an SfiI linker (catalogue #1138, New England Biolabs), resulting in VIJns-tPA. This modification was verified by restriction digestion and agarose gel electrophoresis.

5 The VIJns-tpa vector nucleotide sequence is as follows:

```

TCGCGCGTTT CGGTGATGAC GGTGAAAACC TCTGACACAT GCAGCTCCCG GAGACGGTCA
CAGCTTGTCT GTAAGCGGAT GCCGGGAGCA GACAAGCCCG TCAGGGCGCG TCAGCGGGTG
TTGGCGGGTG TCGGGGCTGG CTTAACTATG CGGCATCAGA GCAGATTGTA CTGAGAGTGC
ACCATATGCG GTGTGAAATA CCGCACAGAT GCGTAAGGAG AAAATACCGC ATCAGATTGG
10 CTATTGGCCA TTGCATACGT TGTATCCATA TCATAATATG TACATTTATA TTGGCTCATG
TCCAACATTA CCGCCATGTT GACATTGATT ATTGACTAGT TATTAATAGT AATCAATTAC
GGGGTCATTA GTTCATAGCC CATATATGGA GTTCCGCGTT ACATAACTTA CGGTAAATGG
CCCGCCTGGC TGACCGCCCA ACGACCCCG CCCATTGACG TCAATAATGA CGTATGTTCC
CATAGTAACG CCAATAGGGA CTTTCCATTG ACGTCAATGG GTGGAGTATT TACGGTAAAC
15 TGCCCACTTG GCAGTACATC AAGTGTATCA TATGCCAAGT ACGCCCCCTA TTGACGTCAA
TGACGGTAAA TGGCCCGCCT GGCATTATGC CCAGTACATG ACCTTATGGG ACTTTCCTAC
TTGGCAGTAC ATCTACGTAT TAGTCATCGC TATTACCATG GTGATGCGGT TTTGGCAGTA
CATCAATGGG CGTGGATAGC GGTTTGACTC ACGGGGATTT CCAAGTCTCC ACCCCATTGA
CGTCAATGGG AGTTTGT TTTT GGCACAAAA TCAACGGGAC TTTCCAAAAT GTCGTAACAA
20 CTCCGCCCA TTGACGCAAA TGGGCGGTAG GCGTGTACGG TGGGAGGTCT ATATAAGCAG
AGCTCGTTTA GTGAACCGTC AGATCGCCTG GAGACGCCAT CCACGCTGTT TTGACCTCCA
TAGAAGACAC CGGGACCGAT CCAGCCTCCG CGGCCGGGAA CGGTGCATTG GAACGCGGAT
TCCCGTGCC AAGAGTGACG TAAGTACCGC CTATAGACTC TATAGGCACA CCCCTTTGGC
TCTTATGCAT GCTATACTGT TTTTGGCTTG GGGCCTATAC ACCCCCGCTT CCTTATGCTA
25 TAGGTGATGG TATAGCTTAG CCTATAGGTG TGGGTATTG ACCATTATTG ACCACTCCCC
TATTGGTGAC GATACTTTCC ATTACTAATC CATAACATGG CTCTTTGCCA CAACTATCTC
TATTGGCTAT ATGCCAATAC TCTGTCCCTC AGAGACTGAC ACGGACTCTG TATTTTTACA
GGATGGGGTC CCATTTATTA TTTACAAAT CACATATACA ACAACGCCGT CCCCCGTGCC
CGCAGTTTTT ATTAAACATA GCGTGGGATC TCCACGCGAA TCTCGGGTAC GTGTTCCGGA
30 CATGGGCTCT TCTCCGGTAG CGGCGGAGCT TCCACATCCG AGCCCTGGTC CCATGCCTCC
AGCGGCTCAT GGTGCTCGG CAGCTCCTTG CTCCTAACAG TGGAGGCCAG ACTTAGGCAC
AGCACAATGC CCACCACCAC CAGTGTGCCG CACAAGGCCG TGGCGGTAGG GTATGTGTCT
GAAAATGAGC GTGGAGATTG GGCTCGCACG GCTGACGCAG ATGGAAGACT TAAGGCAGCG
GCAGAAGAAG ATGCAGGCAG CTGAGTTGTT GTATTCTGAT AAGAGTCAGA GGTAACCTCCC

```

GTTGCGGTGC TGTTAACGGT GGAGGGCAGT GTAGTCTGAG CAGTACTCGT TGCTGCCGCG  
 CGCGCCACCA GACATAATAG CTGACAGACT AACAGACTGT TCCTTTCCAT GGGTCTTTTC  
 TGCAGTCACC GTCCTTAGAT CACCATGGAT GCAATGAAGA GAGGGCTCTG CTGTGTGCTG  
CTGCTGTGTG GAGCAGTCTT CGTTTCGCCC AGCGAGATCT GCTGTGCCTT CTAGTTGCCA  
 5 GCCATCTGTT GTTTGCCCTT CCCCCGTGCC TTCCTTGACC CTGGAAGGTG CCACTCCAC  
 TGTCTTTTCC TAATAAAATG AGGAAATTGC ATCGCATTGT CTGAGTAGGT GTCATTCTAT  
 TCTGGGGGGT GGGGTGGGGC AGGACAGCAA GGGGAGGAT TGGGAAGACA ATAGCAGGCA  
 TGCTGGGGAT GCGGTGGGCT CTATGGCCGC TGCGGCCAGG TGCTGAAGAA TTGACCCGGT  
 TCCTCCTGGG CCAGAAAGAA GCAGGCACAT CCCCTTCTCT GTGACACACC CTGTCCACGC  
 10 CCCTGGTTCT TAGTTCCAGC CCCACTATA GGACACTCAT AGCTCAGGAG GGCTCCGCCT  
 TCAATCCAC CCCTAAAGT ACTTGAGCG GTCTCTCCCT CCCTCATCAG CCCACCAAAC  
 CAAACCTAGC CTCCAAGAGT GGGAAGAAAT TAAAGCAAGA TAGGCTATTA AGTGCAGAGG  
 GAGAGAAAAT GCCTCCAACA TGTGAGGAAG TAATGAGAGA AATCATAGAA TTTCTTCCGC  
 TTCTCGCTC ACTGACTCGC TCGCTCGGT CGTTCGGCTG CGGCGAGCGG TATCAGCTCA  
 15 CTCAAAGGCG GTAATACGGT TATCCACAGA ATCAGGGGAT AACGCAGGAA AGAACATGTG  
 AGCAAAAGGC CAGCAAAAGG CCAGGAACCG TAAAAGGCC GCGTTGCTGG CGTTTTTCCA  
 TAGGCTCCGC CCCCTGACG AGCATCACAA AAATCGACGC TCAAGTCAGA GGTGGCGAAA  
 CCCGACAGGA CTATAAGAT ACCAGGCGTT TCCCCCTGGA AGCTCCCTCG TCGCTCTCC  
 TGTTCCGACC CTGCCGCTTA CCGGATACCT GTCCGCCTTT CTCCCTTCGG GAAGCGTGGC  
 20 GCTTCTCAT AGCTCACGCT GTAGGTATCT CAGTTCGGTG TAGGTCGTTT GCTCCAAGCT  
 GGGCTGTGTG CACGAACCCC CCGTTCAGCC CGACCGCTGC GCCTTATCCG GTAACATCG  
 TCTTGAGTCC AACCCGGTAA GACACGACTT ATCGCCACTG GCAGCAGCCA CTGGAACAG  
 GATTAGCAGA GCGAGGTATG TAGGCGGTGC TACAGAGTTC TTGAAGTGGT GGCCTAACTA  
 CGGCTACACT AGAAGAACAG TATTTGGTAT CTGCGCTCTG CTGAAGCCAG TTACCTTCGG  
 25 AAAAAGAGTT GGTAGCTCTT GATCCGGCAA ACAAACCACC GCTGGTAGCG GTGGTTTTTT  
 TGTTTGCAAG CAGCAGATTA CGCGCAGAAA AAAAGGATCT CAAGAAGATC CTTTGATCTT  
 TTCTACGGGG TCTGACGCTC AGTGAACGA AACTCACGT TAAGGGATT TGGTCATGAG  
 ATTATCAAAA AGGATCTTCA CCTAGATCCT TTAAATTA AAATGAAGTT TTAATCAAT  
 CTAAAGTATA TATGAGTAAA CTTGGTCTGA CAGTTACCAA TGCTTAATCA GTGAGGCACC  
 30 TATCTCAGCG ATCTGTCTAT TTCGTTATC CATAGTTGCC TGAATCGGG GGGGGGGGCG  
 CTGAGGTCTG CCTCGTGAAG AAGGTGTTGC TGAATCATC CAGGCCTGAA TCGCCCATC  
 ATCCAGCCAG AAAGTGAGGG AGCCACGGT GATGAGAGCT TTGTTGTAGG TGGACCACTT  
 GGTGATTTTG AACTTTTGCT TTGCCACGGA ACGGTCTGCG TTGTCGGGAA GATGCGTGAT  
 CTGATCCTTC AACTCAGCAA AAGTTCGATT TATTCAACAA AGCCGCCGTC CCGTCAAGTC

AGCGTAATGC TCTGCCAGTG TTACAACCAA TTAACCAATT CTGATTAGAA AAACATCATCG  
 AGCATCAAAT GAAACTGCAA TTTATTCATA TCAGGATTAT CAATACCATA TTTTGGAAAA  
 AGCCGTTTCT GTAATGAAGG AGAAACTCA CCGAGGCAGT TCCATAGGAT GGCAAGATCC  
 TGGTATCGGT CTGCGATTCC GACTCGTCCA ACATCAATAC AACCTATTAA TTTCCCTCG  
 5 TCAAAAATAA GGTATCAAG TGAGAAATCA CCATGAGTGA CGACTGAATC CGGTGAGAAT  
 GGCAAAAGCT TATGCATTTC TTTCCAGACT TGTTCACAG GCCAGCCATT ACGCTCGTCA  
 TCAAAATCAC TCGCATCAAC CAAACCGTTA TTCATTCTGT ATTGCGCCTG AGCGAGACGA  
 AATACCGCAT CGCTGTAAA AGGACAATTA CAAACAGGAA TCGAATGCAA CCGGCGCAGG  
 AACACTGCCA GCGCATCAAC AATATTTTCA CCTGAATCAG GATATTCTTC TAATACCTGG  
 10 AATGCTGTTT TCCCGGGGAT CGCAGTGGTG AGTAACCATG CATCATCAGG AGTACGGATA  
 AAATGCTTGA TGGTCGGAAG AGGCATAAAT TCCGTCAGCC AGTTTAGTCT GACCATCTCA  
 TCTGTAACAT CATTGGCAAC GCTACCTTTG CCATGTTTCA GAAACAAC TC TGGCGCATCG  
 GGCTTCCCAT ACAATCGATA GATTGTCGCA CCTGATTGCC CGACATTATC GCGAGCCCAT  
 TTATACCCAT ATAAATCAGC ATCCATGTTG GAATTTAATC GCGGCCCTCGA GCAAGACGTT  
 15 TCCCGTTGAA TATGGCTCAT AACACCCCTT GTATTACTGT TTATGTAAGC AGACAGTTTT  
 ATTGTTTCATG ATGATATATT TTTATCTTGT GCAATGTAAC ATCAGAGATT TTGAGACACA  
 ACGTGGCTTT CCCCCCCCCC CCATTATTGA AGCATTATC AGGGTTATTG TCTCATGAGC  
 GGATACATAT TTGAATGTAT TTAGAAAAAT AAACAAATAG GGGTTCCGCG CACATTTCCC  
 CGAAAAGTGC CACCTGACGT CTAAGAAACC ATTATTATCA TGACATTAAC CTATAAAAAT  
 20 AGGCGTATCA CGAGGCCCTT TCGTC (SEQ ID NO:9).

The underlined nucleotides of SEQ ID NO:9 represent the SfiI site introduced into the KpnI site of V1Jneo while the underlined/italicized nucleotides represent the human tPA leader sequence.

25 *VIR* – Vaccine vector *VIR* was constructed to obtain a minimum-sized vaccine vector without unneeded DNA sequences, which still retained the overall optimized heterologous gene expression characteristics and high plasmid yields that V1J and V1Jns afford. It was determined that (1) regions within the pUC backbone comprising the *E. coli* origin of replication could be removed without affecting plasmid yield from bacteria; (2) the 3'-region of the *kan<sup>r</sup>* gene following the  
 30 kanamycin open reading frame could be removed if a bacterial terminator was inserted in its place; and, (3) ~300 bp from the 3'- half of the BGH terminator could be removed without affecting its regulatory function (following the original KpnI restriction enzyme site within the BGH element). *VIR* was constructed by using PCR to synthesize three segments of DNA from V1Jns representing the CMVintA



promoter/BGH terminator, origin of replication, and kanamycin resistance elements, respectively. Restriction enzymes unique for each segment were added to each segment end using the PCR oligomers: SspI and XhoI for CMVintA/BGH; EcoRV and BamHI for the *kan*<sup>r</sup> gene; and, BclI and SalI for the *ori*<sup>r</sup>. These enzyme sites were chosen because they allow directional ligation of each of the PCR-derived DNA segments with subsequent loss of each site: EcoRV and SspI leave blunt-ended DNAs which are compatible for ligation while BamHI and BclI leave complementary overhangs as do SalI and XhoI. After obtaining these segments by PCR each segment was digested with the appropriate restriction enzymes indicated above and then ligated together in a single reaction mixture containing all three DNA segments. The 5'-end of the *ori*<sup>r</sup> was designed to include the T2 rho independent terminator sequence that is normally found in this region so that it could provide termination information for the kanamycin resistance gene. The ligated product was confirmed by restriction enzyme digestion (>8 enzymes) as well as by DNA sequencing of the ligation junctions. DNA plasmid yields and heterologous expression using viral genes within VIR appear similar to V1Jns. The net reduction in vector size achieved was 1346 bp (V1Jns = 4.86 kb; VIR = 3.52 kb). PCR oligomer sequences used to synthesize VIR (restriction enzyme sites are underlined and identified in brackets following sequence) are as follows: (1) 5'-GGTACAAATATTGGCTATTGGC CATTGCATACG-3' (SEQ ID NO:20) [SspI]; (2) 5'-CCACATCTCGAGGAA CCGGGTCAATTCTTCAGCACC-3' (SEQ ID NO:21) [XhoI] (for CMVintA/BGH segment); (3) 5'-GGTACAGATATTCGGAAAGCCACGTTGTG TCTCAAAATC-3' (SEQ ID NO:22) [EcoRV]; (4) 5'-CACATGGATCCGTAAATGCTCTGCCAGTGT TACAACC-3' (SEQ ID NO:23) [BamHI], (for kanamycin resistance gene segment) (5) 5'-GGTACATGATCAGTAGAAAAGATCAAAGGATCTTCTTG-3' (SEQ ID NO:24) [BclI]; (6) 5'-CCACATGTCGACCCGTAAAAAAGGCCGCGTTGCTGG-3' (SEQ ID NO:25): [SalI], (for *E. coli* origin of replication).

The nucleotide sequence of vector VIR is as follows:

TCGCGCGTTT CGGTGATGAC GGTGAAAACC TCTGACACAT GCAGCTCCCG GAGACGGTCA  
 CAGCTTGCTCT GTAAGCGGAT GCCGGGAGCA GACAAGCCCG TCAGGGCGCG TCAGCGGGTG  
 TTGGCGGGTG TCGGGGCTGG CTTAACTATG CGGCATCAGA GCAGATTGTA CTGAGAGTGC  
 ACCATATGCG GTGTGAAATA CCGCACAGAT GCGTAAGGAG AAAATACCGC ATCAGATTGG  
 CTATTGGCCA TTGCATACGT TGTATCCATA TCATAATATG TACATTTATA TTGGCTCATG  
 TCCAACATTA CCGCATGTT GACATTGATT ATTGACTAGT TATTAATAGT AATCAATTAC

GGGGTCATTA GTTCATAGCC CATATATGGA GTTCCGCGTT ACATAACTTA CGGTAAATGG  
 CCCGCCCTGGC TGACCGCCCA ACGACCCCG CCCATTGACG TCAATAATGA CGTATGTTCC  
 CATAGTAACG CCAATAGGGA CTTTCCATTG ACGTCAATGG GTGGAGTATT TACGGTAAAC  
 TGCCCCACTTG GCAGTACATC AAGTGTATCA TATGCCAAGT ACGCCCCCTA TTGACGTCAA  
 5 TGACGGTAAA TGGCCCGCCT GGCATTATGC CCAGTACATG ACCTTATGGG ACTTTCCTAC  
 TTGGCAGTAC ATCTACGTAT TAGTCATCGC TATTACCATG GTGATGCGGT TTTGGCAGTA  
 CATCAATGGG CGTGGATAGC GGTTTGACTC ACGGGGATTT CCAAGTCTCC ACCCCATTGA  
 CGTCAATGGG AGTTTGTTTT GGCACCAAAA TCAACGGGAC TTTCCAAAAT GTCGTAACAA  
 CTCCGCCCCA TTGACGCAAA TGGGCGGTAG GCGTGTACGG TGGGAGGTCT ATATAAGCAG  
 10 AGCTCGTTTA GTGAACCGTC AGATCGCCTG GAGACGCCAT CCACGCTGTT TTGACCTCCA  
 TAGAAGACAC CGGGACCGAT CCAGCCTCCG CGGCCGGGAA CGGTGCATTG GAACGCGGAT  
 TCCCCGTGCC AAGAGTGACG TAAGTACCGC CTATAGAGTC TATAGGCCCA CCCCCTTGCC  
 TTCTTATGCA TGCTATACTG TTTTGGCTT GGGGTCTATA CACCCCGCT TCCTCATGTT  
 ATAGGTGATG GTATAGCTTA GCCTATAGGT GTGGGTATT GACCATTATT GACCACTCCC  
 15 CTATTGGTGA CGATACTTTC CATTACTAAT CCATAACATG GCTCTTTGCC ACAACTCTCT  
 TTATTGGCTA TATGCCAATA CACTGTCCTT CAGAGACTGA CACGGACTCT GTATTTTTAC  
 AGGATGGGGT CTCATTTATT ATTTACAAAT TCACATATAC AACACCACCG TCCCCAGTGC  
 CCGCAGTTTT TATTAAACAT AACGTGGGAT CTCCACGCGA ATCTCGGGTA CGTGTTCGG  
 ACATGGGCTC TTCTCCGGTA GCGGCGGAGC TTCTACATCC GAGCCCTGCT CCCATGCCTC  
 20 CAGCGACTCA TGGTCGCTCG GCAGCTCCTT GCTCCTAACA GTGGAGGCCA GACTTAGGCA  
 CAGCACGATG CCCACCACCA CCAGTGTGCC GCACAAGGCC GTGGCGGTAG GGTATGTGTC  
 TGAAAATGAG CTCGGGGAGC GGGCTTGACAC CGCTGACGCA TTTGGAAGAC TTAAGGCAGC  
 GGCAGAAGAA GATGCAGGCA GCTGAGTTGT TGTGTTCTGA TAAGAGTCAG AGGTAACTCC  
 CGTTGCGGTG CTGTTAACGG TGGAGGGCAG TGTAAGTCTGA GCAGTACTCG TTGCTGCCGC  
 25 GCGCGCCACC AGACATAATA GCTGACAGAC TAACAGACTG TTCTTTTCCA TGGGTCTTTT  
 CTGCAGTCAC CGTCCTTAGA TCTGCTGTGC CTTCTAGTTG CCAGCCATCT GTTGTGTTGCC  
 CCTCCCCCGT GCCTTCCTTG ACCCTGGAAG GTGCCACTCC CACTGTCCTT TCCTAATAAA  
 ATGAGGAAAT TGCATCGCAT TGTCTGAGTA GGTGTCATTC TATTCTGGGG GGTGGGGTGG  
 GGCAGCACAG CAAGGGGGAG GATTGGGAAG ACAATAGCAG GCATGCTGGG GATGCGGTGG  
 30 GCTCTATGGG TACCCAGGTG CTGAAGAATT GACCCGGTTC CTCCTGGGCC AGAAAGAAGC  
 AGGCACATCC CCTTCTCTGT GACACACCCCT GTCCACGCCC CTGGTTCTTA GTTCCAGCCC  
 CACTCATAGG AACTCATAG CTCAGGAGGG CTCCGCCTTC AATCCACCC GCTAAAGTAC  
 TTGAGCGGT CTCTCCCTCC CTCATCAGCC CACCAACCA AACCTAGCCT CCAAGAGTGG  
 GAAGAAATTA AAGCAAGATA GGCTATTAAG TGCAGAGGGA GAGAAAATGC CTCCAACATG

TGAGGAAGTA ATGAGAGAAA TCATAGAATT TCTTCGCTT CCTCGCTCAC TGA CTGCTG  
CGCTCGGTG TTCGGCTGCG GCGAGCGGTA TCAGCTCACT CAAAGGCGGT AATACGGTTA  
TCCACAGAAT CAGGGGATAA CGCAGGAAAG AACATGTGAG CAAAAGGCCA GCAAAAGGCC  
AGGAACCGTA AAAAGGCCGC GTTGCTGGCG TTTTCCATA GGCTCCGCC CCCTGACGAG  
5 CATCACAAA ATCGACGCTC AAGTCAGAGG TGGCGAAACC CGACAGGACT ATAAAGATAC  
CAGGCGTTTC CCCCTGGAAG CTCCCTCGTG CGCTCTCCTG TTCCGACCCT GCCGCTTACC  
GGATACCTGT CCGCCTTTCT CCCTTCGGGA AGCGTGGCGC TTTCTCAATG CTCACGCTGT  
AGGTATCTCA GTTCGGTGTG GGTGTTTCGC TCCAAGCTGG GCTGTGTGCA CGAACCCCC  
GTTACGCCC ACCGCTGCGC CTTATCCGGT AACTATCGTC TTGAGTCCAA CCCGGTAAGA  
10 CACGACTTAT CGCCACTGGC AGCAGCCACT GGTAACAGGA TTAGCAGAGC GAGGTATGTA  
GGCGGTGCTA CAGAGTTCTT GAAGTGGTGG CCTAACTACG GCTACACTAG AAGGACAGTA  
TTTGGTATCT GCGCTCTGCT GAAGCCAGTT ACCTTCGGAA AAAGAGTTGG TAGCTCTTGA  
TCCGGCAAAC AAACCACCGC TGGTAGCGGT GGTTTTTTTG TTTGCAAGCA GCAGATTACG  
CGCAGAAAAA AAGGATCTCA AGAAGATCCT TTGATCTTT CTACGGGGTC TGACGCTCAG  
15 TGGAACGAAA ACTCACGTTA AGGGATTTTG GTCATGAGAT TATCAAAAAG GATCTTCACC  
TAGATCCTTT TAAATTAAAA ATGAAGTTT AAATCAATCT AAAGTATATA TGAGTAACT  
TGGTCTGACA GTTACCAATG CTTAATCAGT GAGGCACCTA TCTCAGCGAT CTGTCTATTT  
CGTTTCATCA TAGTTGCTG ACTCCGGGGG GGGGGGGCGC TGAGGTCTGC CTCGTGAAGA  
AGGTGTTGCT GACTCATACC AGGCCTGAAT CGCCCCATCA TCCAGCCAGA AAGTGAGGGA  
20 GCCACGGTTG ATGAGAGCTT TGTGTAGGT GGACCAAGTG GTGATTTTGA ACTTTTGCTT  
TGCCACGGAA CGGTCTGCGT TGTCGGGAAG ATGCGTGATC TGATCCTTCA ACTCAGCAAA  
AGTTCGATTT ATTCAACAAA GCCGCCGTCC CGTCAAGTCA GCGTAATGCT CTGCCAGTGT  
TACAACCAAT TAACCAATTC TGATTAGAAA AACTCATCGA GCATCAAATG AACTGCAAT  
TTATTCATAT CAGGATTATC AATACCATAT TTTTGAAAAA GCCGTTTCTG TAATGAAGGA  
25 GAAAACTCAC CGAGGCAGTT CCATAGGATG GCAAGATCCT GGTATCGGTC TCGGATTCCG  
ACTCGTCAA CATCAATACA ACCTATTAAT TTCCCTCGT CAAAATAAG GTTATCAAGT  
GAGAAATCAC CATGAGTGAC GACTGAATCC GGTGAGAATG GCAAAAGCTT ATGCATTTCT  
TTCCAGACTT GTTCAACAGG CCAGCCATTA CGCTCGTCAT CAAAATCACT CGCATCAACC  
AAACCGTTAT TCATTCTGTA TTGCGCCTGA GCGAGACGAA ATACGCGATC GCTGTTAAAA  
30 GGACAATTAC AAACAGGAAT CGAATGCAAC CGGCGCAGGA AACTGCCAG CGCATCAACA  
ATATTTTCAC CTGAATCAGG ATATTCTTCT AATACCTGGA ATGCTGTTTT CCCGGGGATC  
GCAGTGGTGA GTAACCATGC ATCATCAGGA GTACGGATAA AATGCTTGAT GGTGGAAGA  
GGCATAAATT CCGTCAGCCA GTTTAGTCTG ACCATCTCAT CTGTAACATC ATTGGCAACG  
CTACCTTTGC CATGTTTCAG AAACAACCTT GCGCATCGG GCTTCCATA CAATCGATAG

ATTGTCGCAC CTGATTGCCC GACATTATCG CGAGCCCAT TATACCCATA TAAATCAGCA  
 TCCATGTTGG AATTTAATCG CGGCCTCGAG CAAGACGTTT CCCGTTGAAT ATGGCTCATA  
 ACACCCCTTG TATTACTGTT TATGTAAGCA GACAGTTTTA TTGTTTCATGA TGATATATTT  
 TTATCTTGTG CAATGTAACA TCAGAGATTT TGAGACACAA CGTGGCTTTC CCCCCCCCCC  
 5 CATTATTGAA GCATTATCA GGGTTATTGT CTCATGAGCG GATACATATT TGAATGTATT  
 TAGAAAAATA AACAAATAGG GGTTCGCGC ACATTTCCCC GAAAAGTGCC ACCTGACGTC  
 TAAGAAACCA TTATTATCAT GACATTAACC TATAAAAATA GCGGTATCAC GAGGCCCTTT  
 CGTC (SEQ ID NO:26) .

10

## EXAMPLE 2

Codon Optimized HIV-1 Nef and HIV-1 Nef Derivatives as DNA Vector Vaccines

*HIV-1 Nef Vaccine Vectors* - Codon optimized nef gene coding for wt Nef protein of HIV-1 jrfl isolate was assembled from complementary, overlapping synthetic oligonucleotides by polymerase chain reaction (PCR). The PCR primers  
 15 used were designed in such that a BglII site was included in the extension of 5' primer and an SrfI site and a BglII site in the extension of 3' primer. The PCR product was digested with BglII and cloned into BglII site of a human cytomeglovirus early promoter-based expression vector, V1Jns (Figure 1A). The proper orientation of nef fragment in the context of the expression cassette was determined by asymmetric  
 20 restriction mapping. The resultant plasmid is V1Jns/nef. The 5' and 3' nucleotide sequence junctions of codon optimized V1Jns/nef are shown in Figure 3A.

The mutant nef (G2A,LLAA) was also made from synthetic oligonucleotides. To assist in cloning, a PstI site and an SrfI site were included in the extensions of 5' and 3' PCR primers, respectively. The PCR product was digested with PstI and SrfI,  
 25 and cloned into the PstI and SrfI sites of V1Jns/nef, replacing the original nef with nef(G2A,LLAA) fragment. This resulted in V1Jns/nef(G2A,LLAA). The 5' and 3' nucleotide sequence junctions of codon optimized V1Jns/nef (G2A,LLAA) are shown in Figure 3B.

To construct the expression vector containing human tissue plasminogen  
 30 activator leader peptide and the nef fusion gene, i.e., V1Jns/tPANef, a truncated nef gene fragment, lacking the coding sequence for the five amino terminal residues, was first amplified by PCR using V1Jns/nef as template. Both 5' and 3' PCR primers used in this reaction contained a BglII extension. The PCR amplified fragment was then digested with BglII and cloned into BglII site of the expression vector, V1Jns/tpa

(Figure 1B). The ligation of the 3' end of tpa leader peptide coding sequence to the 5' end of the nef PCR product restored the BglII site and yielded an in-frame fusion of the two genes. The 5' and 3' nucleotide sequence junctions of codon optimized V1Jns/tPAnef are shown in Figure 3C.

5 Construction of V1Jns/tpanef(LLAA) was carried out by replacing the Bsu36-SacII fragment of V1Jns/tpanef, which contains the 3' half of the nef gene and part of the vector backbone, with the Bsu36-SacII fragment from V1Jns/nef(G2A,LLAA). The 5' and 3' nucleotide sequence junctions of codon optimized V1Jns/tpanef (LLAA) are shown in Figure 3C.

10 All the nef constructs were verified by sequencing. The amino acid junctions of these constructs is shown schematically in Figure 4.

*Transfection and protein expression* - 293 cells (adenovirus transformed human embryonic kidney cell line 293) grown at approximately 30% confluence in minimum essential medium (MEM; GIBCO, Grand Island, MD) supplemented with  
15 10% fetal bovine serum (FBS; GIBCO) in a 100 mm culture dish, were transfected with 4 ug gag expression vector, V1Jns/gag, or a mixture of 4 ug gag expression vector and 4 ug nef expression vector by Lipofectin following manufacture's protocol (GIBCO). Twelve hours post-transfection, cells were washed once with 10 ml of serum-free medium, Opti-MEM I (GIBCO) and replenished with 5 ml of Opti-MEM.  
20 Following an additional 60 hr incubation, culture supernatants and cells were collected separately and used for Western blot analysis.

*Western blot analysis* - Fifty microliter of samples were separated on a 10% SDS-polyacrylamide gel (SDS-PAGE) under reducing conditions. The proteins were blotted onto a piece of PVDF membrane, and reacted to a mixture of gag mAb (#18;  
25 Intracel, Cambridge, MA) and Nef mAbs (aa64-68, aa195-201; Advanced Biotechnologies, Columbia, MD), both at 1:2000 dilution, and horseradish peroxidase (HRP)-conjugated goat anti-rabbit IgG (Zymed, San Francisco, CA). The protein bands were visualized by ECL Western blotting detection reagents, according to the manufacture's protocol (Amersham, Arlington Heights, IL).

30 *Enzyme-linked immunosorbent assay (ELISA)* - 96-well Immulon II, round-bottom plates were coated with 50 ul of Nef protein at the concentration of 2ug/ml in bicarbonate buffer, pH 9.8., per well at 4°C overnight. Plates were washed three times with PBS containing 0.05% Tween-20 (PBST), and blocked with 5% skim milk in PBST (milk-PBST) at 24°C for 2 hr, and then incubated with serial dilutions of

testing samples in milk-PBST at 24°C for 2 hr. Plates were washed with PBST three times, and added with 50 ul of HRP-conjugated goat anti-mouse IgG (Zymed) per well and incubated at 24°C for 1 hr. This was followed by three washes, and the addition of 100 ul of 1 mg/ml ABTS [(2,2'-amino-di-(3-ethylbenzthiozoline sulfonate)] (KPL, Gaithersburg, MD) per well. After 1 hr at 24°C, plates were read at a wavelength of 405nm using an ELISA plate reader.

*Enzyme-linked spot assay (Elispot)* - Nitrocellulose membrane-backed 96 well plates (MSHA plates; Millipore, Bedford, MA) were coated with 50 ul of rat anti-mouse IFN-gamma mAb, capture antibody, (R4-6A2; PharMingen, San Diego, CA) at a concentration of 5ug/ml in PBS per well at 4°C overnight. Plates were washed three times with PBST and blocked with 10% FBS in RPMI-1640 (FBS-RPMI) at 37°C in a CO2 incubator for 2 to 4 hrs. Splenocytes were suspended in RPMI-1640 with 10% FBS at  $4 \times 10^6$  cells per ml. 100 ul cells were added to each well and plates were incubated at 37°C for 20 hrs. Each sample was tested in triplicate wells. After incubation, plates were rinsed briefly with distilled water and washed three times with PBST. Fifty ul of biotinylated rat anti-mouse IFN- $\gamma$  mAb, detecting antibody (XMG1.2; PharMingen), diluted in 1% BSA in PBST at a concentration of 2 ug/ml was then added to each well. Plates were incubated at 24°C for 2 hr, followed by washes with PBST. Fifty ul of streptavidin-conjugated alkaline phosphatase (KPL) at a dilution of 1:1000 in FBS-RPMI was added to each well. The plates were incubated at 24°C for an additional one hr. Following extensive wash with BPST, 100ul BCIT/NBT substrate (KPL) was added for 15 min, and color reaction was stopped by washing the plate with tap water. Plates were air-dried and spots were counterstained using a dissection microscope.

*Cytotoxic T cell (CTL) assay* - Splenocytes from immunized mouse were co-cultured with syngenic peptide-pulsed, irradiated naive splenocytes for 7 days. EL-4 cells were incubated at 37°C for 1 hr with or without 20ug/ml of a designated peptide in the presence of sodium 51Cr-chromate and used as target cells. For the assay,  $10^4$  target cells were added to a 96-well plate along with different numbers of splenocytes cells. Plates were incubated at 37°C for 4 hr. After incubation, supernatants were collected and counted in a Wallac gamma-counter. Specific lysis was calculated as  $[(\text{experimental release} - \text{spontaneous release}) / (\text{maximum release} - \text{spontaneous release})] \times 100\%$ . Spontaneous release was determined by incubating target cells in

medium alone, and maximum release was determined by incubating target cells in 2.5% TritonX-100. The assay was performed with triplicate samples.

*Animal experiments* - Female mice (Charles River Laboratories, Wilmington, MA), 6 to 10 weeks old, were injected in quadriceps with 100 ul of DNA in PBS.

- 5 Two weeks after immunization, spleens from individual mice were collected and used for CTL and Elispot assays.

- Results (DNA Vector Vaccine Construction)* - The exemplified Nef protein sequence is based on HIV-1 clade B jrf1 isolate. A codon-optimized nef gene was chosen for vaccine construction and for use as the parental gene for other exemplified constructs. Figure 2A-B show the comparison of coding sequence of wt nef(jrf1) and the codon optimized nef(jrf1). Two forms of myristylation site mutations were constructed; one contains a Gly2Ala change and the other a human tissue plasminogen activator (tpa) leader sequence was fused to sixth residue, Ser, of Nef (tpanef). The dileucine motif mutation was made by introducing both Leu174Ala and  
10 Leu175Ala changes. Figure 4 shows the schematic depiction of the Nef and Nef mutants. For *in vitro* expression and *in vivo* immunogenicity studies, the nef genes were cloned into expression vector, V1Jns. The resultant plasmids containing wt nef, tpanef, tpanef with dileucine motif mutation, and nef mutant with the Gly2Ala myristylation site and dileucine motif mutations were named as V1Jns/nef,  
15 V1Jns/tpanef, V1Jns/tpanef(LLAA) and V1Jns/(G2A,LLAA), respectively.

- Results - Expression and Western blotting analysis* - To evaluate the expression of the codon optimized nef constructs, adenovirus-transformed human kidney 293 cells were cotransfected with individual nef plasmids and a gag expression vector, V1Jns/gag. 72 hours post transfection, cells and medium were collected  
25 separately and analyzed by Western blotting, using both Nef- and Gag-specific mAbs. The results are shown in Figure 5. Cells transfected with V1Jns/gag only revealed a single distinct band of approximately 55 Kd, whereas the cells cotransfected with gag and nef plasmids revealed, in addition to the 55 Kd band, a major 30 Kd band and several minor bands. This pattern is consistent with that the 55 Kd species represents  
30 Gag polypeptide and the 30 Kd and other minor species are the Nef-related products. Therefore, all the nef constructs were expressed in the transfected cells. When measured against the relatively constant Gag signal as a reference, four nef genes seem to be expressed at different levels, with the following descending order, tpanef, nef, tpanef(LLAA) and nef(G2A, LLAA). With the exception of nef(G2A,LLAA),

products of nef, tpanef, tpanef(LLAA) could be detected in both cellular and medium fractions.

*Mapping of Nef-specific CD8 and CD4 epitopes in mice* – There was no information available with respect to the properties of Nef(jrfl) in eliciting cell-mediated immune responses in mice. Therefore, to characterize immunogenicity of Nef and Nef mutants exemplified herein, CD8 and CD4 epitopes were mapped. An overlapping set of overlapping nef peptides that encompass the entire 216 aa Nef polypeptide were generated. A total 21 peptides were made, which include twenty 20mers and one 16mer. Three strains of mice, Balb/c, C3H and C57BL/6, were immunized with plasmid V1Jns/Nef; splenocytes from immunized and naive mice were isolated and assessed for Nef specific INF-gamma secreting cells (SFC) by the Elispot assay. Figure 6 shows where Elispot assays were performed against separate pools of the Nef peptides. All three strains of immunized mice responded to the Nef plasmid immunization; each developed positive Nef peptide-specific INF- $\gamma$  SFCs. Based on this, further studies were carried out with fractionated CD8 and CD4 cells against individual peptides. The results are shown in Figure 7A-C. In Balb/c mice (Figure 7A), four Nef peptides, namely, aa11-30, aa61-80, aa191-210 and aa200-216, were found to be able to induce significant numbers of CD4 SFCs. In C57BL/6 mice (Figure 7B), only one peptide, ie., aa81-100, elicited significant numbers of CD4 SFCs. Compared to Balb/c and C57BL/6 mice, C3H mice (Figure 7C) showed no dominant CD4 SFC responses with particular peptides; instead, there were modest number of SFCs in response to an array of peptides, including aa21-40, aa31-50, aa121-140 aa131-150, aa181-200 and aa191-210. With respect to CD8 cells, significant SFC responses were detected with a single peptide, ie., aa51-70, in C57BL/6 mice only.

The results from Elispot assay suggested that Nef peptide aa51-70 contained an H-2b restricted CD8 cell epitope. In order to ascertain whether this CD8 epitope also represents the cytotoxic T cell (CTL) epitope, a conventional CTL assay was carried out. The peptide aa51-70 (Figure 8A) induced low level of specific killings only. Peptides longer than 9 amino acids of a typical CTL epitope often have lower binding affinity to MHC class I molecule. It was contemplated that the low specific killings observed with peptide aa51-70 could be potentially resulted from the low binding affinity of this 20 amino acid peptide. Therefore, two shortened peptides, namely, aa60-68 and aa58-70, were synthesized and tested in CTL assays. While the



peptide aa60-68 failed to elicit any specific killings (Figure 8B), the peptide aa58-70 exhibited a drastic increase of specific killing as compared to its longer counterpart, peptide aa61-80 (Figure 8C). For example, the percentage of specific killings induced by peptide aa58-70 at an effector/target ratio of 5 to 1 was comparable to that induced by peptide aa51-80 at an effector/target ratio of 45. Thus, between peptide aa58-70 and peptide aa51-70, the former was almost ten-fold more effective in terms of inducing Nef-specific killing. The results from CTL assay therefore confirmed that the CD8 epitope detected by the Elispot assay was indeed a CTL epitope. To further map the minimum amino acid sequence for the Nef CTL epitope, additional 5 peptides were synthesized and analyzed by Elispot assay, which mapped the CTL epitope to Nef aa58-66, as shown in Table 1.

TABLE 1

Nef peptides**		INF- $\gamma$ SFC*/10 <sup>6</sup> splenocytes
Nef58-70	TAATNADCAWLEA	85
Nef59-69	AATNADCAWLE	1
Nef58-68	TAATNADCAWL	69
Nef58-67	TAATNADCAW	66
Nef58-66	TAATNADCA	92
Medium		1

\* Average of duplicate samples.

15 \*\* Amino acid sequence of all peptides contained within SEQ ID NO:2.

*Results (Evaluation of Immunogenicity of nef Mutants in Mice)* - Having identified H-2b restricted CTL and CD4 cell epitopes, the immunogenicity of the different codon optimized nef constructs in C57BL/6 mice was examined. This was performed in two separate experiments with identical immunization regimens. The first experiment involved nef, tpanef(LLAA) and nef(G2A,LLAA) and the second experiment involved nef, tpanef, tpanef(LLAA) and nef(G2A,LLAA). Mice were immunized with plasmids containing these respective codon optimized nef genes. Two weeks post immunization, splenocytes from individual mice were isolated and analyzed by Elispot assay for Nef-specific CD8 and CD4 IFN-gamma SFCs using Nef peptide aa58-66 and aa81-100, respectively. The results are shown in Figure 9A-B. In the experiment 1 (Figure 9A), among the three groups tested, the mice receiving the codon optimized tpanef(LLAA) construct developed the highest CD8 and CD4 cell responses; comparing between tpanef(LLAA) and the nef, the former elicited about 40-fold higher CD8 SFCs and 10-fold higher CD4 SFCs. In contrast to tpanef(LLAA), nef(G2A,LLAA) mutant was poorly immunogenic; mice receiving this mutant had barely detectable CD8 and CD4 SFCs, under conditions tested. Similar response profiles between the three mutants were also observed in the experiment 2 (Figure 9B), except that the overall CD8 response of mice receiving tpanef(LLAA) was approximately 10-fold higher in experiment 2 than that observed in experiment 1. The tPAnef mutant showed comparable responses as that of tpanef(LLAA). The results therefore showed that both codon optimized tpanef and tpanef(LLAA) had significantly enhanced immunogenicity.

*Results (Evaluation of Immunogenicity of nef Mutants in Rhesus Monkeys)* - Monkeys were immunized with 5 mg of indicated codon optimized plasmids at week 0, 4, and 8. Four weeks after each immunization, peripheral blood mononuclear cells were collected and tested for Nef-specific INF-gamma secreting cells as described for the mice studies in this Example section. The results are shown in Table 2. As with the mouse study, tpanef(LLAA) shows significantly enhanced immunogenicity when compared to tPAnef.

TABLE 2

Vaccine	Animal No.	Nef specific INF-gamma secreting cells/million PBMC							
		Week 0		Week 4		Week 8		Week 12	
		Medium nef		Medium nef		Medium nef		Medium nef	
VIJns-TpaNef (LLAA)	1	74	39	30	208	6	148	89	559
	2	1	3	28	45	13	44	13	146
	3	5	5	14	45	11	11	14	35
VIJns-nef	1	0	1	24	33	16	43	6	34
	2	28	9	31	35	13	34	24	80
	3	1	0	16	31	18	38	13	185
Control	1	1	3	16	33	16	16	18	13

- 5 Monkeys were immunized with 5 mg of indicated plasmids at week 0, 4 and 8. Four weeks after each immunization, peripheral blood mononuclear cells were collected and tested for the Nef-specific IFN-gamma secreting cells.

- 10 A codon-optimized nef gene coding for HIV-1 jrf1 isolate Nef polypeptide was synthesized. The resultant synthetic nef gene was well expressed in the *in vitro* transfected cells. Using this synthetic gene as parental molecule, nef mutants involving myristylation site and dileucine motif mutations were constructed. Two forms of myristylation site mutation were made, one involving a single Gly2Ala change and the other by fusing human plasminogen activator(tpa) leader peptide with the N-terminus of Nef polypeptide. The dileucine motif mutation was generated by
- 15 Leu174Ala and Leu175Ala changes. The resultant nef constructs were named as nef, tpanef, tpanef(LLAA) and nef(G2A,LLAA). The addition of tpa leader peptide sequence resulted in significantly increased expression of the nef gene *in vitro*; in contrast, either Gly2Ala mutation or dileucine mutation reduced the nef gene

expression. In an effort to characterize immunogenicity of nef and nef mutants, experiments were carried out to map nef CTL and Th epitopes in mice. A single CTL epitope and a dominant Th epitope, both restricted by H-2b, were identified.

Consequently, C57BL/6 mice were immunized with different nef constructs by DNA  
5 immunization means, and splenocytes from immunized mice were determined for Nef-specific CTL and Th responses using Elisopt assay and the defined T cell epitopes. The results showed that tpanef and tpanef(LLAA) were significantly more immunogenic than nef in terms of eliciting both CTL and Th responses.

Therefore, these aforementioned polynucleotides, when directly introduced  
10 into a vertebrate *in vivo*, including mammals such as primates and humans, should express the respective HIV-1 Nef protein within the animal and in turn induce at least a cytotoxic T lymphocyte (CTL) response within the host to the expressed Nef antigen.

The present invention is not to be limited in scope by the specific  
15 embodiments described herein. Indeed, various modifications of the invention in addition to those described herein will become apparent to those skilled in the art from the foregoing description. Such modifications are intended to fall within the scope of the appended claims.

20

## WHAT IS CLAIMED IS:

1. A pharmaceutically acceptable DNA vaccine, which comprises:  
(a) a DNA expression vector; and,  
5 (b) a DNA molecule containing a codon optimized open reading frame encoding a Nef protein or immunogenic Nef derivative thereof, wherein upon administration of the DNA vaccine to a host the Nef protein or immunogenic Nef derivative is expressed and generates an immune response which provides a substantial level of protection against HIV-1 infection.  
10
2. A DNA vaccine of claim 1 wherein the DNA molecule encodes wild type Nef.
3. A DNA vaccine of claim 2 wherein the DNA molecule contains the  
15 nucleotide sequence as set forth in SEQ ID NO:1.
4. The DNA vaccine of claim 3 which is V1Jns-opt nef (jrfl).
5. A DNA vaccine of claim 2 wherein the DNA molecule expresses a  
20 wild type Nef protein which comprises the amino acid sequence as set forth in SEQ ID NO:2.
6. A DNA vaccine of claim 1 wherein the DNA molecule encodes an  
25 immunogenic Nef derivative which contains a nucleotide sequence encoding a leader peptide.
7. A DNA vaccine of claim 6 wherein the DNA molecule encodes an  
immunogenic Nef derivative which contains a nucleotide sequence encoding a human  
tissue plasminogen activator leader peptide.  
30
8. A DNA vaccine of claim 7 wherein the DNA molecule contains the  
nucleotide sequence as set forth in SEQ ID NO:3.
9. The DNA vaccine of claim 8 which is V1Jns-opt tpanef.

10. A DNA vaccine of claim 7 wherein the DNA molecule expresses an immunogenic Nef derivative which comprises the amino acid sequence as set forth in SEQ ID NO:4.
- 5
11. A DNA vaccine of claim 6 wherein the DNA molecule encodes an immunogenic Nef derivative modified at the dileucine motif of amino acid residue 174 and amino acid residue 175.
- 10
12. A DNA vaccine of claim 11 wherein the DNA molecule encodes an immunogenic Nef derivative which contains a nucleotide sequence encoding a human tissue plasminogen activator leader peptide.
13. A DNA vaccine of claim 12 wherein the DNA molecule contains the
- 15 nucleotide sequence as set forth in SEQ ID NO:7.
14. The DNA vaccine of claim 13 which is V1Jns-opt tpanef (LLAA).
15. A DNA vaccine of claim 11 wherein the DNA molecule expresses an
- 20 immunogenic Nef derivative which comprises the amino acid sequence as set forth in SEQ ID NO:8.
16. A DNA vaccine of claim 11 wherein the DNA molecule encodes a Nef protein where the glycine residue of amino acid residue 2 of Nef is modified to
- 25 encode for an amino acid residue other the glycine.
17. A DNA vaccine of claim 16 wherein the DNA molecule contains the nucleotide sequence as set forth in SEQ ID NO:5.
18. A DNA vaccine of claim 17 which is V1Jns-opt nef (G2A LLAA).
- 30
19. A DNA vaccine of claim 16 wherein the DNA molecule expresses an immunogenic Nef derivative which comprises the amino acid sequence as set forth in SEQ ID NO:6.

20. A DNA vaccine of claim 1 which further comprises an adjuvant.
21. A DNA vaccine of claim 20 wherein the adjuvant is selected from the  
5 group consisting of aluminum phosphate, calcium phosphate and a non-ionic block copolymer.
22. A pharmaceutically acceptable DNA vaccine, which comprises:  
(a) a DNA expression vector; and,  
10 (b) a DNA molecule containing an open reading frame encoding a Nef protein or immunogenic Nef derivative thereof, wherein upon administration of the DNA vaccine to a host the Nef protein or immunogenic Nef derivative is expressed and generates an immune response which provides a substantial level of protection against HIV-1 infection.  
15
23. The DNA vaccine of claim 22 wherein the DNA molecule expresses a wild type Nef protein which comprises the amino acid sequence as set forth in the group consisting of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6 and SEQ ID NO:8.
- 20 24. A DNA vaccine of claim 22 which further comprises an adjuvant.
25. A DNA vaccine of claim 23 wherein the adjuvant is selected from the group consisting of aluminum phosphate, calcium phosphate and a non-ionic block copolymer.  
25
26. A method for inducing a cell mediated immune (CTL) response against infection or disease caused by virulent strains of HIV which comprises administering into the tissue of a vertebrate host a pharmaceutically acceptable DNA vaccine composition which comprises a DNA expression vector and a DNA molecule  
30 containing a codon optimized open reading frame encoding a Nef protein or immunogenic Nef derivative thereof, wherein upon administration of the DNA vaccine to the vertebrate host the Nef protein or immunogenic Nef derivative is expressed and generates the cell-mediated immune (CTL) response.

27. The method of claim 26 wherein the vertebrate host is a human.

28. The method of claim 26 wherein the DNA vaccine is selected from the group consisting of V1Jns-opt nef (jrfl), V1Jns-opt tpanef, V1Jns-opt tpanef (LLAA),  
5 and V1Jns-opt nef (G2A LLAA).

29. A substantially purified protein which comprises an amino acid sequence selected from the group consisting of SEQ ID NO:4, SEQ ID NO:6, and SEQ ID NO:8.

10






FIG.1B

FIG.1A

2/10

WT	-	ATG GGT GGC AAG TGG TCA AAA CGT AGT GTG CCT GGA TGG TCT	-42
OPT	-	ATG GGC GGC AAG TGG TCC AAG AGG TCC GTG CCC GGC TGG TCC M G G K W S K R S V P G W S	-14
WT	-	ACT GTA AGG GAA AGA ATG AGA CGA GCT GAG CCA GCA GCA GAT	-84
OPT	-	ACC GTG AGG GAG AGG ATG AGG AGG GCC GAG CCC GCC GCC GAC T V R E R M R R A E P A A D	-28
WT	-	AGG GTG AGA CGA ACT GAG CCA GCA GCA GTA GGG GTG GGA GCA	-126
OPT	-	AGG GTG AGG AGG ACC GAG CCC GCC GCC GTG GGC GTG GGC GCC R V R R T E P A A V G V G A	-42
WT	-	GTA TCT CGA GAC CTG GAA AAA CAT GGA GCA ATC ACA AGT AGC	-168
OPT	-	GTG TCC AGG GAC CTG GAG AAG CAC GGC GCC ATC ACC TCC TCC V S R D L E K H G A I T S S	-56
WT	-	AAT ACA GCA GCT ACC AAT GCT GAT TGT GCC TGG CTA GAA GCA	-210
OPT	-	AAC ACC GCC GCC ACC AAC GCC GAC TGC GCC TGG CTG GAG GCC N T A A T N A D C A W L E A	-70
WT	-	CAA GAG GAT GAG GAA GTG GGT TTT CCA GTC AGA CCT CAG GTA	-252
OPT	-	CAG GAG GAC GAG GAG GTG GGC TTC CCC GTG AGG CCC CAG GTG Q E D E E V G F P V R P Q V	-84
WT	-	CCT TTA AGA CCA ATG ACT TAC AAG GGA GCT GTA GAT CTT AGC	-294
OPT	-	CCC CTG AGG CCC ATG ACC TAC AAG GGC GCC GTG GAC CTG TCC P L R P M T Y K G A V D L S	-98
WT	-	CAC TTT TTA AAA GAA AAG GGG GGA CTG GAA GGG CTA ATT CAC	-336
OPT	-	CAC TTC CTG AAG GAG AAG GGC GGC CTG GAG GGC CTG ATC CAC H F L K E K G G L E G L I H	-112
WT	-	TCA CAG AAA AGA CAA GAT ATC CTT GAT CTG TGG GTC TAC CAC	-378
OPT	-	TCC CAG AAG AGG CAG GAC ATC CTG GAC CTG TGG GTG TAC CAC S Q K R Q D I L D L W V Y H	-126
WT	-	ACA CAA GGC TAC TTC CCT GAT TGG CAG AAC TAC ACA CCA GGG	-420
OPT	-	ACC CAG GGC TAC TTC CCC GAC TGG CAG AAC TAC ACC CCC GGC T Q G Y F P D W Q N Y T P G	-140

FIG.2A

SUBSTITUTE SHEET (RULE 26)

3/10

WT	- CCA GGA ATC AGA TTT CCA TTG ACC TTT GGA TGG TGC TTC AAG	-462
OPT	- CCC GGC ATC AGG TTC CCC CTG ACC TTC GGC TGG TGC TTC AAG	
	P G I R F P L T F G W C F K	-154
WT	- CTA GTA CCA GTT GAG CCA GAA AAG GTA GAA GAG GCC AAT GAA	-504
OPT	- CTG GTG CCC GTG GAG CCC GAG AAG GTG GAG GAG GCC AAC GAG	
	L V P V E P E K V E E A N E	-168
WT	- GGA GAG AAC AAC TGC TTG TTA CAC CCT ATG AGC CAG CAT GGG	-546
OPT	- GGC GAG AAC AAC TGC CTG CTG CAC CCC ATG TCC CAG CAC GGC	
	G E N N C L L H P M S Q H G	-182
WT	- ATA GAG GAC CCG GAG AAG GAA GTG TTA GAG TGG AGG TTT GAC	-588
OPT	- ATC GAG GAC CCC GAG AAG GAG GTG CTG GAG TGG AGG TTC GAC	
	I E D P E K E V L E W R F D	-196
WT	- AGC AAG CTA GCA TTT CAT CAC GTG GCC CGA GAG CTG CAT CCG	-630
OPT	- TCC AAG CTG GCC TTC CAC CAC GTG GCC AGG GAG CTG CAC CCC	
	S K L A F H H V A R E L H P	-210
WT	- GAG TAC TAC AAG GAC TGC TGA (SEQ ID NO:30)	-651
OPT	- GAG TAC TAC AAG GAC TGC TAA (contained within SEQ ID NO:1)	
	E Y Y K D C (SEQ ID NO:2)	-216

FIG.2B

VIJns/nef *PstI* *BglII*  
CATGGGTCCTTTCTGCGAGTCACCGTCCTTCGAGATCTGCCACC ATG GGC GGC AAG TGG TCC AAG AGG TCC GTG CCC . . . .  
M G G K W S K R S V P

. . . . . CAC CCC GAG TAC TAC AAG GAC TGC TAA *SrfI* *BglII*  
AGCCCCGGGCAGATCTGCTGTGTGCCCTTCTAGTTGCCAGC (SEQ ID NO:27)  
H P E Y Y K D C \* (contained within SEQ ID NO:2)

FIG.3A

VIJns/nef(G2A,LLAA)  
*PstI* *BglII*  
CATGGGTCCTTTCTGCGAGTCACCGTCCTTCGAGATCTGCCACC ATG GGC GGC AAG TGG TCC AAG AGG TCC GTG CCC . . . .  
M A G K W S K R S V P

. . . . . CAC CCC GAG TAC TAC AAG GAC TGC TAA *SrfI* *BglII*  
AGCCCCGGGCAGATCTGCTGTGTGCCCTTCTAGTTGCCAGC (SEQ ID NO:28)  
H P E Y Y K D C \* (contained within SEQ ID NO:6)

FIG.3B

VIJns/tpanef & VIJns/tpanef(LLAA)  
*PstI* *BglII*  
CATGGGTCCTTTCTGCGAGTCACCGTCCTTCATCTAGATCACC ATG GAT GCA ATG AAG AGA GGG CTC TGC TGT GTG  
M D A M K R G L C C V

CTG CTG CTG TGT GGA GCA GTC TTC GTT TCG CCC AGC GAG ATC TCC TCC AAG AGG TCC GTG CCC . . . .  
L L L C G A V F V S P S E I S S K R S V P

. . . . . CAC CCC GAG TAC TAC AAG GAC TGC TAA *SrfI* *BglII*  
AGCCCCGGGCAGATCTGCTGTGTGCCCTTCTAGTTGCCAGC (SEQ ID NO:29)  
H P E Y Y K D C \* (contained within SEQ ID NO:8)

FIG.3C




FIG.4

6/10




FIG.5

7/10







FIG. 6

8/10








FIG.8C




FIG.8B




FIG.8A

10/10




FIG.9B




FIG.9A

## SEQUENCE LISTING

<110> APPLICANT: Merck & Co., Inc.

<120> TITLE: POLYNUCLEOTIDE VACCINES EXPRESSING CODON  
OPTIMIZED HIV-1 NEF AND MODIFIED HIV-1 NEF

<130> DOCKET/FILE REFERENCE: 20602Y

<160> NUMBER OF SEQUENCES: 30

<170> SOFTWARE: FastSEQ for Windows Version 4.0

<210> SEQ ID NO:1

<211> LENGTH: 671

<212> TYPE: DNA

<213> ORGANISM: Human Immunodeficiency Virus - 1

<220> FEATURE:

<221> NAME/KEY: CDS

<222> LOCATION: (12)...(662)

<400> SEQ ID NO:1

```

gatctgccac c atg ggc ggc aag tgg tcc aag agg tcc gtg ccc ggc tgg      50
      Met Gly Gly Lys Trp Ser Lys Arg Ser Val Pro Gly Trp
          1              5              10

tcc acc gtg agg gag agg atg agg agg gcc gag ccc gcc gcc gac agg      98
Ser Thr Val Arg Glu Arg Met Arg Arg Ala Glu Pro Ala Ala Asp Arg
      15              20              25

gtg agg agg acc gag ccc gcc gcc gtg ggc gtg ggc gcc gtg tcc agg      146
Val Arg Arg Thr Glu Pro Ala Ala Val Gly Val Gly Ala Val Ser Arg
      30              35              40              45

gac ctg gag aag cac ggc gcc atc acc tcc tcc aac acc gcc gcc acc      194
Asp Leu Glu Lys His Gly Ala Ile Thr Ser Ser Asn Thr Ala Ala Thr
          50              55              60

aac gcc gac tgc gcc tgg ctg gag gcc cag gag gac gag gag gtg ggc      242
Asn Ala Asp Cys Ala Trp Leu Glu Ala Gln Glu Asp Glu Glu Val Gly
          65              70              75

ttc ccc gtg agg ccc cag gtg ccc ctg agg ccc atg acc tac aag ggc      290
Phe Pro Val Arg Pro Gln Val Pro Leu Arg Pro Met Thr Tyr Lys Gly
          80              85              90

gcc gtg gac ctg tcc cac ttc ctg aag gag aag ggc ggc ctg gag ggc      338
Ala Val Asp Leu Ser His Phe Leu Lys Glu Lys Gly Gly Leu Glu Gly
          95              100              105

ctg atc cac tcc cag aag agg cag gac atc ctg gac ctg tgg gtg tac      386
Leu Ile His Ser Gln Lys Arg Gln Asp Ile Leu Asp Leu Trp Val Tyr
      110              115              120              125

cac acc cag ggc tac ttc ccc gac tgg cag aac tac acc ccc ggc ccc      434
His Thr Gln Gly Tyr Phe Pro Asp Trp Gln Asn Tyr Thr Pro Gly Pro

```

```

                130                135                140
ggc atc agg ttc ccc ctg acc ttc ggc tgg tgc ttc aag ctg gtg ccc      482
Gly Ile Arg Phe Pro Leu Thr Phe Gly Trp Cys Phe Lys Leu Val Pro
                145                150                155

gtg gag ccc gag aag gtg gag gag gcc aac gag ggc gag aac aac tgc      530
Val Glu Pro Glu Lys Val Glu Glu Ala Asn Glu Gly Glu Asn Asn Cys
                160                165                170

ctg ctg cac ccc atg tcc cag cac ggc atc gag gac ccc gag aag gag      578
Leu Leu His Pro Met Ser Gln His Gly Ile Glu Asp Pro Glu Lys Glu
                175                180                185

gtg ctg gag tgg agg ttc gac tcc aag ctg gcc ttc cac cac gtg gcc      626
Val Leu Glu Trp Arg Phe Asp Ser Lys Leu Ala Phe His His Val Ala
                190                195                200                205

agg gag ctg cac ccc gag tac tac aag gac tgc taa agccccgggc      671
Arg Glu Leu His Pro Glu Tyr Tyr Lys Asp Cys *
                210                215

```

&lt;210&gt; SEQ ID NO:2

&lt;211&gt; LENGTH: 216

&lt;212&gt; TYPE: PRT

&lt;213&gt; ORGANISM:Human Immunodeficiency Virus - 1

&lt;400&gt; SEQ ID NO:2

```

Met Gly Gly Lys Trp Ser Lys Arg Ser Val Pro Gly Trp Ser Thr Val
  1                5                10                15
Arg Glu Arg Met Arg Arg Ala Glu Pro Ala Ala Asp Arg Val Arg Arg
                20                25                30
Thr Glu Pro Ala Ala Val Gly Val Gly Ala Val Ser Arg Asp Leu Glu
                35                40                45
Lys His Gly Ala Ile Thr Ser Ser Asn Thr Ala Ala Thr Asn Ala Asp
                50                55                60
Cys Ala Trp Leu Glu Ala Gln Glu Asp Glu Glu Val Gly Phe Pro Val
                65                70                75                80
Arg Pro Gln Val Pro Leu Arg Pro Met Thr Tyr Lys Gly Ala Val Asp
                85                90                95
Leu Ser His Phe Leu Lys Glu Lys Gly Gly Leu Glu Gly Leu Ile His
                100                105                110
Ser Gln Lys Arg Gln Asp Ile Leu Asp Leu Trp Val Tyr His Thr Gln
                115                120                125
Gly Tyr Phe Pro Asp Trp Gln Asn Tyr Thr Pro Gly Pro Gly Ile Arg
                130                135                140
Phe Pro Leu Thr Phe Gly Trp Cys Phe Lys Leu Val Pro Val Glu Pro
                145                150                155                160
Glu Lys Val Glu Glu Ala Asn Glu Gly Glu Asn Asn Cys Leu Leu His
                165                170                175
Pro Met Ser Gln His Gly Ile Glu Asp Pro Glu Lys Glu Val Leu Glu
                180                185                190
Trp Arg Phe Asp Ser Lys Leu Ala Phe His His Val Ala Arg Glu Leu
                195                200                205
His Pro Glu Tyr Tyr Lys Asp Cys
                210                215

```

&lt;210&gt; SEQ ID NO:3

&lt;211&gt; LENGTH: 719

&lt;212&gt; TYPE: DNA

&lt;213&gt; ORGANISM: Human Immunodeficiency Virus - 1

&lt;220&gt; FEATURE:

&lt;221&gt; NAME/KEY: CDS

&lt;222&gt; LOCATION: (2)...(715)

&lt;400&gt; SEQ ID NO:3

```

c atg gat gca atg aag aga ggg ctc tgc tgt gtg ctg ctg ctg tgt gga      49
  Met Asp Ala Met Lys Arg Gly Leu Cys Cys Val Leu Leu Leu Cys Gly
    1             5             10             15

gca gtc ttc gtt tgc ccc agc gag atc tcc tcc aag agg tcc gtg ccc      97
Ala Val Phe Val Ser Pro Ser Glu Ile Ser Ser Lys Arg Ser Val Pro
    20             25             30

ggc tgg tcc acc gtg agg gag agg atg agg agg gcc gag ccc gcc gcc     145
Gly Trp Ser Thr Val Arg Glu Arg Met Arg Arg Ala Glu Pro Ala Ala
    35             40             45

gac agg gtg agg agg acc gag ccc gcc gcc gtg ggc gtg ggc gcc gtg     193
Asp Arg Val Arg Arg Thr Glu Pro Ala Ala Val Gly Val Gly Ala Val
    50             55             60

tcc agg gac ctg gag aag cac ggc gcc atc acc tcc tcc aac acc gcc     241
Ser Arg Asp Leu Glu Lys His Gly Ala Ile Thr Ser Ser Asn Thr Ala
    65             70             75             80

gcc acc aac gcc gac tgc gcc tgg ctg gag gcc cag gag gac gag gag     289
Ala Thr Asn Ala Asp Cys Ala Trp Leu Glu Ala Gln Glu Asp Glu Glu
    85             90             95

gtg ggc ttc ccc gtg agg ccc cag gtg ccc ctg agg ccc atg acc tac     337
Val Gly Phe Pro Val Arg Pro Gln Val Pro Leu Arg Pro Met Thr Tyr
   100             105             110

aag ggc gcc gtg gac ctg tcc cac ttc ctg aag gag aag ggc ggc ctg     385
Lys Gly Ala Val Asp Leu Ser His Phe Leu Lys Glu Lys Gly Gly Leu
   115             120             125

gag ggc ctg atc cac tcc cag aag agg cag gac atc ctg gac ctg tgg     433
Glu Gly Leu Ile His Ser Gln Lys Arg Gln Asp Ile Leu Asp Leu Trp
   130             135             140

gtg tac cac acc cag ggc tac ttc ccc gac tgg cag aac tac acc ccc     481
Val Tyr His Thr Gln Gly Tyr Phe Pro Asp Trp Gln Asn Tyr Thr Pro
   145             150             155             160

ggc ccc ggc atc agg ttc ccc ctg acc ttc ggc tgg tgc ttc aag ctg     529
Gly Pro Gly Ile Arg Phe Pro Leu Thr Phe Gly Trp Cys Phe Lys Leu
   165             170             175

gtg ccc gtg gag ccc gag aag gtg gag gag gcc aac gag ggc gag aac     577
Val Pro Val Glu Pro Glu Lys Val Glu Glu Ala Asn Glu Gly Glu Asn
   180             185             190

aac tgc ctg ctg cac ccc atg tcc cag cac ggc atc gag gac ccc gag     625
Asn Cys Leu Leu His Pro Met Ser Gln His Gly Ile Glu Asp Pro Glu
   195             200             205

aag gag gtg ctg gag tgg agg ttc gac tcc aag ctg gcc ttc cac cac     673

```

Lys Glu Val Leu Glu Trp Arg Phe Asp Ser Lys Leu Ala Phe His His  
 210 215 220

gtg gcc agg gag ctg cac ccc gag tac tac aag gac tgc taa 715  
 Val Ala Arg Glu Leu His Pro Glu Tyr Tyr Lys Asp Cys \*  
 225 230 235

agcc 719

<210> SEQ ID NO:4  
 <211> LENGTH: 237  
 <212> TYPE: PRT  
 <213> ORGANISM:Human Immunodeficiency Virus - 1

<400> SEQ ID NO:4  
 Met Asp Ala Met Lys Arg Gly Leu Cys Cys Val Leu Leu Leu Cys Gly  
 1 5 10 15  
 Ala Val Phe Val Ser Pro Ser Glu Ile Ser Ser Lys Arg Ser Val Pro  
 20 25 30  
 Gly Trp Ser Thr Val Arg Glu Arg Met Arg Arg Ala Glu Pro Ala Ala  
 35 40 45  
 Asp Arg Val Arg Arg Thr Glu Pro Ala Ala Val Gly Val Gly Ala Val  
 50 55 60  
 Ser Arg Asp Leu Glu Lys His Gly Ala Ile Thr Ser Ser Asn Thr Ala  
 65 70 75 80  
 Ala Thr Asn Ala Asp Cys Ala Trp Leu Glu Ala Gln Glu Asp Glu Glu  
 85 90 95  
 Val Gly Phe Pro Val Arg Pro Gln Val Pro Leu Arg Pro Met Thr Tyr  
 100 105 110  
 Lys Gly Ala Val Asp Leu Ser His Phe Leu Lys Glu Lys Gly Gly Leu  
 115 120 125  
 Glu Gly Leu Ile His Ser Gln Lys Arg Gln Asp Ile Leu Asp Leu Trp  
 130 135 140  
 Val Tyr His Thr Gln Gly Tyr Phe Pro Asp Trp Gln Asn Tyr Thr Pro  
 145 150 155 160  
 Gly Pro Gly Ile Arg Phe Pro Leu Thr Phe Gly Trp Cys Phe Lys Leu  
 165 170 175  
 Val Pro Val Glu Pro Glu Lys Val Glu Glu Ala Asn Glu Gly Glu Asn  
 180 185 190  
 Asn Cys Leu Leu His Pro Met Ser Gln His Gly Ile Glu Asp Pro Glu  
 195 200 205  
 Lys Glu Val Leu Glu Trp Arg Phe Asp Ser Lys Leu Ala Phe His His  
 210 215 220  
 Val Ala Arg Glu Leu His Pro Glu Tyr Tyr Lys Asp Cys  
 225 230 235

<210> SEQ ID NO:5  
 <211> LENGTH: 671  
 <212> TYPE: DNA  
 <213> ORGANISM:Human Immunodeficiency Virus - 1

<220> FEATURE:  
 <221> NAME/KEY: CDS  
 <222> LOCATION: (12)...(662)

<400> SEQ ID NO:5  
 gatctgccac c atg gcc ggc aag tgg tcc aag agg tcc gtg ccc ggc tgg 50  
 Met Ala Gly Lys Trp Ser Lys Arg Ser Val Pro Gly Trp  
 1 5 10  
 tcc acc gtg agg gag agg atg agg agg gcc gag ccc gcc gcc gac agg 98

```

Ser Thr Val Arg Glu Arg Met Arg Arg Ala Glu Pro Ala Ala Asp Arg
  15          20          25
gtg agg agg acc gag ccc gcc gcc gtg ggc gtg ggc gcc gtg tcc agg      146
Val Arg Arg Thr Glu Pro Ala Ala Val Gly Val Gly Ala Val Ser Arg
  30          35          40          45
gac ctg gag aag cac ggc gcc atc acc tcc tcc aac acc gcc gcc acc      194
Asp Leu Glu Lys His Gly Ala Ile Thr Ser Ser Asn Thr Ala Ala Thr
          50          55          60
aac gcc gac tgc gcc tgg ctg gag gcc cag gag gac gag gag gtg ggc      242
Asn Ala Asp Cys Ala Trp Leu Glu Ala Gln Glu Asp Glu Glu Val Gly
          65          70          75
ttc ccc gtg agg ccc cag gtg ccc ctg agg ccc atg acc tac aag ggc      290
Phe Pro Val Arg Pro Gln Val Pro Leu Arg Pro Met Thr Tyr Lys Gly
          80          85          90
gcc gtg gac ctg tcc cac ttc ctg aag gag aag ggc ggc ctg gag ggc      338
Ala Val Asp Leu Ser His Phe Leu Lys Glu Lys Gly Gly Leu Glu Gly
          95          100          105
ctg atc cac tcc cag aag agg cag gac atc ctg gac ctg tgg gtg tac      386
Leu Ile His Ser Gln Lys Arg Gln Asp Ile Leu Asp Leu Trp Val Tyr
  110          115          120          125
cac acc cag ggc tac ttc ccc gac tgg cag aac tac acc ccc ggc ccc      434
His Thr Gln Gly Tyr Phe Pro Asp Trp Gln Asn Tyr Thr Pro Gly Pro
          130          135          140
ggc atc agg ttc ccc ctg acc ttc ggc tgg tgc ttc aag ctg gtg ccc      482
Gly Ile Arg Phe Pro Leu Thr Phe Gly Trp Cys Phe Lys Leu Val Pro
          145          150          155
gtg gag ccc gag aag gtg gag gag gcc aac gag ggc gag aac aac tgc      530
Val Glu Pro Glu Lys Val Glu Glu Ala Asn Glu Gly Glu Asn Asn Cys
          160          165          170
gcc gcc cac ccc atg tcc cag cac ggc atc gag gac ccc gag aag gag      578
Ala Ala His Pro Met Ser Gln His Gly Ile Glu Asp Pro Glu Lys Glu
          175          180          185
gtg ctg gag tgg agg ttc gac tcc aag ctg gcc ttc cac cac gtg gcc      626
Val Leu Glu Trp Arg Phe Asp Ser Lys Leu Ala Phe His His Val Ala
  190          195          200          205
agg gag ctg cac ccc gag tac tac aag gac tgc taa agccccgggc      671
Arg Glu Leu His Pro Glu Tyr Tyr Lys Asp Cys *
          210          215

```

&lt;210&gt; SEQ ID NO:6

&lt;211&gt; LENGTH: 217

&lt;212&gt; TYPE: PRT

&lt;213&gt; ORGANISM: Human Immunodeficiency Virus - 1

&lt;400&gt; SEQ ID NO:6

Met Ala Gly Lys Trp Ser Lys Arg Ser Val Pro Gly Trp Ser Thr Val

```

1           5           10           15
Arg Glu Arg Met Arg Arg Ala Glu Pro Ala Ala Asp Arg Val Arg Arg
20           25           30
Thr Glu Pro Ala Ala Val Gly Val Gly Ala Val Ser Arg Asp Leu Glu
35           40           45
Lys His Gly Ala Ile Thr Ser Ser Asn Thr Ala Ala Thr Asn Ala Asp
50           55           60
Cys Ala Trp Leu Glu Ala Gln Glu Asp Glu Glu Val Gly Phe Pro Val
65           70           75           80
Arg Pro Gln Val Pro Leu Arg Pro Met Thr Tyr Lys Gly Ala Val Asp
85           90           95
Leu Ser His Phe Leu Lys Glu Lys Gly Leu Glu Gly Leu Ile His
100          105          110
Ser Gln Lys Arg Gln Asp Ile Leu Asp Leu Trp Val Tyr His Thr Gln
115          120          125
Gly Tyr Phe Pro Asp Trp Gln Asn Tyr Thr Pro Gly Pro Gly Ile Arg
130          135          140
Phe Pro Leu Thr Phe Gly Trp Cys Phe Lys Leu Val Pro Val Glu Pro
145          150          155          160
Glu Lys Val Glu Glu Ala Asn Glu Gly Glu Asn Asn Cys Ala Ala His
165          170          175
Pro Met Ser Gln His Gly Ile Glu Asp Pro Glu Lys Glu Val Leu Glu
180          185          190
Trp Arg Phe Asp Ser Lys Leu Ala Phe His His Val Ala Arg Glu Leu
195          200          205
His Pro Glu Tyr Tyr Lys Asp Cys Ser
210          215

```

<210> SEQ ID NO:7

<211> LENGTH: 720

<212> TYPE: DNA

<213> ORGANISM: Human Immunodeficiency Virus - 1

<220> FEATURE:

<221> NAME/KEY: CDS

<222> LOCATION: (2)...(715)

<400> SEQ ID NO:7

```

c atg gat gca atg aag aga ggg ctc tgc tgt gtg ctg ctg ctg tgt gga      49
  Met Asp Ala Met Lys Arg Gly Leu Cys Cys Val Leu Leu Leu Cys Gly
    1           5           10           15

gca gtc ttc gtt tcg ccc agc gag atc tcc tcc aag agg tcc gtg ccc      97
Ala Val Phe Val Ser Pro Ser Glu Ile Ser Ser Lys Arg Ser Val Pro
    20           25           30

ggc tgg tcc acc gtg agg gag agg atg agg agg gcc gag ccc gcc gcc      145
Gly Trp Ser Thr Val Arg Glu Arg Met Arg Arg Ala Glu Pro Ala Ala
    35           40           45

gac agg gtg agg agg acc gag ccc gcc gcc gtg ggc gtg ggc gcc gtg      193
Asp Arg Val Arg Arg Thr Glu Pro Ala Ala Val Gly Val Gly Ala Val
    50           55           60

tcc agg gac ctg gag aag cac ggc gcc atc acc tcc tcc aac acc gcc      241
Ser Arg Asp Leu Glu Lys His Gly Ala Ile Thr Ser Ser Asn Thr Ala
    65           70           75           80

gcc acc aac gcc gac tgc gcc tgg ctg gag gcc cag gag gac gag gag      289
Ala Thr Asn Ala Asp Cys Ala Trp Leu Glu Ala Gln Glu Asp Glu Glu

```



	85	90	95	
gtg ggc ttc ccc gtg agg ccc cag gtg ccc ctg agg ccc atg acc tac				337
Val Gly Phe Pro Val Arg Pro Gln Val Pro Leu Arg Pro Met Thr Tyr				
	100	105	110	
aag ggc gcc gtg gac ctg tcc cac ttc ctg aag gag aag ggc ggc ctg				385
Lys Gly Ala Val Asp Leu Ser His Phe Leu Lys Glu Lys Gly Gly Leu				
	115	120	125	
gag ggc ctg atc cac tcc cag aag agg cag gac atc ctg gac ctg tgg				433
Glu Gly Leu Ile His Ser Gln Lys Arg Gln Asp Ile Leu Asp Leu Trp				
	130	135	140	
gtg tac cac acc cag ggc tac ttc ccc gac tgg cag aac tac acc ccc				481
Val Tyr His Thr Gln Gly Tyr Phe Pro Asp Trp Gln Asn Tyr Thr Pro				
	145	150	155	160
ggc ccc ggc atc agg ttc ccc ctg acc ttc ggc tgg tgc ttc aag ctg				529
Gly Pro Gly Ile Arg Phe Pro Leu Thr Phe Gly Trp Cys Phe Lys Leu				
	165	170	175	
gtg ccc gtg gag ccc gag aag gtg gag gag gcc aac gag ggc gag aac				577
Val Pro Val Glu Pro Glu Lys Val Glu Glu Ala Asn Glu Gly Glu Asn				
	180	185	190	
aac tgc gcc gcc cac ccc atg tcc cag cac ggc atc gag gac ccc gag				625
Asn Cys Ala Ala His Pro Met Ser Gln His Gly Ile Glu Asp Pro Glu				
	195	200	205	
aag gag gtg ctg gag tgg agg ttc gac tcc aag ctg gcc ttc cac cac				673
Lys Glu Val Leu Glu Trp Arg Phe Asp Ser Lys Leu Ala Phe His His				
	210	215	220	
gtg gcc agg gag ctg cac ccc gag tac tac aag gac tgc taa				715
Val Ala Arg Glu Leu His Pro Glu Tyr Tyr Lys Asp Cys *				
	225	230	235	
agccc				720

&lt;210&gt; SEQ ID NO:8

&lt;211&gt; LENGTH: 237

&lt;212&gt; TYPE: PRT

&lt;213&gt; ORGANISM:Human Immunodeficiency Virus - 1

&lt;400&gt; SEQ ID NO:8

Met Asp Ala Met Lys Arg Gly Leu Cys Cys Val Leu Leu Leu Cys Gly				
1	5	10	15	
Ala Val Phe Val Ser Pro Ser Glu Ile Ser Ser Lys Arg Ser Val Pro				
	20	25	30	
Gly Trp Ser Thr Val Arg Glu Arg Met Arg Arg Ala Glu Pro Ala Ala				
	35	40	45	
Asp Arg Val Arg Arg Thr Glu Pro Ala Ala Val Gly Val Gly Ala Val				
	50	55	60	
Ser Arg Asp Leu Glu Lys His Gly Ala Ile Thr Ser Ser Asn Thr Ala				
	65	70	75	80
Ala Thr Asn Ala Asp Cys Ala Trp Leu Glu Ala Gln Glu Asp Glu Glu				
	85	90	95	
Val Gly Phe Pro Val Arg Pro Gln Val Pro Leu Arg Pro Met Thr Tyr				
	100	105	110	

Lys Gly Ala Val Asp Leu Ser His Phe Leu Lys Glu Lys Gly Gly Leu  
 115 120 125  
 Glu Gly Leu Ile His Ser Gln Lys Arg Gln Asp Ile Leu Asp Leu Trp  
 130 135 140  
 Val Tyr His Thr Gln Gly Tyr Phe Pro Asp Trp Gln Asn Tyr Thr Pro  
 145 150 155 160  
 Gly Pro Gly Ile Arg Phe Pro Leu Thr Phe Gly Trp Cys Phe Lys Leu  
 165 170 175  
 Val Pro Val Glu Pro Glu Lys Val Glu Glu Ala Asn Glu Gly Glu Asn  
 180 185 190  
 Asn Cys Ala Ala His Pro Met Ser Gln His Gly Ile Glu Asp Pro Glu  
 195 200 205  
 Lys Glu Val Leu Glu Trp Arg Phe Asp Ser Lys Leu Ala Phe His His  
 210 215 220  
 Val Ala Arg Glu Leu His Pro Glu Tyr Tyr Lys Asp Cys  
 225 230 235

&lt;210&gt; SEQ ID NO:9

&lt;211&gt; LENGTH: 4945

&lt;212&gt; TYPE: DNA

&lt;213&gt; ORGANISM: E. coli

&lt;400&gt; SEQ ID NO:9

tcgcgcgttt	cggtgatgac	ggtgaaaacc	tctgacacat	gcagctcccc	gagacgggtca	60
cagcttgtct	gtaagcggat	gccgggagca	gacaagcccc	tcagggcgcg	tcagcgggtg	120
ttggcggttg	tcggggctgg	cttaactatg	cggtatcaga	gcagattgta	ctgagagtgc	180
accatatgcg	gtgtgaaata	ccgcacagat	gcgtaaggag	aaaataccgc	atcagattgg	240
ctattggcca	ttgcatacgt	tgtatccata	tcataatatg	tacattttata	ttggctcatg	300
tccaacatta	ccgccatggt	gacattgatt	attgactagt	tattaatagt	aatcaattac	360
ggggctcatta	gttcatagcc	catatatgga	gttccgcgtt	acataactta	cggtaaatgg	420
ccgcctgggc	tgaccgcca	acgacccccg	cccattgacg	tcaataatga	cgtatgttcc	480
catagtaacg	ccaataggga	ctttccattg	acgtcaatgg	gtggagtatt	tacggtaaac	540
tgccactctg	gcagtacatc	aagtgtatca	tatgccaagt	acgcccccta	ttgacgtcaa	600
tgacggtaaa	tggccgcct	ggcattatgc	ccagtacatg	accttatggg	actttcctac	660
ttggcagtag	atctacgtat	tagtcatcgc	tattaccatg	gtgatgcggg	tttggcagta	720
catcaatggg	cgtggatagc	ggtttgactc	acgggggatt	ccaagtctcc	acccatttga	780
cgtcaatggg	agtttgtttt	ggcaccaaaa	tcaacgggac	tttccaaaat	gtcgtaaaca	840
ctccgccccca	ttgacgcaaa	tgggcggtag	gcgtgtacgg	tgggaggtct	atataagcag	900
agctcgttta	gtgaaccgtc	agatcgctg	gagacgccat	ccacgctgtt	ttgacctcca	960
tagaagacac	cgggaccgat	ccagcctccg	cggccgggaa	cgtgtcattg	gaacgcggat	1020
tccccgtgcc	aagagtgcag	taagtaccgc	ctatagactc	tataggcaca	cccccttggc	1080
tcttatgcat	gctatactgt	ttttggcttg	gggcctatac	acccccgctt	ccttatgcta	1140
taggtgatgg	tatagcttag	cctatagggt	tgggttattg	accattattg	accactcccc	1200
tattggtgac	gatactttcc	attactaatc	cataacatgg	ctctttgccca	caactatctc	1260
tattggctat	atgccaatac	tctgtccttc	agagactgac	acggactctg	tatttttaca	1320
ggatgggggc	ccattttatta	tttacaatt	cacatataca	acaacgccgt	cccccggtcc	1380
cgcagttttt	attaaacata	gcgtgggatc	tccacgcgaa	tctcgggtac	gtgttccgga	1440
catgggctct	tctccggtag	cggcggagct	tccacatccg	agccctggtc	ccatgcctcc	1500
agcggctcat	ggtcgctcgg	cagctccttg	ctcctaacag	tggaggccag	acttaggcac	1560
agcacaatgc	ccaccaccac	cagtggtgccg	cacaaggccg	tggcggtagg	gtatgtgtct	1620
gaaaatgagc	gtggagattg	ggctcgcacg	gctgacgcag	atggaagact	taaggcagcg	1680
gcagaagaag	atgcaggcag	ctgagttggt	gtattctgat	aagagtcaga	ggtaactccc	1740
gttgcggtgc	tggttaacgg	ggagggcagt	gtagtctgag	cagtactcgt	tgctgccgcg	1800
cgcgccacca	gacataatag	ctgacagact	aacagactgt	tcctttccat	gggtcttttc	1860
tgcagtcacc	gtccttagat	caccatggat	gcaatgaaga	gagggctctg	ctgtgtgctg	1920
ctgctgtgtg	gagcagtcct	cgtttcgccc	agcgagatct	gctgtgcctt	ctagttgcca	1980
gccatctggt	gtttgccctt	ccccgtgcc	ttccttgacc	ctggaagggtg	ccactcccac	2040
tgtcctttcc	taataaaatg	aggaaattgc	atcgcatgtg	ctgagtaggt	gtcattctat	2100
tctggggggg	gggggtgggg	aggacagcaa	gggggaggat	tgggaagaca	atagcaggca	2160
tgctggggat	gcggtgggct	ctatggccgc	tgcggccagg	tgctgaagaa	ttgaccgggt	2220
tcctcctggg	ccagaaagaa	gcaggcacat	cccttctct	gtgacacacc	ctgtccacgc	2280

```

ccctggttct tagttccagc cccactcata ggacactcat agctcaggag ggctccgcct 2340
tcaatcccac ccgctaaagt acttgagcgc gtctctccct ccctcatcag cccaccaaac 2400
caaacctagc ctccaagagt gggaagaaat taaagcaaga taggctatta agtgacagagg 2460
gagagaaaaa gcctccaaca tgtgaggaag taatgagaga aatcatagaa tttcttccgc 2520
ttcttcgcgc actgactcgc tgcgctcggc cgttcggctg cggcgagcgg tatcagctca 2580
ctcaaaaggcg gtaatacggc tatccacaga atcaggggat aacgcaggaa agaacatgtg 2640
agcaaaaggc cagcaaaagg ccagggaaccg taaaaaggcc gcgttgctgg cgtttttcca 2700
taggctccgc cccctcgacg agcatcaca aaatcgacgc tcaagtcaga ggtggcgaaa 2760
cccgcacagg ctataaagat accaggcgtt tccccctgga agctccctcg tgcgctctcc 2820
tgttccgacc ctgccgctta ccgatacct gtccgccttt ctcccttcgg gaagcgtggc 2880
gctttctcat agctcacgct gtaggtatct cagttcgggt taggtcgttc gctccaagct 2940
gggctgtgtg cacgaacccc ccgttcagcc cgaccgctgc gccttatccg gtaactatcg 3000
tcttgagtc aacccggtaa gacacgactt atcgccactg gcagcagcca ctggtaacag 3060
gattagcaga gcgaggtatg taggcggtgc tacagagttc ttgaagtggg ggctaacta 3120
cggctacact agaagaacag tatttggtat ctgcgctctg ctgaagccag ttaccttcgg 3180
aaaaagagtt ggtagctctt gatccggcaa acaaacacc gctggtagcg gtgggttttt 3240
tgtttgcaag cagcagatta cgcgcagaaa aaaaggatct caagaagatc ctttgatctt 3300
ttctacgggg tctgacgctc agtggaacga aaactcacgt taagggtatt tggctcagag 3360
attatcaaaa aggatcttca cctagatcct tttaaattaa aaatgaagtt ttaaataaat 3420
ctaaagtata tatgagtaaa cttggtctga cagttaccaa tgcttaatca gtgaggcacc 3480
tatctcagcg atctgtctat ttcgttcac catagttgct tgactcgggg gggggggggc 3540
ctgaggtctg cctcgtgaag aagttcgatt tattcaacaa agccgcgct ccgtcaagtc 3600
atccagccag aaagtggagg agccacggtt gatgagagct ttgttgtagg tggaccagtt 3660
ggtgattttg aacttttgct ttgccacgga acggtctgct ttgtcgggaa gatgcgtgat 3720
ctgatccctc aactcagcaa aagttcgatt tattcaacaa agccgcgct ccgtcaagtc 3780
agcgtaatgc tctgccagtg ttacaaccaa ttaaccaatt ctgattagaa aaactcatcg 3840
agcatcaaat gaaactgcaa ttatttcata tcaggattat caataccata tttttgaaaa 3900
agccgtttct gtaatgaagg aaaaaactca ccgaggcagt tccataggat ggcaagatcc 3960
tggtatcggg ctgcgattcc gactcgtcca acatcaatac aacctattaa tttccctcg 4020
tcaaaaaata gggtatcaag tgagaaatca ccatgagtga cgactgaatc cggtgagaat 4080
ggcaaaagct tatgcatctt tttccagact tgttcaacag gccagccatt acgctcgtca 4140
tcaaaatcac tcgcatcaac caaaccggtt ttcatctcgt attgcgcctg agcgagacga 4200
aatacgcgat cgctgttaaa aggacaatta caaacaggaa tcgaatgcaa cgggcgcagg 4260
aacactgcca gcgcatcaac aatattttca cctgaatcag gatattcttc taatacctgg 4320
aatgctgttt tccccgggat cgcagtggtg agtaaccatg catcatcagg agtacggata 4380
aaatgcttga tggtcggaag aggcataaat tccgtcagcc agtttagtct gaccatctca 4440
tctgtaacat cattggcaac gctacctttg ccatgtttca gaaacaactc tggcgcatcg 4500
ggcttcccat acaatcgata gattgtcgca cctgattgct cgacattatc gcgagcccat 4560
ttatacccat ataaatcagc atccatgttg gaatttaatc ggggcctcga gcaagacggt 4620
tcccgtgaa tatggctcat aacacccctt gtattactgt ttatgtaagc agacagtttt 4680
attgttcatg atgatattt tttatcttgt gcaatgtaac atcagagatt ttgagacaca 4740
acgtggcttt cccccccccc ccattattga agcatttatc agggttattg tctcatgagc 4800
ggatacatat ttgaatgtat ttagaaaaat aaacaaatag gggttccgag cacattttcc 4860
cgaaaagtgc cacctgacgt ctaagaaacc attattatca tgacattaac ctataaaaa 4920
aggcgtatca cgaggccctt tcgtc 4945

```

<210> SEQ ID NO:10

<211> LENGTH: 23

<212> TYPE: DNA

<213> ORGANISM:Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: oligonucleotide

<400> SEQ ID NO:10

ctatataagc agagctcgtt tag

23

<210> SEQ ID NO:11

<211> LENGTH: 30

<212> TYPE: DNA  
 <213> ORGANISM:Artificial Sequence  
  
 <220> FEATURE:  
 <223> OTHER INFORMATION: oligonucleotide  
  
 <400> SEQ ID NO:11  
 gtagcaaaga tctaaggacg gtgactgcag 30  
  
 <210> SEQ ID NO:12  
 <211> LENGTH: 39  
 <212> TYPE: DNA  
 <213> ORGANISM:Artificial Sequence  
  
 <220> FEATURE:  
 <223> OTHER INFORMATION: oligonucleotide  
  
 <400> SEQ ID NO:12  
 gtatgtgtct gaaaatgagc gtggagattg ggctcgcac 39  
  
 <210> SEQ ID NO:13  
 <211> LENGTH: 39  
 <212> TYPE: DNA  
 <213> ORGANISM:Artificial Sequence  
  
 <220> FEATURE:  
 <223> OTHER INFORMATION: oligonucleotide  
  
 <400> SEQ ID NO:13  
 gtgcgagccc aatctccacg ctcatTTTca gacacatac 39  
  
 <210> SEQ ID NO:14  
 <211> LENGTH: 4432  
 <212> TYPE: DNA  
 <213> ORGANISM:E. coli  
  
 <400> SEQ ID NO:14  
 tcgCGcgttt cggTgatgac ggtgaaaacc tctgacacat gcagctcccg gagacggtca 60  
 cagcttTgtct gtaagcggat gccgggagca gacaagcccg tcagggcgcg tcagcgggtg 120  
 ttggcgggtg tcggggctgg cttaactatg cggcatcaga gcagattgta ctgagagtgc 180  
 accatatgCG gtgtgaaata ccgcacagat gcgtaaggag aaaataccgc atcagattgg 240  
 ctattggcca ttgcatacgt tgtatccata tcataaatatg tacatttata ttgggtcatg 300  
 tccaacatta ccgccatgtt gacattgatt attgactagt tattaatagt aatcaattac 360  
 ggggtcatta gttcatagcc catatatgga gttccgcgtt acataactta cggtaaatgg 420  
 ccgcctggc tgaccgcca acgaccccg cccattgacg tcaataatga cgtatgttcc 480  
 catagtaacg ccaataggga ctttccattg acgtcaatgg gtggagtatt tacggtaaac 540  
 tgcccacttg gcagtacatc aagtgtatca tatgccaagt acgcccccta ttgacgtcaa 600  
 tgacggtaaa tggccgcct gccattatgc ccagtacatg accttatggg actttcctac 660  
 ttggcagtag atctacgtat tagtcacgc tattaccatg gtgatgcggg tttggcagta 720  
 catcaatggg cgtggatagc ggtttgactc acgggggattt ccaagtctcc accccattga 780  
 cgtcaatggg agtttgTTTT ggcacaaaa tcaacgggac tttccaaaat gtcgtaacaa 840  
 ctccgcccc ttgacgcaa tgggcggtag gcgtgtacgg tgggaggtct atataagcag 900  
 agctcgttta gtgaaccgtc agatcgctg gagacgccat ccacgctgtt ttgacctcca 960  
 tagaagacac cgggaccgat ccagcctccg cggccgggaa cggtgattg gaacgcgat 1020  
 tccccgtgcc aagagtgcg taagtaccgc ctatagagtc tataggccca cccccttggc 1080  
 ttcttatgca tgctatactg tttttggtt ggggtctata ccccccgct tctcatgtt 1140  
 ataggTgatg gtatagctta gcctataggt gtgggttatt gaccattatt gaccactccc 1200  
 ctattggTga cgatactttc cattactaat ccataacatg gctctttgcc acaactctct 1260  
 ttattggcta tatgccaata cactgtcctt cagagactga cacggactct gtatttttac 1320  
 aggatgggt ctcatTTTatt atttacaat tcacatatc aacaccaccg tccccagtgc 1380  
 ccgCagTTTT tattaacat aacgtgggat ctccacgcga atctcgggta cgtgttccgg 1440

```

acatgggctc ttctccggta gcggcggagc ttctacatcc gagccctgct cccatgcctc 1500
cagcgactca tgggtcgctcg gcagctcctt gctcctaaca gtggaggcca gacttaggca 1560
cagcacgatg cccaccacca ccagtggtgc gcacaaggcc gtggcggtag ggtatgtgtc 1620
tgaaaatgag ctccggggagc gggcttgac cgctgacgca tttggaagac ttaaggcagc 1680
ggcagaagaa gatgcaggca gctgagttgt tgtgttctga taagagtcag aggtaaacct 1740
cgttgcggtg ctgttaacgg tggagggcag tgtagtctga gcagtactcg ttgctgccgc 1800
gcgcgccacc agacataata gctgacagac taacagactg ttccctttcca tgggtctttt 1860
ctgcagtcac cgtccttaga tctgctgtgc ctctagtgtg ccagccatct gttgtttgct 1920
cctccccgtg gcttctcttg accctggaag gtgccactcc cactgtcctt tcctaataaa 1980
atgaggaat tgcatcgcat tgtctgagta ggtgtcattc tattctgggg ggtggggtgg 2040
ggcagcacag caagggggag gattgggaag acaatagcag gcatgctggg gatgcggtg 2100
gctctatggg taccaggtg ctgaagaatt gacccggttc ctctggggc agaaagaagc 2160
aggcacatcc ccttctctgt gacacacct gtccacgccc ctggttctta gttccagccc 2220
cactcatagg acactcatag ctccaggagg ctccgccttc aatccacccc gctaaagtac 2280
ttggagcggt ctctccctcc ctcatcagcc caccaaaacca aacctagcct ccaagagtgg 2340
gaagaaatta aagcaagata ggctattaag tgcaaggaga gaaaaatgc ctccaacatg 2400
tgaggaagta atgagagaaa tcatagaatt tcttccgctt cctcgctcac tgactcgctg 2460
cgctcggtcg ttcggctgctg gcgagcggta tcagctcact caaaggcggg aatacggtta 2520
tccacagaat caggggataa cgcaggaaag aacatgtgag caaaaggcca gcaaaaggcc 2580
aggaaccgta aaaaggccgc gttgctggcg tttttccata ggctccgccc ccctgacgag 2640
catcacaaaa atcgacgctc aagtcagagg tggcgaaacc cgacaggact ataaagatac 2700
caggcgtttc cccctggaag ctccctcgtg cgctctcctg ttccgacctt gccgcttacc 2760
ggatacctgt ccgcctttct ccttccggga agcgtggcgc tttctcaatg ctacgctgt 2820
aggatatcca gtccggtgta ggtcggtcgc tccaagctgg gctgtgtgca cgaacccccc 2880
gttcagcccg accgctgcgc cttatccggt aactatcgct ttgagtcaca cccggtaaga 2940
cacgacttat cgccactggc agcagccact ggtaacagga ttagcagagc gaggatgta 3000
ggcggtgcta cagagtctct gaagtgttgg cctaactacg gctacactag aaggacagta 3060
tttggtatct gcgctctgct gaagccagtt accctcgga aaagagttgg tagctcttga 3120
tccggcaaac aaaccaccgc tggtagcggg ggtttttttg tttgcaagca gcagattacg 3180
cgcaaaaaa aaggatctca agaagatcct ttgatctttt ctacggggtc tgacgctcag 3240
tggaaacgaaa actcacgcta agggattttg gtcatgagat tatcaaaaag gatcttcacc 3300
tagatccttt taaattaaaa atgaagtttt aaatcaatct aaagtatata tgagtaaaact 3360
tgggtctgaca gttaccaatg cttaatcagt gaggcaccta tctcagcgat ctgtctatct 3420
cggttcaccca tagttgcctg actccccgtc gtgtagataa ctacgatacg ggagggctta 3480
ccatctggcc ccagtgtcgc aatgataccg cgagaccac gctcaccgct tccagattta 3540
tcagcaataa accagccagc cggaaaggcc gagcgagaa gtggtcctgc aactttatcc 3600
gcctccatcc agtctattaa ttgttgccgg gaagctagag taagtagttc gccagttaat 3660
agtttgcgca acgttgttgc cattgtaca ggcatcgtgg tgtcacgctc gtcgtttggt 3720
atggcttcac tcagctccgg tttccaaacg tcaaggcgag ttacatgac ccccatgtt 3780
tgcaaaaaa cggttagctc cttcggctct ccgatcgtt tcaagagtaa gttggccgca 3840
gtgttatcac tcatggttat ggcagcactg cataattctc ttactgtcat gccatccgta 3900
agatgctttt ctgtgactgg tgagtactca accaagtcac tctgagaata gtgtatcgcg 3960
cgaccgagtt gctcttgccc ggcgtcaata cgggataata ccgcgccaca tagcagaact 4020
ttaaagtgct tcatcattgg aaaacgttct tcggggcgaa aactctcaag gatcttaccg 4080
ctgttgagat ccagttcgat gtaacccact cgtgcaccca actgatcttc agcatctttt 4140
actttcacca gcgtttcttg gtgagcaaaa acaggaaggc aaaatgccgc aaaaaaggga 4200
ataaggcgca cagggaatg ttgaatactc atactcttcc tttttcaata ttattgaagc 4260
atttatcagg gttattgtct catgagcgga tacatatatt aatgtattta gaaaaataaa 4320
caaatagggg ttccgcgcac atttccccga aaagtgccac ctgacgtcta agaaaccatt 4380
attatcatga cattaacctc cgtatcacga ggccttttcg tc 4432

```

&lt;210&gt; SEQ ID NO:15

&lt;211&gt; LENGTH: 4864

&lt;212&gt; TYPE: DNA

&lt;213&gt; ORGANISM: E. coli

&lt;400&gt; SEQ ID NO:15

```

tcgcgcgttt cggtgatgac ggtgaaaacc tctgacacat gcagctcccg gagacggtca 60
cagcttctgt gtaagcggat gccgggagca gacaagcccg tcagggcgcg tcagcgggtg 120
ttggcgggtg tcggggctgg cttaaactat cggtatcaga gcagattgta ctgagagtg 180
accatatgcg gtgtgaaata ccgcacagat gcgtaaggag aaaataccgc atcagattgg 240

```

ctattggcca	ttgcatacgt	tgtatccata	tcataatatg	tacatttata	ttggctcatg	300
tccaacatta	ccgccatggt	gacattgatt	attgactagt	tattaatagt	aatcaattac	360
gggggtcatta	gttcatagcc	catatatgga	gttccgcgtt	acataactta	cggtaaatgg	420
cccgcttggc	tgaccgccca	acgacccccc	cccatagacg	tcaataatga	cgtatgttcc	480
catagtaacg	ccaatagggg	ctttccattg	acgtcaatgg	gtggagtatt	tacggtaaac	540
tgcccacttg	gcagtacatc	aagtgtatca	tatgccaaat	acgcccccta	ttgacgtcaa	600
tgacggtaaa	tggcccgctt	ggcattatgc	ccagtacatg	accttatggg	actttcctac	660
ttggcagtac	atctacgtat	tagtcacgcg	tattaccatg	gtgatgcggt	tttggcagta	720
catcaatggg	cgtggatagc	ggtttgactc	acgggggatt	ccaagtctcc	acccccattga	780
cgtcaatggg	agtttggttt	ggcaccaaaa	tcaacgggac	tttccaaaat	gtcgtataca	840
ctccgcccc	ttgacgcaaa	tggggcgtag	gcgtgtacgg	tgggaggtct	atataagcag	900
agctcgttta	gtgaaccgtc	agatcgccct	gagacgccat	ccacgctgtt	ttgacctcca	960
tagaagacac	cgggaccgat	ccagcctccg	cggccgggaa	cgggtgcattg	gaacgcggat	1020
tcccctggcc	aagagtgcag	taagtaccgc	ctatagagtc	tataggccca	cccccttggc	1080
ttcttatgca	tgtctacttg	tttttggctt	gggggtctata	cacccccgct	tcctcatgtt	1140
atagggtgat	gtatagctta	gcctataggt	gtgggttatt	gaccattatt	gaccactccc	1200
ctattgggta	cgatactttc	cattactaat	ccataacatg	gctctttgcc	acaactctct	1260
ttattgggta	tatgccaaata	cactgtcctt	cagagactga	cacggactct	gtatttttac	1320
aggatggggg	ctcattttatt	atttacaat	tcacatatac	aacaccaccg	tccccagtg	1380
ccgcagtttt	tattaaacat	aacgtgggat	ctccacgcga	atctcgggta	cgtgttccgg	1440
acatgggctc	ttctccggtc	gcggcgagc	ttctacatcc	gagccctgct	cccatgcctc	1500
cagcgactca	tggctcgctc	gcagctcctt	gctcctaaca	gtggaggcca	gacttaggca	1560
cagcacgatg	cccaccacca	ccagtgtgcc	gcacaaggcc	gtggcggtag	ggtatgtgtc	1620
tgaatgatg	ctcggggagc	gggcttgac	cgctgacgca	tttgaagac	taaggcagc	1680
ggcagaagaa	gatgcaggca	gctgagttgt	tgtgttctga	taagagtcag	aggtaactcc	1740
cgttgcgggt	ctgttaacgg	tggagggcag	tgtagtctga	gcagtactcg	ttgctgccgc	1800
gcgcgcacc	agacataata	gctgacagac	taacagactg	ttcttttcca	tgggtctttt	1860
ctgcagtcac	cgctcttaga	tctgtgtg	cttctagtgt	ccagccatct	gtgttttggc	1920
ctccccctg	gccttctctg	accctggaag	gtgccactcc	cactgtcctt	tcctaataaa	1980
atgaggaaat	tgcacgcgat	tgtctgagta	ggtgtcattc	tattctgggg	ggtgggggtg	2040
ggcagcacag	caagggggag	gattgggaag	acaatagcag	gcattgctgg	gatgcgggtg	2100
gtctctatgg	taccaggtg	ctgaagaatt	gacccgggtc	ctctctggcc	agaaagaagc	2160
aggcacatcc	ccttctctgt	gacacaccct	gtccacgccc	ctgggtctta	gttccagccc	2220
caactcatagg	acactcatag	ctcaggaggg	ctccgccttc	aatcccaccc	gctaaagtac	2280
ttggagcggg	ctctccctcc	ctcatcagcc	caccaaacca	aacctagcct	ccaagagtgg	2340
gaagaaatta	aagcaagata	ggctatttag	tgcagaggga	gagaaatgc	ctccaactag	2400
tgaggaaagta	atgagagaaa	tcatagaatt	tcttccgctt	cctcgtcac	tgactcgctg	2460
cgctcggctg	ttcggctcg	gcgagcggtg	tcagctcact	caaaggcggg	aatacgggtg	2520
ttcacagaaa	caggggataa	cgcaggaag	aacatgtgag	caaaaggcca	gcaaaaggcc	2580
aggaaccgta	aaaaggccgc	gttgcgtggc	tttttccata	ggctccgccc	ccctgacgag	2640
catcacaaaa	atcgacgctc	aagtcagagg	tggcgaaacc	cgacaggact	ataaagatac	2700
caggcggttc	cccctggaag	ctccctcggt	cgctctcctg	ttccgacctc	gccgcttacc	2760
ggatacctgt	ccgcctttct	cccttcggga	agcgtggcgc	ttctcfaatg	ctcacgctgt	2820
aggatctctca	gttcgggtgta	ggtcggttcg	tccaagctgg	gctgtgtgca	cgaaccccc	2880
gttcagcccg	accgctgctc	cttatccggt	aactatcgct	ttgagtccaa	cccggtaaga	2940
cacgacttat	cgccactggc	agcagccact	ggtaacagga	ttagcagagc	gaggtatgta	3000
ggcgggtgcta	cagagtctct	gaagtgggtg	cctaactacg	gctacactag	aaggacagta	3060
tttgggtatct	gcgctctgct	gaagccagtt	accttcggaa	aaagagtggg	tagctcttga	3120
tcgggcaaac	aaaccaccgc	tggtagcggt	gggttttttg	tttgcaagca	gcagattacg	3180
gcgagaaaaa	aaggatctca	agaagatcct	ttgatctttt	ctacggggct	tgacgctcag	3240
tggaaacgaaa	actcacgtta	agggattttg	gtcatgagat	tatcaaaaag	gatcttcacc	3300
tagatccttt	taaatataaa	atgaagtttt	aatcaatct	aaagtatata	tgagtaaact	3360
tggctctgaca	gttaccatag	cttaatcagt	gaggcaccta	tctcagcgat	ctgtctatct	3420
cgctcatcca	tagttgcctg	actccggggg	ggggggggcg	tgaggctctg	ctcgtgaaga	3480
agggtgtgct	gactcatacc	aggcctgaat	cgcccatca	tccagccaga	aagtgaaggga	3540
gccacgggtg	atgagagctt	tgttgttaggt	ggaccagttg	gtgattttga	acttttgcct	3600
tgccacggaa	cggctctgct	tgtcgggaag	atgcgtgatc	tgatccttca	actcagcaaa	3660
agttcgattt	attcaacaaa	gcgcgcctcc	cgtaaatgca	cgtaaatgct	ctgcagtggt	3720
tacaaccaat	taaccaattc	tgattagaaa	aactcatcga	gcatacaaat	aaactgcaat	3780
ttattcatat	caggattatc	aataccatat	ttttgaaaaa	gccgtttctg	taatgaaggga	3840
gaaaactcac	cgaggcagtt	ccataggatg	gcaagatcct	ggtatcggtc	tgcgattccg	3900

actcgtccaa	catcaataca	acctattaat	ttcccctcgt	caaaaaataag	gttatcaagt	3960
gagaaatcac	catgagtgc	gactgaatcc	ggtgagaatg	gcaaaagctt	atgcatttct	4020
ttccagactt	gttcaacagg	ccagccatta	cgctcgtcat	caaaatcact	cgcatcaacc	4080
aaaccgttat	tcattcgtga	ttgcgcctga	gcgagacgaa	atacgcgac	gctgttaaaa	4140
ggacaattac	aaacaggaat	cgaatgcaac	cggcgcagga	acactgccag	cgcatcaaca	4200
atattttcac	ctgaatcagg	atattcttct	aatacctgga	atgctgtttt	cccggggatc	4260
gcagtgggtga	gtaaccatgc	atcatcagga	gtacggataa	aatgcttgat	ggtcggaaga	4320
ggcataaatt	ccgtcagcca	gtttagtctg	accatctcat	ctgtaacatc	attgggcaacg	4380
ctacctttgc	catgtttcag	aaacaactct	ggcgcatcgg	gcttcccata	caatcgatag	4440
attgtcgcac	ctgattgccc	gacattatcg	cgagcccat	tatacccata	taaatcagca	4500
tcctatgttg	aatttaacg	cgccctcgag	caagacgttt	cccgttgaat	atggctcata	4560
acaccccttg	tattactgtt	tatgtaagca	gacagtttta	ttgttcata	tgatatattt	4620
ttatcttgtg	caatgtaaca	tcagagattt	tgagacacaa	cgtggctttc	ccccccccc	4680
ctattattga	gcatttatca	gggttattgt	ctcatgagcg	gatacatatt	tgaaatgtatt	4740
tagaaaaata	aacaaatagg	gggtccgcgc	acatttcccc	gaaaagtgcc	acctgacgtc	4800
taagaaacca	ttattatcat	gacattaacc	tataaaaaata	ggcgtatcac	gaggcccttt	4860
cgtc						4864

&lt;210&gt; SEQ ID NO:16

&lt;211&gt; LENGTH: 4867

&lt;212&gt; TYPE: DNA

&lt;213&gt; ORGANISM: E. coli

&lt;400&gt; SEQ ID NO:16

tcgcgcgttt	cggtgatgac	ggtgaaaacc	tctgacacat	gcagctcccg	gagacggtca	60
cagcttgtct	gtaagcggat	gccgggagca	gacaagcccc	tcagggcgcg	tcagcgggtg	120
ttggcgggtg	tcggggcttg	cttaactatg	cggcacacaga	gcagattgta	ctgagagtgc	180
accatattcg	ggtgaaata	ccgcacagat	gcgtaaggag	aaaaatccgc	atcagattgg	240
ctattggcca	ttgcatacgt	tgtatccata	tcataaatatg	tacatttata	ttggctcatg	300
tccaacatta	ccgccatggt	gacattgatt	attgactagt	tattaatagt	aatcaattac	360
ggggtcatta	gttcatagcc	catatatgga	gttccgcgtt	acataactta	cggtaaatgg	420
ccgcctcggc	tgaccgcccc	acgacccccg	cccattgacg	tcaataatga	cgtatgttcc	480
catagtaacg	ccaataggga	ctttccattg	acgtcaatgg	gtggagtatt	tacggtaaac	540
tgcccacttg	gcagtacatc	aagtgtatca	tatgccaagt	acgcccccta	ttgacgtcaa	600
tgacggtaaa	tgccccgcct	ggcattatgc	ccagtacatg	accttatggg	actttcctac	660
ttggcagtac	atctacgtat	tagtcacgcg	tattaccatg	gtgatgcggt	tttggcagta	720
catcaatggg	cgtggatagc	gggttgactc	acgggggattt	ccaagtctcc	acccccattga	780
cgtcaatggg	agttttgttt	ggcaccaaaa	tcaacgggac	tttccaaaat	gtcgtaaaca	840
ctccgcacca	ttgacgcaaa	tggcgggtag	gcgtgtacgg	tgggagggtct	atataagcag	900
agctcgttta	gtgaaccgtg	agatcgccctg	gagacgccat	ccacgctgtt	ttgacctcca	960
tagaagacac	cgggaccgat	ccagcctccg	cgcccgga	cggtgcattg	gaacgcggat	1020
tcccctgccc	aagagtgcg	taagtaccgc	ctatagactc	tataggcaca	cccccttggc	1080
tcttatgcat	gctatactgt	ttttggcttg	gggcctatac	acccccgctt	ccttatgcta	1140
taggtgatgg	tatagcttag	cctatagggt	tgggttattg	accattattg	accactcccc	1200
tattgggtgac	gatactttcc	attactaatc	cataacatgg	ctctttgcca	caactatctc	1260
tattggctat	atgccaatat	tctgtccttc	agagactgac	acggactctg	tatttttaca	1320
ggatggggtc	ccattttatta	tttacaatt	cacatataca	acaacgccgt	cccccggtcc	1380
cgcagttttt	attaaacata	gcgtgggatc	tccacgcgaa	tctcgggtac	gtgttccgga	1440
catgggctct	tctccggtag	cgccggagct	tccacatccg	agccctggtc	ccatgcctcc	1500
agcggctcat	ggtcgtcgg	cagctccttg	ctcctaacag	tggaggccag	acttaggcac	1560
agcacaatgc	ccaccaccac	cagtgtgcgg	cacaaggccg	tggcggtagg	gtatgtgtct	1620
gaaaatgagc	gtggagattg	ggctcgcacg	gctgacgcag	atggaagact	taaggcagcg	1680
gcagaagaag	atgcaggcag	ctgagttgtt	gtattctgat	aagagtcaga	ggtaactccc	1740
gttgcggtgc	tgttaacggt	ggagggcagt	gtagtctgag	cagtactcgt	tgctgcccgc	1800
cgcgccacca	gacataatg	ctgacagact	aacagactgt	tcctttccat	gggtcttttc	1860
tgcatgcacc	gtccttagat	ctgctgtgcc	ttctagtgtc	cagccatctg	ttgtttgccc	1920
ctcccccggtg	ccttccctga	ccttggaagg	tgccactccc	actgtccttt	cctaataaaa	1980
tgaggaaatt	gcatacgcat	gtctgagtga	gtgtcattct	attctggggg	gtggggtggg	2040
gcaggacagc	aagggggagg	attgggaaga	caatagcagg	catgctgggg	atgctggggg	2100
ctctatggcc	gctgcggcca	gggtgctgaag	aattgacccg	gttcctcctg	ggccagaaaag	2160
aagcaggcac	atccccctct	ctgtgacaca	ccctgtccac	gcccctggtt	cttagttcca	2220

gccccactca	taggacactc	atagctcagg	agggctccgc	cttcaatccc	acccgctaaa	2280
gtacttggag	cggctctctc	ctccctcatc	agcccaccaa	accaaacccta	gcctccaaga	2340
gtgggaagaa	attaaagcaa	gataggctat	taagtgcaga	gggagagaaa	atgcctccaa	2400
catgtgagga	agtaatgaga	gaaatcatag	aatttcttcc	gcttcctcgc	tactgactc	2460
gctgcgctcg	gtcgttcggc	tgccggcagc	ggtatcagct	caactcaagg	cggtaatcag	2520
gttatccaca	gaatcagggg	ataacgcagg	aaagaacatg	tgagcaaaag	gccagcaaaa	2580
ggccaggaac	cgtaaaaagg	ccgcgttgct	ggcgttttcc	cataggctcc	gccccctga	2640
cgagcatcac	aaaaatcgac	gctcaagtca	gaggtggcga	aacccgacag	gactataaag	2700
ataccaggcg	tttccccctg	gaagctccct	cgtgcgctct	cctgttccga	ccctgcccgt	2760
taccgggatac	ctgtccgcct	ttctcccttc	gggaagcgtg	gcgctttctc	atagctcacg	2820
ctgtagggtat	ctcagttcgg	tgtaggctcg	tcgctccaag	ctgggctgtg	tgcacgaacc	2880
ccccgttcag	cccgaccgct	gcgccttatc	cggtaaatat	cgtcttgagt	ccaacccggt	2940
aagacacgac	ttatcgccac	tggcagcagc	cactggtaac	aggattagca	gagcgaggta	3000
tgtaggcggt	gctacagagt	tcttgaagtg	gtggcctaac	tacggctaca	ctagaagAAC	3060
agtatattggt	atctgcgctc	tgctgaagcc	agttaccttc	ggaaaaagag	ttggtagctc	3120
ttgatccggc	aaacaaacca	ccgctggtag	cggtggtttt	tttgtttgca	agcagcagat	3180
tacgcgcaga	aaaaaaggat	ctcaagaaga	tcctttgatc	ttttctacgg	ggtctgacgc	3240
tcagtggaac	gaaaactcac	gttaagggat	tttggctatg	agattatcaa	aaaggatctt	3300
cacctagatc	cttttaaatt	aaaaatgaag	ttttaaatac	atctaaagta	tatatgagta	3360
aacttggtct	gacagttacc	aatgcttaat	cagtgaggca	cctatctcag	cgatctgtct	3420
atttcgttca	tccatagttg	cctgactcgg	gggggggggg	cgctgaggtc	tgccctcgtga	3480
agaaggtggt	gctgactcat	accaggcctg	aatcgcccca	tcattccagc	agaaagtga	3540
ggagccacgg	ttgatgagag	ctttgttgta	ggtggaccag	ttggtgattt	tgaacttttg	3600
ctttgccacg	gaacggtctg	cgtgtgcggg	aagatgcgtg	atctgatcct	tcaactcagc	3660
aaaagtctga	tttattcaac	aaagccgccc	tcccgtaag	tcagcgtaat	gctctgccag	3720
tgttacaacc	aattaaccaa	ttctgattag	aaaaactcat	cgagcatcaa	atgaaactgc	3780
aatttattca	tatcaggatt	atcaatacca	tatttttgaa	aaagccgttt	ctgtaatgaa	3840
ggagaaaact	caccgaggca	gttccatagg	atggcaagat	cctgggtatcg	gtctgcgatt	3900
ccgactcgtc	caacatcaat	acaacctatt	aatttcccct	cgtcaaaaaat	aagggttatca	3960
agtgagaaat	caccatgagt	gacgactgaa	tccggtgaga	atggcaaaag	cttatgcatt	4020
tctttccaga	cttgttcaac	aggccagcca	ttacgctcgt	catcaaaatc	actcgcacat	4080
accaaaccgt	tattcattcg	tgattgcgcc	tgagcgagac	gaaatacgcg	atcgctgtta	4140
aaaggacaat	tacaaacagg	aatcgaatgc	aaccggcgca	ggaacactgc	cagcgcatca	4200
acaatatattt	cacctgaatc	aggatattct	tctaatacct	ggaatgctgt	tttccggggg	4260
atcgcagtg	tgagtaacca	tgcatcatca	ggagtacgga	taaaatgctt	gatggctgga	4320
agaggcataa	attccgtcag	ccagtttagt	ctgaccatct	catctgtaac	atcattggca	4380
acgctacctt	tgccatgttt	cagaacaac	tctggcgcat	cgggcttccc	atacaatcga	4440
tagattgtcg	cacctgattg	cccgcacatta	tcgcgagccc	atttataccc	atataaatca	4500
gcatccatgt	tggaatttaa	tcgcggcctc	gagcaagacg	tttcccggtg	aatatggctc	4560
ataacacccc	ttgtattact	gtttatgtaa	gcagacagtt	ttattgttca	tgatgatata	4620
tttttatctt	gtgcaatgta	acatcagaga	ttttgagaca	caacgtggct	ttcccccccc	4680
ccccattatt	gaagcattta	tcagggttat	tgtctcatga	gcggatacat	atttgaatgt	4740
atttagaaaa	ataaacaaat	aggggttccg	cgcacatttc	ccgaaaagt	gccacctgac	4800
gtctaagaaa	ccattattat	catgacatta	acctataaaa	ataggcgat	cagcaggccc	4860
tttcgtc						4867

&lt;210&gt; SEQ ID NO:17

&lt;211&gt; LENGTH: 78

&lt;212&gt; TYPE: DNA

&lt;213&gt; ORGANISM:Artificial Sequence

&lt;220&gt; FEATURE:

&lt;223&gt; OTHER INFORMATION: oligonucleotide

&lt;400&gt; SEQ ID NO:17

gatcaccatg	gatgcaatga	agagagggct	ctgctgtgtg	ctgctgtgtg	gtggagcagt	60
cttcgttttcg	cccagcga					78

&lt;210&gt; SEQ ID NO:18

&lt;211&gt; LENGTH: 78



<212> TYPE: DNA  
<213> ORGANISM:Artificial Sequence

<220> FEATURE:  
<223> OTHER INFORMATION: oligonucleotide

<400> SEQ ID NO:18  
gatctcgctg ggcgaaacga agactgctcc acacagcagc agcacacagc agagccctct 60  
cttcattgca tccatggt 78

<210> SEQ ID NO:19  
<211> LENGTH: 27  
<212> TYPE: PRT  
<213> ORGANISM:Homo sapien

<400> SEQ ID NO:19  
Met Asp Ala Met Lys Arg Gly Leu Cys Cys Val Leu Leu Leu Cys Gly  
1 5 10 15  
Ala Val Phe Val Ser Pro Ser Glu Ile Ser Ser  
20 25

<210> SEQ ID NO:20  
<211> LENGTH: 33  
<212> TYPE: DNA  
<213> ORGANISM:Artificial Sequence

<220> FEATURE:  
<223> OTHER INFORMATION: oligonucleotide

<400> SEQ ID NO:20  
ggtacaaata ttggctattg gccattgcat acg 33

<210> SEQ ID NO:21  
<211> LENGTH: 36  
<212> TYPE: DNA  
<213> ORGANISM:Artificial Sequence

<220> FEATURE:  
<223> OTHER INFORMATION: oligonucleotide

<400> SEQ ID NO:21  
ccacatctcg aggaaccggg tcaattcttc agcacc 36

<210> SEQ ID NO:22  
<211> LENGTH: 38  
<212> TYPE: DNA  
<213> ORGANISM:Artificial Sequence

<220> FEATURE:  
<223> OTHER INFORMATION: oligonucleotide

<400> SEQ ID NO:22  
ggtacagata tcggaaagcc acgttggtgc tcaaaatc 38

<210> SEQ ID NO:23  
<211> LENGTH: 36  
<212> TYPE: DNA  
<213> ORGANISM:Artificial Sequence

<220> FEATURE:  
<223> OTHER INFORMATION: oligonucleotide

<400> SEQ ID NO:23  
cacatggatc cgtaatgctc tgccagtgtt acaacc 36

<210> SEQ ID NO:24  
<211> LENGTH: 39  
<212> TYPE: DNA  
<213> ORGANISM:Artificial Sequence

<220> FEATURE:  
<223> OTHER INFORMATION: oligonucleotide

<400> SEQ ID NO:24  
ggtacatgat cacgtagaaa agatcaaagg atcttcttg 39

<210> SEQ ID NO:25  
<211> LENGTH: 35  
<212> TYPE: DNA  
<213> ORGANISM:Artificial Sequence

<220> FEATURE:  
<223> OTHER INFORMATION: oligonucleotide

<400> SEQ ID NO:25  
ccacatgtcg acccgtaaaa aggccgcgtt gctgg 35

<210> SEQ ID NO:26  
<211> LENGTH: 4864  
<212> TYPE: DNA  
<213> ORGANISM:E. coli

<400> SEQ ID NO:26  
tcgcgcgttt cggatgatgac ggtgaaaacc tctgacacat gcagctcccg gagacgggtca 60  
cagcttgtct gtaagcggat gccgggagca gacaagcccc tcagggcgcg tcagcgggtg 120  
ttggcgggtg tcggggctgg cttactatg cggcatcaga gcagattgta ctgagagtgc 180  
accatatgct gtgtgaaata ccgcacagat gcgtaaggag aaaataccgc atcagattgg 240  
ctattggcca ttgcatacgt tgtatccata tcataaatatg tacatttata ttgggtcatg 300  
tccaacatta ccgccatgtt gacattgatt attgactagt tattaatagt aatcaattac 360  
gggggtcatta gttcatagcc catatatgga gttccgcgtt acataactta cggtaaatgg 420  
ccgcctggc tgaccgcca acgacccccg cccattgacg tcaataatga cgtatgttcc 480  
catagtaacg ccaataggga ctttccattg acgtcaatgg gtggagtatt tacggtaaac 540  
tgcccacttg gcagtacatc aagtgtatca tatgccaagt acgcccccta ttgacgtcaa 600  
tgacggtaaa tggcccgctt ggcattatgc ccagtacatg accttatggg actttcctac 660  
ttggcagtac atctacgtat tagtcacgc tattaccatg gtgatgcggt ttggcagta 720  
catcaatggg cgtggatagc ggtttgactc acggggattt ccaagtctcc accccattga 780  
cgtcaatggg agtttgtttt ggcacaaaa tcaacgggac tttccaaaat gtcgtaacaa 840  
ctccgcccc ttgacgcaaa tggcggtag gcgtgtacgg tgggaggtct atataagcag 900  
agctcgttta gtgaaccgtc agatcgccctg gagacgccat ccacgctgtt ttgacctcca 960  
tagaagacac cgggaccgat ccagcctccg cggccgggaa cgggtgcattg gaacgaggat 1020  
tccccgtgcc aagagtgcgc taagtaccgc ctatagagtc tataggccca cccccttggc 1080  
ttcttatgca tgctatactg tttttggctt ggggtctata caccctcgct tctcatgtt 1140  
ataggtgatg gtatagctta gcctataggt gtgggttatt gaccattatt gaccactccc 1200  
ctattgggtga cgatactttc cattactaat ccataacatg gctctttgcc acaactctct 1260  
ttattggcta tatgccaata cactgtcctt cagagactga cacggactct gtatttttac 1320  
aggatggggt ctcatttatt atttacaat tcacatatac aacaccaccg tccccagtgc 1380  
ccgcagtttt tattaacat aacgtgggat ctccacgcga atctcgggta cgtgttccgg 1440  
acatgggctc ttctccgta cggcgagc ttctacatcc gagccctgct cccatgcctc 1500  
cagcgactca tggctcgtcg gcagctcctt gctcctaaca gtggaggcca gacttaggca 1560  
cagcacgatg cccaccacca ccagtgtgcc gcacaaggcc gtggcggtag ggtatgtgtc 1620  
tgaaaatgag ctccgggagc gggcttgac cgctgacgca tttggaagac ttaaggcagc 1680  
ggcagaagaa gatgcaggca gctgagttgt tgtgttctga taagagtcag aggttaactcc 1740

```

cggtgcggtg ctgttaacgg tggagggcag tgtagtctga gcagtactcg ttgctgcccgc 1800
gcgcgccacc agacataata gctgacagac taacagactg ttcctttcca tgggtcctttt 1860
ctgcagtcac cgtccttaga tctgctgtgc cttctagtgg ccagccatct gttgtttgcc 1920
cctccccgt gccttccttg accctggaag gtgccactcc cactgtcctt tcctaataaa 1980
atgaggaat tgcatcgcat tgtctgagta ggtgtcattc tattctgggg ggtgggggtg 2040
ggcagcacag caagggggag gattgggaag acaatagcag gcatgctggg gatgcggtgg 2100
gctctatggg taccaggtg ctgaagaatt gaccgggttc ctctggggcc agaaagaagc 2160
aggcacatcc ccttctctgt gacacaccct gtccacgccc ctggttctta gttccagccc 2220
cactcatagg acactcatag ctccaggagg ctccgccttc aatccccacc gctaaagtac 2280
ttggagcggt ctctccctcc ctcatcagcc caccaaacca aacctagcct ccaagagtgg 2340
gaagaaatta aagcaagata ggctattaag tgcagagggg gagaaaatgc ctccaacatg 2400
tgaggaagta atgagagaaa tcatagaatt tcttccgctt cctcgctcac tgactcgctg 2460
cgctcggtcg ttcggctgag gcgagcggta tcagctcact caaaggcggt aatcgggtta 2520
tccacagatc caggggataa cgcaggaag aacatgtgag caaaaggcca gcaaaaggcc 2580
aggaaccgta aaaaggccgc gttgctggcg tttttccata ggctccgccc ccctgacgag 2640
catcacaaaa atcgacgctc aagtcagagg tggcgaaacc cgacaggact ataaagatac 2700
caggcggttc cccctggaag ctccctcgtg cgctctctcg ttcggaccct gccgcttacc 2760
ggatacctgt ccgcctttct ccttctggga agcgtggcgc tttctcaatg ctcacgctgt 2820
aggtatctca gttcggtgta ggtcggttcgc tccaagctgg gctgtgtgca cgaaccccc 2880
gttcagcccg accgctgccc cttatccggt aactatcgct ttgagtccaa cccggtaaga 2940
cacgacttat cgccactggc agcagccact ggtaacagga ttacgagagc gaggtagtga 3000
ggcgggtgta cagagtctct gaagtggtag cctaactacg gctacactag aaggacagta 3060
tttggtatct gcgctctgct gaagccagtt accttcggaa aaagagttgg tagctcttga 3120
tccggcaaac aaaccaccgc tggtagcggg ggtttttttg tttgcaagca gcagattacg 3180
cgagaaaaaa aaggatctca agaagatcct ttgatctttt ctacgggggc tgacgctcag 3240
tggaacgaaa actcacgtta agggattttg gtcatgagat tatcaaaaaa gatcttcacc 3300
tagatccttt taaattaaaa atgaagtttt aaatcaatct aaagtatata tgagtaaaact 3360
tggtctgaca gttaccaatg cttaatcagt gaggcaccta tctcagcgat ctgtctattt 3420
cgttcatcca tagttgcctg actccggggg gggggggcgc tgagggtctgc ctcgtaaga 3480
aggtgtgtgt gactcatacc aggcctgaat cgccccatca tccagccaga aagtgaggga 3540
gccacgggtg atgagagctt tgtgttaggt ggaccagttg gtgattttga acttttgctt 3600
tgccacggaa cggctctgct tgtcggggag atgcgtgac tgatccttca actcagcaaa 3660
agttcgattt attcaacaaa gccgccgtcc cgtcaagtea gcgtaatgct ctgccagtgt 3720
tacaaccaat taaccaattc tgattagaaa aactcatcga gcatcaaatg aaactgcaat 3780
ttattcatat caggattatc aataccatat ttttgaaaaa gccgtttctg taatgaagga 3840
gaaaactcac cgaggcagtt ccataggatg gcaagatcct ggtatcggtc tgcgattccg 3900
actcgtccaa catcaatata acctattaat ttccctcgt caaaaataag gttatcaagt 3960
gagaaatcac catgagtac gactgaatcc ggtgagaatg gcaaaagctt atgcatttct 4020
ttccagactt gttcaacagg ccagccatta cgctcgtcat caaaatcact cgcataacc 4080
aaaccgttat tcatctgtga ttgcgcctga gcgagacgaa atacgcgac gctgttaaaa 4140
ggacaattac aaacaggaat cgaatgcaac cggcgcagga acactgccag cgcatacaaa 4200
atattttcac ctgaatcagg atattcttct aatacctgga atgctgtttt cccggggatc 4260
gcagtgggtg gtaaccatgc atcatcagga gtacggataa aatgcttgat ggtcggaaga 4320
ggcataaatt ccgtcagcca gtttagtctg accatctcat ctgtaacatc attggcaacg 4380
ctacctttgc catgtttcag aaacaactct ggcgcacggt gcttcccata caatcgatag 4440
attgtcgcac ctgattgccc gacattatcg cgagccatt tataccata taaatcagca 4500
tccatgttgg aatttaatcg cggcctcgag caagacgttt cccgttgaat atggctcata 4560
acaccccttg tattactgtt tatgtaagca gacagtttta ttgttcatga tgatataatt 4620
ttatcttgtg caatgtaaca tcagagattt tgagacacaa cgtgggtttt ccccccccc 4680
cattattgaa gcatttatca gggttattgt ctcatgagcg gatcacatatt tgaatgtatt 4740
tagaaaaata aacaaatagg ggttccgcgc acatttcccc gaaaagtgcc acctgacgtc 4800
taagaaacca ttattatcat gacattaacc tataaaaaa ggcgtatcac gaggcccttt 4860
cgtc

```

&lt;210&gt; SEQ ID NO:27

&lt;211&gt; LENGTH: 139

&lt;212&gt; TYPE: DNA

&lt;213&gt; ORGANISM: E. coli / HIV-1

&lt;400&gt; SEQ ID NO:27

catgggtctt ttctgcagtc accgtccttg agatctgcca ccatgggcgg caagtggctc 60

aagagggtccg tgccccaccc cgagtactac aaggactgct aaagcccggg cagatctgct 120  
gtgccttcta gttgccagc 139

<210> SEQ ID NO:28  
<211> LENGTH: 139  
<212> TYPE: DNA  
<213> ORGANISM:E. coli / HIV-1

<400> SEQ ID NO:28  
catgggtcctt ttctgcagtc accgtccttg agatctgcca ccatggccgg caagtgggcc 60  
aagagggtccg tgccccaccc cgagtactac aaggactgct aaagcccggg cagatctgct 120  
gtgccttcta gttgccagc 139

<210> SEQ ID NO:29  
<211> LENGTH: 203  
<212> TYPE: DNA  
<213> ORGANISM:E. coli / HIV-1

<400> SEQ ID NO:29  
catgggtcctt ttctgcagtc accgtcctta tatctagatc accatggatg caatgaagag 60  
agggctctgc tgtgtgctgc tgctgtgtgg agcagctctc gtttcgcccc gcgagatctc 120  
ctccaagagg tccgtgcccc accccgagta ctacaaggac tgctaaagcc cgggcagatc 180  
tgctgtgcct tctagtgtgc agc 203

<210> SEQ ID NO:30  
<211> LENGTH: 651  
<212> TYPE: DNA  
<213> ORGANISM:Human Immunodeficiency Virus - 1

<400> SEQ ID NO:30  
atgggtggca agtgggtcaaa acgtagtgtg cctggatggt ctactgtaag ggaaagaatg 60  
agacgagctg agccagcagc agataggggtg agacgaactg agccagcagc agtaggggtg 120  
ggagcagtat ctgcagacct ggaaaaacat ggagcaatca caagtagcaa tacagcagct 180  
accaatgctg attgtgcctg gctagaagca caagaggatg aggaagtggg ttttcagtc 240  
agacctcagg tacctttaag accaatgact tacaaggag ctgtagatct tagccacttt 300  
ttaaagaaa aggggggact ggaagggtta attcactcac agaaaagaca agatatcctt 360  
gatctgtggg tctaccacac acaagggtac ttccctgatt ggcagaacta cacaccaggg 420  
ccaggaatca gatttccatt gacctttgga tgggtgctta agctagtacc agttgagcca 480  
gaaaaggtag aagaggccaa tgaaggagag aacaactgct tgttacacc tatgagccag 540  
catgggatag aggacccgga gaaggaagtg ttagagtgga ggtttgacag caagctagca 600  
tttcatcacg tggcccgaga gctgcatccg gactactaca aggactgctg a 651

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



FOR MORE INFORMATION ON THIS APPLICATION, SEE THE PCT GAZETTE FOR THE MONTH OF JUNE 2001

(43) International Publication Date  
21 June 2001 (21.06.2001)

PCT

(10) International Publication Number  
**WO 01/43693 A3**

- (51) International Patent Classification<sup>7</sup>: C07H 21/04, C12N 15/00, A61K 39/00 (74) Common Representative: MERCK & CO., INC.: 126 East Lincoln Avenue, Rahway, NJ 07065-0907 (US).
- (21) International Application Number: PCT/US00/34162 (81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.
- (22) International Filing Date: 15 December 2000 (15.12.2000)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data: 60/172,442 17 December 1999 (17.12.1999) US (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
- (71) Applicant (*for all designated States except US*): MERCK & CO., INC. [US/US]; 126 East Lincoln Avenue, Rahway, NJ 07065-0907 (US).
- (72) Inventors; and
- (75) Inventors/Applicants (*for US only*): SHIVER, John, W. [US/US]; 126 East Lincoln Avenue, Rahway, NJ 07065-0907 (US). LIANG, Xiaoping [CA/US]; 126 East Lincoln Avenue, Rahway, NJ 07065-0907 (US). FU, Tong-Ming [US/US]; 126 East Lincoln Avenue, Rahway, NJ 07065-0907 (US).
- Published:  
— with international search report
- (88) Date of publication of the international search report:  
21 February 2002
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*



WO 01/43693 A3

(54) Title: POLYNUCLEOTIDE VACCINES EXPRESSING CODON OPTIMIZED HIV-1 NEF AND MODIFIED HIV-1 NEF

(57) Abstract: Pharmaceutical compositions which comprise HIV Nef DNA vaccines are disclosed, along with the production and use of these DNA vaccines. The nef-based DNA vaccines of the invention are administered directly introduced into living vertebrate tissue, preferably humans, and express the HIV Nef protein or biologically relevant portions thereof, inducing a cellular immune response which specifically recognizes human immunodeficiency virus-1 (HIV-1). The DNA molecules which comprise the open reading frame of these DNA vaccines are synthetic DNA molecules encoding codon optimized HIV-1 Nef and derivatives of optimized HIV-1 Nef, including nef modifications comprising amino terminal leader peptides, removal of the amino terminal myristylation site, and/or modification of the Nef dileucine motif. These modifications may effect wild type characteristics of Nef, such as myristylation and down regulation of host CD4.

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/US00/34162

**A. CLASSIFICATION OF SUBJECT MATTER**

IPC(7) : C07H 21/04; C12N 15/00; A61K 39/00

US CL : 536/23.4; 435/320.1; 424/184.1

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**Minimum documentation searched (classification system followed by classification symbols)  
U.S. :

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)  
Medline, caplus, biosis, embase, scisearch, wpids.**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	TOBERY, T. et al. Cutting Edge: Induction of Enhanced CTL-Dependent Protective Immunity in vivo by N-End Rule Targeting of a Model tumor Antigen. 15 Jan 1999, 162 (2) 639-642. (see abstract)	1,2,6,7,20-22, 26-28.
X	GIRARD, M. New prospect for the development of a vaccine against human immunodeficiency virus type 1. An overview. Comptes Rendus de L Academie Des sciences. Serie III, Sciences de la vie, November 1999, 322 (11) 959-66.	1,2,6,7,20-22, 26-28
Y	US 5,851,813 A (DESROSIERS) 22 December 1998, see abstract	1,2,6,7,20-22, 26-28

☐ Further documents are listed in the continuation of Box C.☐ See patent family annex.

## \* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T"

later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X"

document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y"

document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"Δ"

document member of the same patent family

Date of the actual completion of the international search

May 4, 2001

Date of mailing of the international search report

06 JUN 2001

Name and mailing address of the ISA/US

Commissioner of Patents and Trademarks

Box PCT

Washington, D.C. 20231

Facsimile No. (703)305-3230

Authorized officer

Eleanor Sorbello

Telephone No. 703-308-0196

# INTERNATIONAL SEARCH REPORT

International application No.

PC 500/34162

## Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claim Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☒ Claim Nos.: 3-5, 8-19, 23-25 and 29  
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:  
Please See Continuation Sheet
3. ☐ Claim Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This international Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest ☐ The additional search fees were accompanied by the applicant's protest.  
☐ No protest accompanied the payment of additional search fees.

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/US00/34162

**Continuation of Box I Reason2:** Claims 3-5, 8-19, 23-25 and 29 were not searched as the application did not comply with sequence rules. The CRF was found to be defective. A CRF Error Report was faxed to Mark Hand on March 3, 2001. However, corrected diskette has not been submitted.



**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☒ FADED TEXT OR DRAWING
- ☐ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☐ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**